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The central dogma of molecular biology, which states that “DNA makes RNA and 
RNA makes protein” offers a framework for understanding the sequential transfer for 
genetic information within a biological system that begets cellular and organismal 
phenotype. Under this premise, the genome of a cell provides the basic blueprint for the 
synthesis of proteins needed for cell survival. Although the basic principle of the central 
dogma has remained unchanged during the past five decades, the complexity has 
profoundly increased. Indeed, the completion of genome sequencing of several 
organisms, including human, revealed that the relationship between genes and proteins 
is far from simple. For example, the human proteome, or collection of all expressed 
proteins in an organism, is estimated to be nearly five times larger than the number of 
genes in the human genome. This unexpected gap between genome and proteome size 
has led to a fundamental question: how can such a small number of genes be sufficient to 
support the observed cellular and organismal phenotypic complexity?  
In general, the wide gap between genome, proteome, and phenotypic complexity 
can be explained by processes occurring during two distinct phases of information 
transfer: First, through the transcription and processing of messenger RNA (mRNA) from 
DNA; and second, through the post-translational modification of protein. Indeed, DNA 
transcription and RNA processing are well known points of control, through epigenetic 
DNA and histone modification-based regulation and through mRNA editing and RNA 
splicing. Likewise, proteins translated from mRNA can undergo significant diversification 
through the introduction of post-translational modifications (PTMs), which are chemical or 
proteinaceous modifications to the native structure of an expressed protein. Indeed, the 
diversity of PTM types and the amino acids on which they can be found provides an 
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exponentially expansive landscape of possible proteoforms, each of which may exhibit a 
distinctive structural and functional behavior.  
An important distinction between both transcriptional and post-translational points 
of control is in the rate at which they occur, which defines the rate at which they can 
influence cellular phenotype. Introducing variation through transcription and RNA 
processing occurs slowly, whereas the formation of unique proteoforms through PTM 
occurs very rapidly. Moreover, most PTMs are also reversible and can therefore function as 
a highly versatile switch to dynamically control protein structure, localization and/or function. 
Furthermore, globally, concurrent PTM of several proteins can also conditionally re-wire cellular 
networks so as to shape the behavioral and phenotypic traits of an organism. Thus, PTMs 
represent a form of proteomic control that is fast, dynamic, and highly versatile, and hence, 
they are often found to regulate many different biological processes including cell signaling 
pathways, cell adhesion and migration, cellular proliferation and differentiation, and many 
more.  
Currently, more than 200 types of discrete enzymatically-catalyzed PTMs are 
known that range from covalent addition/removal of chemical entities (such as phosphate-
, acetyl-, alkyl-, glycosyl- groups) to a side chain residue in a protein to covalent cleavage 
of peptide backbones in proteins. Nearly all proteins are modified by either one or multiple 
types of PTMs, and/or are multiply modified by the same kind of modification. Indeed, 
technological advances in high-throughput mass spectrometry (MS) have fostered an 
exponential increase in the rate and precision at which PTMs are discovered, far beyond 
what could be possible through classical biochemical/biophysical methods. However, due 
to the much slower rate at which PTMs can be studied for functionality, this exponential 
increase has led to a major knowledge gap between the existence of a PTM and whether 
it is biologically important. Therefore, developing tools that prioritize functional relevance 
of PTMs, is a fundamental challenge of our time.  
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In an attempt to address the bottleneck between PTM knowledge and PTM 
function, the Torres lab has developed a computational method - Systematic Analysis of 
PTM Hotsposts (SAPH-ire) – a quantitative PTM ranking method that enables functional 
prioritization of PTMs based on a variety of protein features. This model for function 
potential prediction provides a useful guide for empirical functional studies of PTMs. The 
net effect of these computational advances and the increasing availability of high 
throughput MS-derived PTM data represents a key breakthrough for rapid acceleration of 
the pace of biological research. 
My overriding goal in this thesis is to understand PTM-mediated regulation of two 
diverse, yet extremely important physiological processes - G-protein signaling (primary 
doctoral project) and extracellular matrix mediated cell adhesion and migration 
(collaborative project with Dr. Barker). The first part of this thesis will discuss canonical G-
protein signaling, for which I have discovered novel regulatory properties of 
phosphorylation sites in the N-terminal tails of G protein gamma subunits that were 
initiated through SAPH-ire predictions. This part of the thesis is accentuated by highly 
mechanistic molecular genetics studies that build on pre-existing models of a canonical G 
protein signaling pathway. The second part of this thesis will discuss how I have employed 
MS-based characterization of citrullination, a rare and understudied extracellular PTM that 
is known to disrupt cell adhesion and migration signaling in humans. My hope is that the 
discoveries made in this thesis will not only further our understanding of PTM-based 
regulatory mechanisms that exist in G-protein signaling but will also open avenues for 
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Heterotrimeric G proteins, composed of G, G, and G subunits, are essential for 
converting extracellular chemical stimuli into appropriate intracellular responses. The 
principal mechanism of G protein signal transduction is highly conserved throughout 
eukaryotes, including yeast. Binding of extracellular signal to cell surface receptors 
activates G proteins through a well characterized process involving GTP binding on the 
G subunit, dissociation of the heterotrimeric complex into G and G subunits, and 
activation of downstream effectors that elicit a response to the stimulus. As mediators 
between transmembrane receptors and intracellular effectors, heterotrimeric G proteins 
are well positioned to serve as PTM-mediated regulators of G-protein signaling. Indeed, 
three primary PTMs are essential for G proteins to function: N-terminal myristoylation and 
palmitoylation of G subunits, and C-terminal prenylation of G subunits, all three of which 
function as a lipid bar code to anchor heterotrimeric G proteins to specialized 
microdomains in the plasma membrane of cells and also confer functional interaction with 
other proteins. In this context, while the signaling roles of G and G subunits and the 
PTMs which occur on these subunits are widely identified; G subunits are thought to 
serve the limited role of a membrane anchor for its obligate partner G and no other 
regulatory role was known. 
This study highlights a previously unknown role of G subunit in the regulation of 
G-protein signaling mediated through phosphorylation of their N-terminal intrinsically 
disordered region. Using a yeast model organism, Saccharomyces cerevisiae, that 
harbors a single canonical G-protein signaling system to regulate a yeast mating pathway, 
we have identified a novel phosphorylation-dependent regulatory role of G subunit in 
yeast (Ste18). A number of unique discoveries have ensued that provide a foundation for 
 xvii 
future studies in mammalian systems, where G protein signaling serves as a major drug 
target for the treatment of human disease. First, Ste18 is dynamically phosphorylated in 
response to GPCR activation. Second, this phosphorylation event is dependent on a 
MAPK (Fus3), which is the ortholog of human Erk2. Third, Ste18 phosphorylation, in 
conjunction with phosphorylation of a G effector scaffold protein (Ste5), negatively 
regulates activation of the yeast mating pathway that is responsible for phosphorylation-
based activation of Fus3. Fourth, negative regulation by phosphorylated Ste18/Ste5 is 
mechanistically achieved by reducing binding affinity between G/(Ste4/18) and effector 
Ste5, which results in controlling the bulk rate of active signaling complex formation at the 
plasma membrane in response to a GPCR stimulus.  Fifth, Ste18/Ste5 phosphorylation 
regulates the sensitivity of the yeast mating process by altering its switch-like behavior. I 
go on to demonstrate that Ste18 phosphorylation can be promoted by signals other than 
GPCR stimulation. Specifically, I show that Ste18 phosphorylation is also sensitive to 
osmotic stress and cell-cycle progression, both of which may represent cross-talk 
mediated responses that funnel through the aforementioned Ste18/Ste5 regulatory 
mechanism. Together, these findings reveal that combinatorial phosphorylation of Ste18 
and the G effector protein (Ste5) constitute a dynamic regulatory module that mediates 
negative regulation of G protein signaling in yeast and provide a foundation for 
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ROLE OF G SUBUNIT AS A NEGATIVE FEEDBACK PHOSPHO-REGULATOR 





















Cells of both unicellular and multicellular organisms communicate with other cells 
both near and far as well as respond to continuous changes in their environment to 
perform important physiological processes necessary for survival. This fundamental 
process is mediated through signal transduction systems which sense and process the 
dynamic temporal information in the microenvironment of the cell into appropriate cellular 
response. All signal transduction systems consist of a transmembrane receptor which 
receives the extracellular signal and subsequently transfers the information to intracellular 
effector proteins which generates an intracellular signal. During this transduction process, 
the signal is often amplified before evoking a cellular response. Additionally, feedback 
pathways regulate the entire signaling process.  
G-protein signal transduction system, so called due to the requirement of GTP 
bound proteins (G-proteins) for signaling, is one of the most extensively studied signaling 
system, primarily due to their involvement in diverse physiological processes in humans 
and wide pharmacological relevance (1–8). The first evidence of the GTP dependence of 
receptor activation of cAMP came from the Martin Rodbell group, suggesting the presence 
of an unknown GTP-binding transducer protein, which were later discovered by Alfred 
Gilman in 1979 (reviewed in (9)) Since then the field has immensely benefitted from the 
advent of powerful recombinant DNA techniques, advances in protein engineering, X-ray 
crystallography, and mass spectrometry, which together with classical biochemistry 
expanded the understanding about the key players and the standard model of activation 




1.1. The basic model of G-protein signaling system 
The well-established understanding of the standard model of the activation of the 
G-protein signaling system has stemmed from studies across diverse organisms such as 
yeast and humans. The basic elements of G-protein signaling system include G-protein 
coupled receptors (GPCRs), heterotrimeric G-proteins (G), G-protein linked effectors, 
and regulators of G protein signaling (RGS)(10). GPCRs, by virtue of their seven 
transmembrane-domain helical structure, provide a ligand binding pocket at the 









Figure 1.1. Schematic diagram of canonical G-protein signaling 
system. Activation of the G protein coupled receptor (GPCR) at the cell 
surface triggers exchange of GDP with GTP on G subunit, dissociation 
of G and G subunit, activation of downstream effectors and finally 
culminates with appropriate cellular response. The system is deactivated 
by the hydrolysis of GTP to GDP on G subunit, which is accelerated by 
the regulator of G protein signaling (RGS) protein. 
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Under resting state, heterotrimeric G-proteins comprising of G subunit, and the 
obligate heterodimer G subunits, are tightly bound as a closed complex; and the G 
subunit is coupled to GDP. In humans, there are approximately 1000 GPCRs which 
recognize a structurally diverse repertoire of ligands, such as photons, hormones, 
chemokines, amino acids, and neurotransmitters (10–12). Activation of GPCRs by binding 
of a ligand triggers conformational changes in the receptor. Activated GPCRs act as a 
guanine nucleotide exchange factor (GEF) and catalyze the exchange of GDP for GTP on 
Gα subunit, leading to the dissociation of G and G subunit. The G and G subunits 
are then free to transmit the signal by interacting with a variety of downstream effector 
proteins, eventually generating a physiological response to the stimuli(11,13–15). 
Conventionally, G subunits are viewed as the primary transducers of the signal; whereas 
G subunits act as a guanine nucleotide dissociation inhibitor (GDI). However, in recent 
years the number and variety of effectors that are known to be modulated by G subunits 
have increased(4,16). The system is desensitized by the intrinsic GTPase activity of G 
that hydrolyzes the bound GTP to GDP, the rate of which is accelerated by the GTPase 
accelerating (GAP) activity of RGS proteins (Figure 1.1). The GDP bound G has a lower 
affinity for effectors, but rather re-associates with G subunits with high affinity to form a 
closed heterotrimeric complex(17,18).   
 
 
1.2. The key elements of G-protein signaling system 
1.2.1. G-protein coupled receptors (GPCRs) – GPCRs are the largest superfamily of 
cell surface receptors and are so named as they transmit signal across the membrane by 
activating the heterotrimeric guanine nucleotide binding proteins (G-proteins) bound to the 
cytosolic tail of GPCRs, which then activates downstream effectors. In humans, about 1% 
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of the genome, encodes for approximately 1000 GPCRs with sequence length between 
289 and 3312, with most GPCRs consisting of 300–500 amino acid residues (19,20). 
Together, they mediate cellular responses to a variety of extracellular signals ranging from 
photons and small molecules to peptides and proteins(10,11). Despite differences in the 
sequence and ligand sensitivity, the overall structural architecture of these receptors is 
highly homologous as was revealed by the exponential growth in the crystallography of 
GPCRs. Currently, there are structural records of 53 unique receptor from over 200 PDB 
entries spanning a range of conformational states from multiple inactive states, active-
intermediate states, and active states in complex with G proteins(reviewed in (21–24)).  
All GPCRs share an identical structural topology comprising of seven 
transmembrane -helices (7TMH) connected by three extracellular loops (ECL1-3) and 
three intracellular loops (ICL1-3) (reviewed in (22–24)). Interestingly, the transmembrane 
helices of GPCRs are frequently tilted with varied tilt and rotation angles that depend not 
only on the receptor type but also on its activation state. Additionally, the 7TMH structure 
contains a number of kinks, mostly produced by presence of helix breakers such as 
cysteine and proline residues, that roughly divide the structure into two regions- 
extracellular region and intracellular region. While the extracellular region of GPCRs, 
which includes the N-terminus, ECL 2, and ECL3, is responsible for ligand binding; the 
intracellular region of GPCRs is involved in interaction with heterotrimeric G-proteins. 
Moreover, the intracellular region of GPCRs which interacts with G-proteins is subjected 
to much larger conformational changes upon receptor activation than the extracellular 
region. These activation-related conformational changes in the helices is accompanied by 
rotamer changes in highly conserved side chains that stabilize the global movements of 
helices and help prime the intracellular side of a GPCR to act as a guanine exchange 
factor (GEF) for the heterotrimeric G-proteins (reviewed in (22–24)).  
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Activation of a GPCR triggers exchange of GTP for GDP on G and subsequent 
dissociation of G and G subunits. Depending on the type of G protein to which the 
receptor is coupled, a variety of downstream effectors are activated in a cascade manner 
(reviewed in (25,26)). The signal is attenuated by receptor phosphorylation and binding of 
a -arrestins which mediates internalization of the receptor (27).  
 
1.2.2. Heterotrimeric G-proteins - Heterotrimeric G-proteins comprising of G, G and 
G subunits are intracellular partners of GPCRs that transduce signal from the ligand 
bound receptor to downstream effector proteins. In their inactive form, GDP bound G 
subunit binds tightly to the obligate heterodimer of G subunit and is coupled to the C-
terminus of GPCR as a closed complex. Ligand binding to the GPCRs promotes exchange 
of GTP for GDP and the functional dissociation of G and G subunits, each of which is 
now free to interact with downstream effectors(10,28). Signal is terminated by the intrinsic 
GTP hydrolysis rate of the G subunit and the subsequent reassociation of G- GDP and 
G subunits. The GTPase action of G subunit is regulated by accessory protein, 
regulator of G-protein signaling (RGS) proteins(17,18). Resolution of crystal structures for 
inactive, active, and transition-state G-proteins, as well as several biochemical and genetic 
studies, have provided the framework for understanding the role of heterotrimeric G-
proteins as molecular switches or transducers(reviewed in (10,11)). 
 
1.2.2.1. The G subunits – There are 23 G proteins in the human that can be divided 
into four families, Gs, Gi / Go, Gq / G11, and G12 / G13. Each family has multiple 
members that share both sequence and functional similarities (29). The Gs has two 
members- the ubiquitously expressed Gs and the Golf expressed in olfactory sensory 
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neurons. When activated, both of these proteins activate adenylyl cyclase and result in 
increased concentration of intracellular cyclic AMP. On the other hand, Gi / Go class 
contains Gi1, Gi2, Gi3, Go, Gt, Gg, and Gz subunits that are expressed in wide range 
of cells such as neurons, rods and cone cells of the eye, taste receptor cells, and in 
platelets. Unlike Gs, members of Gi / Go inhibit cyclic AMP production. The Gq / G11 
has five members, Gq, G11, G14, G15, and G16. While Gq and G11 are widely 
expressed in mammalian cells; others are specifically expressed in stromal, epithelial and 
hematopoietic cells. The Gq / G11 family of proteins activate the pathway by regulating 
the -isotype of phospholipase C (PLC-) which cleaves phosphoinositol diphosphate into 
diacylglycerol and inositol triphosphate, which in turn activate protein kinase C and 
mobilize calcium respectively. The fourth class of G family has only two members, G12 
and G13, which are expressed in most types of cells, and activate Rho GTPase nucleotide 
exchange factors (RhoGEFs) which in turn activates the small G-protein RhoA that 
regulates cell shape and mobility (reviewed in (30)). 
Crystallography of G subunits revealed a conserved structure consisting of two 
domains, namely the Ras-like domain and the -helical domain. While the Ras-like domain 
provides essential GTPase and nucleotide exchange activity; the helical domain 
contributes to the specificity of interaction with GPCRs and effectors. G subunits also 
contain an extended N-terminal region that interacts with the G subunit and with the 
membrane via myristate and/or palmitate group covalently attached at/near their N-
termini, which together stabilize the location of G subunits at the membrane. Two flexible 
linkers connect the Ras-like domain and the helical domain, allowing movement of these 
two domains relative to each other (31,32). Additionally, these domains participate in the 
formation of a deep cleft for the binding of either the GDP or GTP nucleotide. Three switch 
regions in the GTPase domain- switch I, II, and III- interacts with the phosphates of the 
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bound nucleotide and forms an interface with the activated receptor (GEF) as well as the 
RGS protein (GAP). The cumulative effect of all the interactions between the switch 
region, nucleotide, and other proteins dictates whether G subunit exists in a GDP-bound 
inactive closed complex or GTP-bound effector-binding active state (reviewed in (10,14)).  
 
1.2.2.2 The G dimers – The G heterodimer consists of two obligate partners- G and 
G subunits- that interact to form the irreversible G dimer rapidly after 
synthesis(reviewed in(33)). Currently, 5 distinct members of G family and 13 different 
members of G family have been identified in human. In the G family, G1-4 share 80% 
amino acid sequence identity compared to the 50% identity for G5; whereas, there is 
significantly lower identity in G subunits (reviewed in (34)). Most of the different types of 
G and G subunits can pair to form a large number of potential G dimers, with few 
exceptions. For example, G1 can combine with all G subunits, whereas G2 pairs with 
G2 but not G1 subunit (35). Although the functional relevance of the variability in G 
dimers is not completely understood, several knockout studies suggest that specific G 
subtypes interact with specific GPCRs and are responsible for specificity of pathway 
activation. For example, studies done in mice where G7 subunit was genetically deleted, 
resulted in distinct behavioral changes associated with specific loss of cyclic AMP 
production in the striatum (36). In another study, deletion of G3 results in changes in 
metabolism resulting in resistance to a high fat diet (37). In both of these cases loss of the 
specific G subunits also resulted in a loss in specific G expression, indicating roles for 
specific G combinations in these phenotypes (36,37). 
The G subunits have been crystallized, either alone or in combination with known 
effectors, all of which generated similar -propeller structure in G subunits that is 
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associated with a helical G subunit (38–40). All G subunits contain seven WD-40 
repeats, a tryptophan and aspartic acid sequence that repeats every 40 amino acids and 
forms antiparallel -strands which fold into a seven bladed -propeller or torus-like 
structure. Additionally, the N-terminus of the G subunits form an -helix structure (38–
40). The G subunits folds into two -helices. The N-terminal -helix of G is involved in a 
coiled-coil interaction with the -helix of G subunits; whereas the C-terminal -helix of 
G extensively interacts with the base of the G propeller (38–40). Moreover, the C-
terminus of all G subunits contain the CAAX motif (where C is cysteine, a is aliphatic 
amino acid, and X is any amino acid); the cysteine residue of which is subjected to 
prenylation, a lipid modification critical for the membrane localization of the G dimer 
(41,42). In this process of prenylation, the last three amino acids (-AAX) is proteolytically 
removed and the newly generated C-terminal cysteine is carboxymethylated (41,42). 
Dissociation of the G subunits from the heterotrimer complex does not trigger massive 
conformational changes in G dimer, rather it exposes the residues required for binding 
and activation of the effectors (39).  
 
1.2.3. G-protein linked effectors-  
1.2.3.1 G effectors – Currently, the effectors of all four classes of G subunits are well 
established. Adenylyl cyclase was the first effector to be discovered by Sutherland and 
Rall(43). These enzymes are large membrane bound proteins responsible for the 
production of cAMP and are activated by the GTP- bound Gs class of subunits. There 
are 9 isoforms of adenylyl cyclase that are generally widely expressed, although type I 
and type II are primarily restricted to neurons. Similarly, type III adenylyl cyclase are 
specifically expressed in olfactory cells. Despite the difference in expression, all isoforms 
of adenylyl cyclase are activated by Gs subunits. Interestingly, some isoforms of adenylyl 
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cyclase are inhibited by G subunits. These G subunits belong to the Gi class (where i 
= inhibitor), and can directly inhibit the types I, V, and VI adenylyl cyclase (reviewed in 
(10)). Unlike adenylyl cyclase which is activated or inhibited by direct interaction with Gs 
or Gi respectively, the Ca2+, Na+, and Cl-  ion channels in cardiac cells are regulated by 
Gs and Gi by an unknown mechanism (reviewed in (10)). The retinal Gt mediates 
regulation of cGMP phosphodiesterase by photon activated rhodopsin. The enzyme 
cGMP phosphodiesterase catalyzes the hydrolysis of cGMP, causing closure of cGMP-
gated cation channels and in hyperpolarization of the cell membrane. The Gq class of 
proteins activate phosphoinositide-specific phospholipase C- type (PLC-), which 
hydrolyzes the phosphoester bond of the plasma membrane lipid phosphatidylinositol 4,5-
biphosphate into the calcium mobilizing second messenger inositol 1,4,5- trisphosphate 
(IP3) and the protein kinase C-activating second messenger diacylglycerol (DAG). 
Additionally the activities of a broad range of membrane, cytoskeletal, and cytosolic 
proteins also are directly regulated by PLC-mediated changes in membrane 
concentrations of PtdIns(4,5)P2 (reviewed in (10)). Comparatively less is known about the 
G12/13 family, but few studies have shown that activated G12 or G13 interact with Rho-
family guanine nucleotide exchange factors (RhoGEFs), which in turn activate small G-
protein RhoA which plays a key role in the regulation of the actin cytoskeleton, cell shape, 
cell polarity, cell migration and cell growth. (reviewed in (10)). 
 
1.2.3.2 G effectors - In recent years, the roles of G subunits have expanded from 
being just a negative regulator (as a GDI) for G subunits to a more central participant in 
G-protein signaling. G subunits are now known to interact with Gα subunits, GPCRs, 
and several downstream effector proteins(16).  
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As a negative regulator of Gα signaling, G subunits prevent the spontaneous 
activation of Gα subunits in the absence of receptor stimulation (reviewed in (44)). 
Interaction of G dimer with Gα subunit induces multiple changes in Gα subunits 
including conformational changes that stabilizes the switch regions I and II of Gα, 
decrease the dissociation rate of GDP from Gα, and simultaneously increasing the rate of 
dissociation of GTP from Gα. Thus, G subunits act as a guanine dissociation inhibitor 
(GDI) of Gα by facilitating increased affinity of Gα for GDP which favors heterotrimeric 
complex formation (reviewed in (16)).  
The G subunits also enhance coupling of heterotrimeric complex to its 
appropriate receptor. This effect is independent of the enhanced stability of heterotrimeric 
complex at the membrane, compared to the stability of Gα and G  subunits post-
disassociation from the heterotrimeric form (reviewed in (16)). The ability of G subunits 
to bind to receptors is influenced by the type of G subunit in the dimer. For example, G1 
when paired with G1 subunit facilitates binding of Gt to rhodopsin, but not when G1 pairs 
with G2 subunit (35). However, the site on G subunits which confers this ability to bind to 
receptors is currently not known. 
Although G subunits were primarily considered as a GDI for Gα subunits, a large 
body of work revealed that free G subunits can activate a large number of its own 
downstream effectors (reviewed in (4,10,34)). The first evidence of such a direct effector 
of G in humans were the G-protein regulated inward rectifier K+ channels (GIRK). 
GIRKs are expressed in various tissues such as heart, pancreas, and brain; and has a 
homotetramer structure, wherein the N- terminus of one subunit folds with the C-terminus 
of the adjacent subunit. Additionally, GIRK has multiple G binding sites, one on the N-
terminus and two on the C-terminus of each subunit. The binding sites on N- and C-
terminus of adjacent subunits are brought close in proximity in the holochannel and is 
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recognized by one G subunit. Different receptor/GIRK combinations are recognized by 
different G dimers. The presence of multiple binding site allows for graded activation of 
the channel which leads to increasing hyperpolarization of the cells (reviewed in (4,10)). 
Voltage-gated Ca2+ channels localized in the presynaptic terminal of neurons 
mediate calcium ion influx across plasma membrane and is inhibited by G subunit in 
response to norepinephrine. Voltage-gated Ca2+ channels are oligomeric complex of three 
different subunits- 1 subunit,  subunit, and 2 subunit. Much like the subunits in GIRK 
channel, 1 subunit of voltage-gated Ca2+ channels contain three G binding sites, one 
each in the N-terminus, C-terminus, and intracellular loop connecting transmembrane 
domains. However, in contrast to multiple G binding to GIRK, only a single G occupies 
the binding sites per Ca2+channel, as the multiple binding sites fold into proximity in the 
native structure of the channel. While the involvement of G1 and G3 have been shown 
in this process, much less is known about the specificity of G or the mechanism by which 
the binding of G inhibits the channel (reviewed in (4,16,34)). 
Adenylyl cyclase is another well studied effector of G. In humans, there are 9 
isoforms of adenylyl cyclase, all of which are activated by GTP-bound active Gs, but only 
a subset of them are directly regulated by G. While type I adenylyl cyclase is inhibited 
by G, types II, IV, V, and VI adenylyl cyclases are stimulated by G. The structure of 
all AC isoforms includes a highly variable N terminus (NT) and two well conserved catalytic 
domains (C1, C2). While the C1/C2 domains form the catalytic pocket for cAMP 
production, the NT harbors one or more regulatory binding sites for G and/or other 
regulatory proteins such as G. However, it was later determined that interactions 
between G and the regulatory sites in the NT of adenylyl cyclase has little role in the 
stimulation of adenylyl cyclase. Instead, recent study showed that G also interacts with 
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the catalytic domains (C1, C2) of isotypes V and VI of adenylyl cyclase; and this interaction 
is necessary for activation of adenylyl cyclase. On the other hand, inhibition of type I 
adenylyl cyclase by G is comparatively less well understood. It was observed that G 
released from Gs-coupled receptors, but not Gi- coupled receptors, mediate inhibition 
of type I adenylyl cyclase. However, the detailed mechanism underlying the inhibition of 
type I adenylyl cyclase is not completely understood (4,45). 
Another effector of G is phospholipase-C (PLC) which cleaves phosphoinositol 
diphosphate into diacylglycerol and inositol triphosphate. The two end products in turn 
regulate important cellular processes- diacylglycerol directly activates phospholipase 
kinase C while inositol triphosphate diffuses to the endoplasmic reticulum and mobilizes 
intracellular calcium stores. Of the 13 currently known isoforms of PLC, only the , , and 
-isoforms are regulated by G mediated by direct interactions between the PH and 
catalytic domains of PLC. The magnitude of PLC activation was dependent on the G 
combination (G12 being the most efficient) and on the isoform of PLC (reviewed in 
(4,16,34)). 
Direct interaction between G and phosphoinositide 3-kinases (PI3K) activates 
the latter and triggers the phosphorylation of phosphatidylinositols at the position 3-
hydroxyl group of the inositol ring, producing phosphatidylinositol 3,4,5-triphosphate 
(PIP3). This, in turn, recruits and activates cytosolic effectors with PIP3-binding pleckstrin 
homology (PH) domains, thereby controlling important cellular functions such as 
proliferation, survival, or chemotaxis. Like other effectors, PI3Ks demonstrate G 
specificity, with combinations of G1-4 with G2 stimulating PI3Ks to equivalent levels, 
whereas dimer of G5 and G2 is unable to activate PI3K (reviewed in (4,16,34)) 
G-protein coupled receptor kinases (GRKs) are serine/threonine protein kinases 
that phosphorylate numerous GPCRs and are activated by free G. Phosphorylation of 
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GPCRs by GRKs promotes the recruitment of -arrestins which subsequently leads to 
receptor internalization and desensitization. Unlike many other kinases, GRKs do not need 
to be phosphorylated to achieve an activation state. Instead, docking of GRKs with ligand 
bound receptor leads to activation of GRKs. This docking is mediated by direct interaction 
between the carboxyl terminal of the kinase and the membrane-localized free G dimer 
which serves to target this enzyme to its membrane-incorporated receptor substrate 
(46,47). Once activated, GRKs phosphorylate the intracellular loops and the carboxyl 
terminal of GPCRs which facilitates the receptor’s binding to -arrestins with high affinity. 
This binding event both physically prohibits receptors from further coupling to 
heterotrimeric G-proteins and targets the receptors to clathrin-coated pits, where receptor 
endocytosis occurs. Thus, resulting in receptor desensitization (46,48). 
 
1.2.4. Regulator of G-protein signaling (RGS) – RGS proteins are a family of 30 
members that negatively regulate G-protein signaling via GTPase accelerating activity of 
their RGS homology (RH) domain (17). The first RGS protein was discovered in 
Saccharomyces cerevisae, wherein the G-protein signaling pathway mediates response 
to mating pheromone (49). The study revealed that loss of Sst2 (yeast RGS protein) 
rendered the yeast supersensitive to pheromone and was later shown to interact directly 
with and negatively regulate Gpa1 (yeast G subunit) (49). Multiple homologs of Sst2 
were later discovered, including the first mammalian homolog BL34 (later renamed as 
RGS1) in B-lymphocytes (50). Each of these RGS proteins consist of the conserved RH 
domain of 130 amino acids that folds in to a bundle of nine helices. The RH domain 
interacts with the switch III region of G subunits, and the RH/switch interface primarily 
dictates the selectivity for the G subunit (50). For example, RGS2 demonstrates a 
stronger selectivity for Gq,  but not other classes of G subunits (Gs, Gi, G12/13) (51). 
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This interaction promotes the transition state for GTP hydrolysis within the nucleotide 
binding domain and thus facilitate deactivation of G (52). Moreover, RGS proteins can 
physically block the interaction between certain G-proteins and its effectors, such as in the 
case of RGS4 which binds to Gq and inhibits interaction with the effector protein, PLC-1 
(53)  
The modular nature of G-protein signaling system with multiple components 
enables cells to assemble vast combinations of complex signaling units that allow different 
cells to respond adequately to different extracellular signals. Furthermore, it allows for an 




1.3 Pharmacological significance of G-protein signaling 
Components of the G-protein signaling system, most prominently GPCRs, have 
been of long-standing interest as drug targets, as they regulate numerous diverse 
physiological processes. Indeed, abnormalities in G-protein signaling system have been 
implicated in various metabolic, immunological, and neurodegenerative diseases, along 
with cancer(1,2,4,5,8,54–58). Although the underlying physiology of any disorder is often 
complex and multifactorial, several GPCRs that play a key role in the pathophysiology 
have been identified and are employed as drug targets.  In fact, currently, 475 drugs 
(approximately 34% of all marketable drug targets approved by FDA) act on 108 unique 
GPCRs and account for a global sales volume of over 180 billion US dollars annually(59–
61). Examples of major GPCR pharmacological targets include angiotensin II receptor 
(cardiovascular disease)(62), glucagon receptor (type 2 diabetes)(63), serotonin receptor 
(Alzheimer’s disease)(63), CXCR2 and CXCR4 (cancer)(64,65), to name a few.  
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Moreover, additional 321 pharmacological agents are currently under clinical trials, of 
which approximately 20% target novel 66 GPCRs(61,62,66,67). However, GPCRs 
targeted by drugs show genetic variation in their functional regions such as drug- and 
effector-binding sites in the human population, thus, leading to altered or adverse drug 
response(68). Increased understanding of the system has fostered the development of 
alternative drugs which target and inhibit the RGS proteins, or heterotrimeric G-proteins 
as an approach to treat certain pathologies(4,69,70).  
Targeting RGS proteins presents a unique and challenging paradigm to modulate 
the pathway output downstream of GPCR activation. Thus, a lot of effort has been given 
to the discovery of peptides or small molecules that can physically block the RGS/G 
protein-protein interaction or alter the expression levels or localization of an RGS protein 
within a cell (69). To date the common approach toward modulating RGS protein function 
has focused on disrupting the protein-protein interaction between the RGS proteins and 
their Gα subunit partners. These efforts have resulted in the identification of both peptide 
and small molecules that disrupt RGS activity at G proteins. For example, Wang et al. 
identified a unique peptide sequence P17 (Val-Arg-His-Val-Ala-Val-Glu-Val-Gly-Gly-Val-
Val-Val-Val-Val-Gly) that blocked the interaction between RGS4 and Gi1, with specificity 
over RGS7, and functionally inhibited RGS4 action (71). The N-terminal Arg as well as the 
C-terminal Val-Gly were essential for the inhibitory action of the peptide (71). Other 
examples of peptide inhibitors include YJ34 (72) and P2 (73). Additionally, small 
molecules such as the pyrido [1,2-a] pyrimidine derivatives CCG-63802 and CCG-63808 
which prevent association between RGS4 and Go have also been identified (3).   
Positioned between activated GPCRs and downstream effectors, heterotrimeric G 
proteins play the pivotal role of a transducer in G-protein signaling signaling; and thus, 
have been obvious targets for drug development (11,16). Indeed, several small molecules 
 16 
that target either G or G subunits have been developed (4,70). These molecules bind 
the different G protein subunits and primarily modulate the activation/deactivation cycle of 
heterotrimeric complex. For example, suramin and its analogues (NF449 and NF503) is a 
polysulfonated naphthylamine-benzamide derivative that bind specifically to Gs subunit. 
This binding inhibits GPCR promoted GDP release followed by GDP/GTP exchange as 
well as the interaction of Gs with its effector, adenylyl cyclase (reviewed in (70)). Other 
examples of small molecules which target G subunits are BIM-46175 (Gs), YM-254890 
(Gs), YM-280193 (Gs), and FR-900359 (Gs) hinder GDP/GTP exchange as well as G 
- G dissociation (reviewed in (70)). Additionally, G subunits have recently been 
investigated as a potential drug target. Indeed, many small molecule inhibitors have been 
identified that prevent interaction of G subunits with specific downstream effectors. The 
inhibitor peptide GRK2ct (βARKct) consisting of a C-terminal 194 amino-acid peptide of 
GRK2 is one of the most famous G binder and modulator (74). This peptide is known to 
interfere with GRK2 activity through disrupting its G -mediated membrane translocation 
(74). Additionally, various non-peptide inhibitor molecules have been developed by 
Smrcka and group. Among these molecules, M119 was one of the most potent 
compounds with high apparent affinity for G12. This small molecule inhibits the activation 
of G effectors, PLC- and PI3K, and their related cell response including neutrophil 
chemotaxis and inflammation, in a concentration dependent manner (reviewed in (4)). 
However, M119 had no effect on Ca2+ release, thus nicely illustrating the specificity of 
M119 on G dependent responses (reviewed in (4)). Other small molecules, such as 
M119B, M158C, and M201, have also been identified to differentially inhibit G effectors 
(reviewed in (4)). 
Though GPCRs continue to be the major drug target, there is a strong drive for 
innovation in the pharmaceutical industry for discovery of new protein targets and new 
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binding sites within known targets. Enhanced understanding of the mechanism and 
regulation of the G-protein signaling system continues to provide further opportunities for 
the development of new and improved targeted therapeutics. 
 
 
1.4 Post-translational regulation of G-protein signaling 
G-protein signal transduction, like other cellular processes, relies heavily on 
reversible post-translational protein modifications (PTMs) for fine tuning the signaling 
output. All key components of the pathway, including GPCRs, heterotrimeric G proteins 
(G), effector proteins, and RGS are subject to a variety of covalent modifications, which 
occur both in normal and pathological contexts (56,75–93). Most of these PTMs are added 
or removed in a highly dynamic manner, which allows for rapid reprogramming of the 
pathway. The most prominent PTMs which occur on members of G-protein signaling 
pathway are lipid modification, phosphorylation, and ubiquitination (56,75–93). Lipid 
modifications to proteins include prenylation, myristolyation, and palmitoylation. 
Prenylation consists of farnesylation or geranylgeranylation of cysteine residues of target 
proteins; whereas myristoylation occurs on N-terminal glycine residues of a target protein. 
Both prenylation and myristoylation are irreversible PTMs. On the other hand, 
palmitoylation is a reversible lipid modification which occurs by thioesterification of 
cysteine residues and covalent attachment of palmitic acid on target proteins. These lipid 
modifications regulate the localization of the protein at the membrane, and hence 
activation of some proteins (reviewed in (94)).  
Phosphorylation is the addition of phosphate moiety to either serine, threonine, or 
tyrosine residue of a protein, and primarily regulates the activation state of the protein, 
protein-protein interaction profile, or primes the protein for degradation (reviewed in (94)). 
 18 
Ubiquitination is a highly dynamic, coordinated, and enzymatically catalyzed 
covalent attachment of a small regulatory protein, ubiquitin, to proteins which are then 
targeted for degradation and recycling (reviewed in (94)).  
Together, these modifications regulate various components of the G-protein 
signaling pathway, and hence provide another layer of dynamic regulation of the pathway 
output (56,75–93).  
 
1.4.1. Post-translational modifications of GPCRs- GPCRs are heptahelical integral 
plasma membrane proteins that contain seven membrane-spanning domains, and thus, 
lipid modifications seem unlikely to contribute to the localization of the receptor protein at 
the membrane. Nevertheless, many examples of GPCRs that are subject to lipid 
modification wherein palmitate is attached to one or more cysteine residues exist in 
literature. Rhodopsin was the first GPCR to be identified as a target for palmitoylation, and 
it was suggested that the attached palmitate might be incorporated into the plasma 
membrane bilayer, thereby creating an additional intracellular loop (95). The palmitoylated 
cysteine were found in the cytoplasmic tail of the protein, positioned 10-14 amino acids 
downstream of the last transmembrane domain (95). Later many GPCRs including the 2-
adrenergic receptor (96), human somatostatin receptor (97), human thyrotropin receptor 
(98) and others, were shown to possess cysteine residues in the C-terminus at an 
analogues position to that in rhodopsin. Site-directed mutagenesis of these cysteine 
residues which block palmitoylation of the receptor affects GPCR trafficking in some 
cases, while in others affects the receptors ability to couple to G-proteins. Mutation of 
palmitoylation sites in -opiod receptor, H2 histamine receptor, chemokine CCR5 receptor, 
and vasopressin V2 receptor, resulted in intracellular accumulation of the receptors. While 
receptors like  2-adrenergic receptor and endothelin receptor are uncoupled from their 
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corresponding G-protein, through a less understood mechanism, upon elimination of 
palmitoylation (reviewed in (99)).  
Almost all GPCRs are regulated by phosphorylation which leads to receptor 
desensitization (100). Phosphorylation occurs on the C-terminal tail and the intracellular 
loops of GPCRs which contain multiple serine and threonine residues clusters that get 
unmasked due to agonist-induced conformational changes. These sites are primarily 
phosphorylated by GRKs which promotes interaction with -arrestin at higher affinity 
(reviewed in (82)). This was illustrated in the case of rhodopsin which bound -arrestins 
at 10-fold higher affinity when phosphorylated (101). This increase in affinity of 
phosphorylated receptors for -arrestins is not universal for all GPCRs, with some receptor 
phosphorylation mediating no or small change in affinity for -arrestins (reviewed in (82)). 
Interestingly, GPCRs are multiply phosphorylated in a sequential manner with the precise 
location of phosphorylation depending on the ligand type and concentration as well as the 
cell type (reviewed in (76)). While it has been suggested that the receptor- -arrestin 
interaction is dependent on the bulk negative charge rather than the precise location of 
phosphorylation; the phosphorylation pattern dictates the heterogeneity in the affinity and 
type of interaction between -arrestin and receptor (reviewed in (76,82)). Furthermore, it 
was suggested that multi-site phosphorylation of GPCRs likely reflects action of multiple 
kinases. Indeed, increasing evidences have shown other kinases such as PKA and PKC 
to phosphorylate GPCRs, such 1 -adrenergic receptor (102) and D2-dopamine receptor 
(103), and mediate desensitization, albeit through an unclear mechanism. 
In addition to palmitoylation and phosphorylation, many GPCRs are subject to 
ubiquitination in which either a single ubiquitin moiety is added to one or several lysine 
residues (monoubiquitination or multi-monoubiquitination), or a chain of ubiquitin is added 
to K48 residue. The best characterized role of ubiquitination on GPCRs is to function as a 
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lysosomal sorting signal (reviewed in (56,77)). Indeed, studies done in yeast 
Saccharomyces cerevisae and in mammals showed that Ste2 (yeast GPCR) (104) as well 
as many mammalian GPCR (most prominently the chemokine CXCR4 receptor) (105) get 
mono ubiquitinated and internalized into lysosome after chronic stimulation. Ubiquitination 
of receptors is required for the interaction with ESCRT (endosomal sorting complex 
required for transportation) machinery which is responsible for trafficking ubquitinated 
receptors from early endosomes to late endosomes where receptors are degraded in the 
lumen of lysosome (reviewed in (56,77)). In contrast, non-ligand mediated or basal 
ubiquitination of GPCRs, such as chemokine CXCR7 receptor and protease activated 
receptor PAR1, is essential for retention of the receptor at the plasma membrane. In these 
cases, ubiquitination of lysine inhibits the constitutive internalization of the receptor by 
precluding binding of clathrin adaptor protein to the receptor (reviewed in (56,77)). The 
density of functional receptors at the plasma membrane is also regulated by 
polyubiquitination of GPCRs, which marks the misfolded GPCRs in endoplasmic reticulum 
for degradation. This has been illustrated for - and - opiod receptors as well as many 
other GPCRs (reviewed in (56,77)). Thus, post translational modification of GPCRs is 
essential for proper receptor signaling and appropriate cellular response. 
 
1.4.2 Post-translational modifications of heterotrimeric G proteins- Heterotrimeric G 
proteins (G) must be stably anchored at the plasma membrane to transmit signal. Lipid 
modifications that occur on G and G subunits serve as hydrophobic anchors (reviewed 
in (89,99)). 
All G subunits have a myristate and/or palmitate group covalently attached at or 
near their N-termini. While myristoylation occurs exclusively on G of the Gi family; all 
mammalian G subunits (except Gt) undergo palmitoylation. N- myristoylation involves 
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addition of 14-carbon fatty acid myristate through an irreversible amide bond to a glycine 
residue at the extreme N-terminus (after the initiating methionine has been cleaved). The 
reaction is catalyzed by N-myristoyl transferase, and enzyme with strict requirement for 
N-terminal glycine, followed usually by a serine or threonine (regulation of G-protein by 
covalent modification by C Chen). Thus, Gs subunits which have a N-terminal glycine but 
lack the serine or threonine are not subject to myristoylation. Palmitoylation represents 
attachment of a 16-carbon fatty acid palmitate through a thioester bond to a cysteine 
residue within the first 20 N-terminal amino acids of G subunits. Unlike the case for 
myristoylation, the biochemistry of palmitoylation is not well understood (reviewed in 
(89,93,99)).  
The G protein  subunits are covalently modified by the 20-carbon isoprenoid 
geranylgeranyl, or in the case of G1, G9, and G11 by the 15-carbon farnesyl moiety. 
These modifications occur on a C-terminal cysteine in the CAAX motif, in which cysteine 
is followed by two aliphatic amino acids and the X amino acid is any amino acid that 
specifies recognition by geranylgeranyl transferase or farnesyl transferase. Following 
prenylation G subunits undergo two consecutive modifications, that is proteolytic removal 
of the last three amino acids (-AAX) and caboxy methylation of the cysteine; however, the 
exact role of these two subsequent modifications are still not clear (reviewed in (89,99)).  
Lipid modification of G proteins is essential for their signaling function. Indeed, 
numerous site-directed mutagenesis studies have shown that elimination of lipid 
modification prevents G-proteins from localizing at the membrane and result in signaling 
defects (reviewed in (89,99)). 
Several G subunits have been shown to be phosphorylated at serine/threonine 
or tyrosine residues, with phosphorylation of Gz in human platelets being the first to be 
identified (reviewed in (93)). This phosphorylation reaction was catalyzed by protein 
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kinase C; and occurred on serine-27 and to a lesser extent on serine-16 in the N-terminus 
of Gz subunit, preferentially for the GDP bound form. PKC also mediates phosphorylation 
of G12 subunit which is present endogenously in human platelets. The phosphorylation 
occurs within the N terminal 50 residues but haven’t been mapped further. In both the 
cases, Gz and G12 when phosphorylated showed reduced interaction with G subunit. 
Phosphorylation of Gz also inhibits its interaction with RGS proteins, thus prolonging the 
activation of Gz (reviewed in (93)). Additionally, Gz is a substrate for phosphorylation by 
the p21 activated kinase (PAK1). Much like the PKC mediated phosphorylation, PAK1 
phosphorylates a serine residue in the N-terminus of Gz and inhibits its interaction with 
G subunit. In contrast, Gt is phosphorylated on serine by PKC and on tyrosine residues 
by the insulin receptor kinase with the physiological significance still unknown (reviewed 
in (106)). Additionally, Gs subunits have been reported to be phosphorylated by the 
kinase pp60 which belongs to the tyrosine protein kinase Src family. This phosphorylation 
event moderately increased the steady state GTP hydrolysis rate of Gs subunit (reviewed 
in (106)). 
Among G subunits, only G12 is reported to be phosphorylated on a serine residue 
in the N-terminus by PKC. Phosphorylation increased the affinity of G12 for Gi, thus 
promoting the formation of a more stable heterotrimer (reviewed in (93)). Phosphorylation 
of G12 was also reported to have an inhibitory effect on interaction with the effector 
protein, adenylyl cyclase but had no impact on the activation of PLC- , indicating 
selectivity in the effect of phosphorylation on effector activation by G12 (reviewed in (93)).  
Among mammalian G proteins, Gs, Gq, and Gi2 have been shown to be 
polyubiquitinated and targeted for degradation by the proteasomal pathway (107–109). 
Furthermore, it has been shown that this ubiquitination of G subunits is inhibited by the 
guanine nucleotide exchange factor, Ric-8, through a lesser known mechanism. However, 
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the importance of the interaction between the C-terminal of G subunits and Ric-8 for the 
suppression of polyubiquitination of G subunits is well established (109).  
 
1.4.3 Post-translational modifications of RGS proteins – Much like GPCRs and 
heterotrimeric G proteins, RGS proteins undergo modifications such as palmitoylation and 
phosphorylation. Although most RGS proteins do not contain consensus motifs for the 
covalent addition of either myristate or isoprenoids, but they do contain exposed cysteine 
residues undergo palmitoylation. Indeed, several RGS proteins, such as RGS4, RGS7, 
RGS10, RGS16, and RGS19 have been shown to be palmitoylated. Palmitoylation of RGS 
proteins regulates the localization as well as protein interactions of RGS. For example, 
abrogation of palmitoylation of RGS16 dampens its ability to interact with Gi and Gq 
subunits (reviewed in (110)).  
RGS proteins also undergo phosphorylation which can either enhance or inhibit 
GAP activity, based on the RGS and kinase involved. For example, RGS2 phosphorylation 
by protein kinase C (PKC) reduces its GAP activity, thus resulting in the increase of Gq/11 
signals (111). Similarly, phosphorylation of RGS16 by an unknown kinase reduced its GAP 
activity (112). These examples of phosphorylation represent a positive feedback loop to 
enhance receptor signals. On the other hand, the GAP activity of RGS-19 is increased by 
ERK-mediated phosphorylation, resulting in negative feedback regulation of ERK 
activation (113). Phosphorylation along with ubiquitination can also change the stability of 
RGS protein. This is evident for RGS7 which is subject to ubiquitination mediated 
proteasomal degradation and has a short half-life. However, phosphorylation of a p38-
recognition motif on RGS7 dampens its proteolysis, probably due to the stabilizing effect 
provided by an interacting partner (reviewed in (110)).  
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Thus, PTMs offer alternate regulatory mechanisms for G protein signaling; 
continued search and understanding of which can have important implications in the 
successful development of therapeutic targets. Indeed, constant addition of new PTMs 
from studies done in humans as well as model organisms, using traditional biochemical 
techniques as well as modern techniques such as mass spectrometry, have enormously 
contributed to the field. 
 
 
1.5 Yeast as a model organism 
The budding yeast, Saccharomyces cerevisae, is a powerful model organism for 
studying fundamental aspects of eukaryotic cell biology, including the G-protein signaling 
system responsible for the mating process(114). Indeed, the studies done in yeast played 
a significant role in establishing many signaling landmarks and paradigms, including the 
prototype RGS protein, Sst2(49,92,115,116). Furthermore, Saccharomyces cerevisae has 
been instrumental in understanding the roles of many PTM-based regulators including 
phosphorylation mediated regulation (117–119). Several aspects of yeast make it an 
attractive model to study G protein signaling system- (1) The G protein signaling pathway 
in yeast is very well characterized. Importantly, the pathway activation can be easily 
monitored with long established assays that probe into various steps in the pathway. (2) 
Many of the yeast proteins including G proteins have mammalian orthologs, which 
broadens the relevance of studies done in yeast to humans. (3) The yeast genome is fully 
sequenced and annotated. (4) The ease of genetic manipulation of yeast facilitates 
analysis of gene knockouts and point mutants. (5) Yeast can be used for large- scale 
protein expression and purification that facilitates proteomic studies(120).  
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1.5.1 The yeast mating pathway as a model for G protein signaling- The G-protein 
signaling system in yeast mediates the mating response, wherein the two mating types - 
MATa and MAT, fuse to form a diploid cell. This process is triggered by the binding of 
pheromones - a-factor and -factor secreted by MATa and MAT respectively - to its 
specific GPCRs. The -factor binds to Ste2 expressed only on Mata cells; whereas a-
factor binds to Ste3 expressed only on Mat cells(121). As with other G protein systems, 
receptor activation upon binding of a ligand (pheromone) stimulates the exchange of GDP 
to GTP on Gα (Gpa1) and dissociation of Gα (Gpa1) and G (Ste4/Ste18). The 
dissociated G (Ste4/Ste18) interact with multiple effector proteins, of which three key 
effectors are (i) the scaffold protein, Ste5 (ii) the p21-activated kinase Ste20, and (iii) the 
Cdc24/Cdc42/Far1 complex. Together, these interactions lead to the flow of information 
via the sequential activation of the four-tiered kinase cascade to nuclear transcription 
factors and other targets. The process culminates in the expression of about 200 mating-
specific genes (about 3% of the genome), arrest in the G1 phase of the cell-cycle, oriented 
growth (shmoos) towards the mating partner, and eventually fusion of the two mating cells. 
This entire process is well regulated and takes about 4h(121,122). 
Upon pheromone stimulation, the free Ste4/Ste18 interacts with Cdc24, the GEF 
for the small Ras like protein Cdc42. This interaction is abridged by a scaffold protein 
Far1(123,124). Both Far1 and Cdc24 shuttle between the nucleus and cytosol; and are 
sequestered in the nucleus in the absence of pheromone. On pheromone stimulation, 
Far1-Cdc24 accumulates in the cytosol and localize at the shmoo tip along with 
Ste4/Ste18; serving as a landmark for orienting the cytoskeleton during the polarized 
growth, presumably by generating a highly localized GTP-bound Cdc42(125–127). The 
exchange of GDP to GTP on Cdc42 facilitates its interaction with Ste20, which serves the 
dual role of localizing Ste20 to the membrane and activating the kinase(128). Moreover, 
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the direct interaction between Ste20 and Ste4/Ste18 also aids the localization of Ste20 to 
the membrane(129,130). Activation of the Ste20 triggers sequential activation of 
Ste11(MAPKKK), Ste7(MAPKK), Fus3(MAPK), and Kss1(MAPK). This three-tiered signal 
transduction module known as MAPK cascade, which is conserved throughout the 
eukaryotes, was first discovered in yeast. In yeast, a significant fraction of the pool of 
Ste11, Ste7, and Fus3 are bound to the scaffold protein, Ste5. Like Far1, Ste5 is present 
in the nucleus in the absence of pheromone stimulus and is exported to the cytosol after 
exposure to pheromone(115,131–133). Physical interaction between the RING domain of 
Ste5 and Ste4/Ste18, along with the interaction of PM and PH domains with the plasma 
membrane, localizes Ste5 to the membrane(134–136). This localization brings the MAPK 
cascade module in close vicinity to Ste20, thus, facilitating the sequential flow of activation 
from Ste20 to Ste11, Ste7 and finally to the mating-specific MAPK, Fus3 as well as the 
unscaffolded MAPK, Kss1. Fully-activated Fus3 is phosphorylated at two sites, T180 and 
Y182 (referred to here as di-phosphorylated or activated Fus3); and drives the mating 
process by phosphorylating many downstream effectors, primarily the transcription factor, 
Ste12 and the scaffold protein, Far1 (137). Ste12 induces the transcription of genes 
required for mating, whereas Far1 enables cell-cycle arrest and proper shmoo formation. 
Upon phosphorylation by Fus3, Far1 acts as a cyclin-dependent kinase (CDK) inhibitor 
and blocks exit from G1 phase of the cell cycle(138,139). The arrest of cells in G1 ensures 
all cells have only one copy of their genetic material prior to conjugation, thereby 
preventing aneuploidy. In parallel, the pheromone-dependent localization Far1 to the 
membrane, where the Ste4/Ste18-Far1-Cdc24-Cdc42 complex establishes a site for 
polarized growth by recruiting polarity proteins(124,127). All these events are highly 
coordinated and regulated at various levels. Several proteins and PTM-based regulators 
participate in the regulation of the G-protein signaling system, including a secreted 
protease (Bar1) that destroys α-factor pheromone(140,141), enzymes that modify 
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(ubiquitinate, phosphorylate) the pheromone receptors and promote their 
internalization(142,143), GAPs for both Gpa1Gα (Sst2) (49) and Cdc42 (Bem3, Rga1, 
Rga2)(144), and phosphatases (Msg5, Ptp2, Ptp3) that deactivate Fus3(145,146).  
Recent studies have also uncovered the unexpected role of the scaffold protein, 
Ste5, in restricting the mating pathway output. This inhibition is mediated by a partially 
phosphorylated form of Fus3, which is allosterically auto-phosphorylated at Y182 upon 
binding to the Fus3 binding domain (FBD) of Ste5(147). Additionally, Ste5 harbors four 
MAPK sites (T267, S276, T287, and S329), very close to a Fus3 binding domain (FBD) 
and proximal to the RING domain which binds to Ste4/Ste18. When phosphorylated by 
the mono-phosphorylated Fus3, these sites negatively regulate full activation of Fus3 and 
the pheromone response(148). Inhibitory phosphorylation at these sites is presumably 
short lived as the phosphatase, Ptc1, competes with Fus3 for access and de-
phosphorylates the inhibitory sites, enabling complete pathway activation(149) (Figure 
1.2). However, the exact mechanism by which Ste5 phosphorylation mediates the 









Figure 1.2 Working model of the mating pathway of Saccharomyces cerevisae. To 
facilitate clarity, a contemporary model of the pheromone pathway is shown here, which 
is inferred from prior studies described in the text. The mating pathway of Saccharomyces 
cerevisae is triggered in response to pheromone-dependent activation of the G protein 
coupled receptor, Ste2 and subsequent recruitment of Ste5 to the plasma membrane 
(PM), mediated by Ste5PM and Ste5PH domains as well as the Ste5RING domain that binds 
directly to free G/Ste4. Under resting conditions, Ste5/PM association and MAPK 
activation is disfavored due to hyper-phosphorylation at positions surrounding Ste5PM 
(sites marked as sticks), auto-inhibition of the Ste5PH domain through a competitive 
interaction with Ste5VWA, and the lack of free G/Ste4 that is sequestered by GDP-bound 
G/Gpa1. Pathway activation is also inhibited by the Ste5FBD, which allosterically activates 
Fus3 to promote phosphorylation of Ste5T287 and three other phosphosites proximal to 
Ste5FBD and Ste5RING (P-lollipops). Upon pheromone stimulation, cascade activation of 
MAP kinases relies on PM recruitment and stable association of Ste5 that is concomitant 
with several state changes including (but not limited to): (1) up-regulated expression of the 
phosphatase Ptc1, which competes with Fus3 for binding to Ste5FBD and promotes Ste5 
de-phosphorylation; (2) a large conformational change in Ste5 accompanied by de-
inhibition of Ste5VWA; and (3) MAPK cascade activation of Fus3 and Kss1. For simplicity, 
interactions involving proteins such as Ste20, Far1, Cdc42, Cdc24 and many more 
involved in shmoo formation are not shown. Central components of the model discussed 
extensively here as a framework for this work include the Ste5FBD and phosphoregulatory 
control by Fus3 and Ptc1 captured in part by (116,147,149), conformational dynamics and 
PM association of Ste5 captured in part by (150,151), and the role of G/Ste5RING as an 
essential feature for Ste5/PM association captured in part by (134). Several more 
contributions have been cited in the main text. 
 
1.5.2. Co-ordination between the mating pathway and other pathways- Yeast live in 
a dynamic environment and must coordinate multiple external and internal cues to make 
proper cell fate decisions. While stress conditions, such as an increase in external 
osmolarity (referred to as hyperosmotic stress), or depletion of glucose (nutrient stress) 
are common external stimuli; the phase of the cell cycle is an important internal clue. Both 
the stress signals and the cell-cycle cues are often co-integrated with mating signals. 
Thus, the yeast mating pathway serves as a unique model to study signal integration and 
cross-talk with other pathways (88,127,139,152,153).  
One such pathway is the HOG pathway which responds to hypersosmotic stress, 
and is composed of two independent branches, SHO1 and SLN1. Both of these branches 
converge on the MAPKK, Pbs2, which also serves as a scaffold for the upstream 
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MAPKKKs and the downstream MAPK, Hog1. Like the mating pathway, the HOG pathway 
employs a three-tiered kinase cascade consisting of sequential activation of Ste11 
(MAPKKK), Pbs2 (MAPKK) and finally Hog1 (MAPK)(154,155). Activated Hog1 
phosphorylates several cytoplasmic and nuclear targets to ensure rapid adaptation to 
hyperosmotic conditions, including the activation of a glycolytic enzyme Pfk26 that is 
involved in the production of glycerol precursors.  In fact, glycerol accounts for 95% of the 
solute accumulated during stress recovery(155,156). On the other hand, yeast adapts to 
nutrient limitation by adopting an altered morphological growth pattern referred to as 
filamentation(157). Interestingly, several components are shared between the HOG, 
filamentation, and the mating pathway; despite which the fidelity of the signal transduction 
pathway is maintained(154). Alternatively, cross-talk between these pathways ensures 
that stress response takes priority over mating during co-stimulation, by inhibiting the 
mating pathway via phosphorylation of key proteins in the signaling cascade. For instance, 
activated Hog1 inhibits the mating response by phosphorylating a protein kinase Rck2 and 
the adaptor protein Ste50, thereby inhibiting pheromone induced protein translation and 
dampening Fus3 (mating specific MAPK) activation(118,119).  
The mating signal is also integrated with the cell division status of individual cells. 
Indeed, mating pheromones induce a growth arrest at the G1 phase of the cell cycle only. 
Whereas, cells that have already passed the G1/S or “start” checkpoint, are refractory to 
pheromone arrest. While the inhibitory action of Far1 on Cdc28 is responsible for the 
growth arrest(138,158); the repression of pheromone signaling relies on the degradation 
of Far1 in a G1-cyclin (Cln1/2) dependent manner(159). Additionally, the G1/CDK activity 
phosphorylates a cluster of sites flanking the PM (plasma membrane binding) domain of 
Ste5, thereby disrupting the localization of Ste5 at the membrane, which is otherwise 
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critical for activation of the mating pathway(158). The G subunit, Gpa1, is also 
phosphorylated and ubiquitinated in response to cell cycle changes(88).  
Thus, stress response pathways as well as cell-cycle delay mating under 
suboptimal conditions, primarily through mediating post-translational modifications of 
multiple pathway components, identification of which continues to add insight into the 
mechanism. 
 
1.6. Overview of the dissertation 
In Dewhurst et.al., SAPH-ire (our in-house PTM-prioritization tool) was employed 
to reveal novel PTM regulatory elements in discrete protein families including the 
heterotrimeric G-proteins (160). This study revealed that N-terminal tail (Nt) of G protein 
gamma (G) subunits contain phosphorylation hotspots which have a high likelihood to 
have regulatory/impactful biological function (160). However, any correlation of these 
phosphorylation sites with a biological function was missing. 
 
1.6.1. State-of-knowledge of the G subunits (prior to this work) - In comparison to 
the precisely ascribed signaling roles of G subunits, those of G and G are rarely 
distinguished independently due to their obligate heterodimeric interaction. Within this 
context, G subunits have essential functionality as membrane anchors for G subunits, 
mediated through prenylation of cysteine residues in their C-terminal tails(35,161,162). 
Beyond this role, any additional signaling attributes of G subunits have remained 
somewhat elusive. Moreover, the structure of G subunits is significantly disordered 
(between 15% - 40%), and therefore unresolved by x-ray crystallography studies(160).  
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The vast majority of intrinsic disorder in G subunits is contained within the N-
terminal region of all G subunits throughout eukarya(160). Intrinsically disordered regions 
are often hotspots for PTMs, and PTM-dependent regulation is essential for G protein 
signaling. Structural analysis of PTM hotspots observed across all eukaryotic members of 
the G protein family recently revealed that G subunits, including yeast Ste18, exhibit 
PTM loads (number of PTMs observed relative to the residue length of the protein) 2-fold 
greater than any other signaling component, including GPCRs, RGS proteins, G and G 
subunits. Furthermore, nearly half of all G PTMs (41%) are condensed within the N-
terminal tail, which harbors 5-fold greater PTM load compared to the rest of the protein. 
Phosphorylation is the predominant modification in G subunits, nearly 60% of which are 
also found in the N-terminal tail. Finally, all G subunits harbor at least 2 serine or threonine 
residues in the tail region. However, the functional significance of the phosphorylation on 
the N-terminal tail of G subunits is unknown(160).  
 
1.6.2 Hypothesis and overview of main dissertation - This dissertation is founded on 
the broad hypothesis that the unstructured N-terminal tails of G subunits act as a 
phospho-regulator of G protein signaling. We tested this hypothesis in the eukaryotic 
model organism, Saccharomyces cerevisae, which harbors a single canonical G-protein 
signaling system that controls mating(121). As one of the most well-studied signaling 
pathway, the yeast mating pathway has been and continues to be instrumental in the 
discovery of various regulatory elements including the RGS protein and several PTM-
based regulators(80,87,88,92,163,164).  
The study presented in chapter 2 interrogates the role of G subunit N-terminal tail, 
Ste18-Nt, in the feedback regulation of the mating pathway. We show that Ste18-Nt is 
dynamically and rapidly phosphorylated in response to GPCR activation in a Fus3-
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dependent manner. Furthermore, we show that the phosphorylated Ste18-Nt, together 
with the inhibitory phosphorylation of the scaffold protein, Ste5, constitute a negative 
regulatory system that synergistically controls the activation of the MAPKs, Fus3 and 
Kss1. Moreover, phosphorylation of Ste18 and Ste5, weaken the binding between G 
and Ste5 and also prevent rapid and stable association of Ste5 at the plasma membrane. 
Elimination of this phosphor-inhibitory complex via point mutations on Ste18 and Ste5 
results in ultra-rapid and robust Fus3 activation and Ste5/PM recruitment. These results 
provide support for the broad hypothesis that G N-terminal tails function as intrinsically 
disordered PTM regulatory elements in G protein signaling systems, and also further 
resolve the underlying mechanism of feedback inhibition of the pathway. 
In chapter 3, we explore the possible role of phosphorylated Ste18-Nt in regulating 
cross-talk with stress-response pathways, such as osmotic and glucose stress. Here we 
show that Ste18-Nt undergoes phosphorylation in response to multiple independent 
stimuli such osmotic stress, and cell-cycle progression, including the previously described 
GPCR activation. Moreover, unlike the pheromone stimulated phosphorylation of Ste18-
Nt, the phosphorylation events in response to osmotic stress and cell-cycle were 
independent of Fus3. However, no effect of glucose deprivation was seen on Ste18 
phosphorylation. Extrapolating from the evidence for the inhibitory phosphorylation of 
Ste18, we propose a model in which phosphorylation of the intrinsically disordered N-
terminal tail of Ste18 inhibits premature activation of the mating pathway in conditions of 
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Heterotrimeric G proteins (G) are essential transducers in G protein signaling 
systems in all eukaryotes. In yeast, G protein signaling differentially activates mitogen-
activated protein kinases (MAPKs) – Fus3 and Kss1 – a phenomenon controlled by 
plasma membrane (PM) association of the scaffold protein Ste5. Here we show that 
phosphorylation of the yeast G subunit (Ste18), together with Fus3 docking on Ste5, 
control the rate and stability of Ste5/PM association. Disruption of either element alone by 
point mutation has mild but reciprocal effects on MAPK activation. Disabling both elements 
results in ultra-fast and stable bulk Ste5/PM localization and Fus3 activation that is 6-times 
faster and 4-times amplified compared to wild type cells. These results further resolve the 
mechanism by which MAPK negative feedback phosphorylation controls pathway 
activation and provides compelling evidence that G subunits can serve as intrinsic 
regulators of G protein signaling. 
 
 
2.2 INTRODUCTION  
Canonical G protein signaling systems – including 7-transmembrane G-protein 
coupled receptors (GPCRs), heterotrimeric G-proteins (G) and diverse effector 
proteins – comprise a highly conserved system enabling the transduction of extracellular 
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signaling molecules such as hormones, neurotransmitters, and chemokines (11,165). As 
one of the primary signal transduction mechanisms in eukaryotes, G protein signaling 
pathways control a wide range of processes in both single-cell and multi-cellular 
organisms such as yeast and humans (166–170). Owing to their high degree of structural 
conservation, fundamental mechanisms underlying the regulation of G protein signaling 
have emerged from empirical studies conducted across widely diverse organisms from 
yeast to human. Such attributes have also helped to solidify their prominent role as 
pharmaceutical targets for the treatment of human disease (171).  
The yeast model system for G protein signaling remains one of the most well-
characterized signaling pathways in history, and has been instrumental in the discovery 
of G protein regulatory mechanisms including regulators of G-protein signaling (RGS) 
proteins, and post-translational modification (PTM) based regulators (49,87,172–179). In 
budding yeast Saccharomyces cerevisiae, a single canonical G protein signaling pathway 
controls the process of mating, wherein two yeast of opposite and complementary mating 
type, MATa and MAT, fuse to form an a/ diploid cell (180). As in the case of multicellular 
organisms including mammals, G protein signaling in yeast is initiated by agonist-
dependent activation of a GPCR at the cell surface (180). In MATa cells, a single peptide 
mating pheromone ( factor) serves as the agonist of the pheromone GPCR, Ste2, and 
upon binding promotes the exchange of GDP for GTP on the Gα subunit (Gpa1). GTP 
binding stabilizes a conformational change in G and dissociation of the heterotrimer into 
G and Gβ (Ste4/Ste18) components (173,181). In yeast, G serves as the primary 
activator of the mating pathway whereas G serves primarily to sequester G (180). 
When not sequestered, G nucleates the formation of a protein complex at the plasma 
membrane that includes a p21-activated protein kinase (PAK; Ste20); a protein scaffold 
(Ste5) in complex with a MAPKKK (Ste11), MAPKK (Ste7), MAPK (Fus3), as well as 
 35 
additional proteins important for cell polarization (182,183). Activation of the pheromone 
response pathway through this process drives a phosphorylation cascade resulting in 
double phosphorylation (referred to here as di-phosphorylation or activation) of 
Kss1T183,Y185 and Fus3T180,Y182 – highly conserved orthologs of the human MAPKs Erk1 and 
Erk2 – which phosphorylate several targets necessary for a complete mating response. 
Once activated, Fus3 translocates to the nucleus wherein it phosphorylates the 
transcription factor Ste12 and other proteins necessary to drive a gene transcription 
program resulting in morphological change, cell cycle arrest, and eventual mating 
(137,184). Signaling is terminated by hydrolysis of GTP to GDP on the  G subunit and 
re-association of the heterotrimeric complex, a process that is accelerated by the RGS 
protein (Sst2) (49).  
Several aspects of pheromone pathway behavior – such as switch-like vs graded 
dose-responsiveness and differential activation of MAPKs Fus3 and Kss1 – have been 
linked directly to the Ste5 scaffold, which plays a major role in nearly all aspects of pathway 
control. Ste5 contains multiple domains that effectively tune the pheromone activation 
profile of Fus3, which binds to Ste5, distinctly from Kss1, which does not (Figure 1.2 in 
Chapter 1). The Fus3 binding domain (FBD) plays a critical role in this process by 
allosterically activating the autophosphorylation of Fus3Y182 (referred to here as mono-
phosphorylation) in a manner independent of pheromone stimulation (147). Mono-
phosphorylated Fus3 phosphorylates Ste5T287 and three other phosphosites proximal to 
the RING domain, which functions to inhibit full activation of Fus3 and the mating pathway 
(185). Inhibition is relieved in part by the action of the pheromone dependent phosphatase, 
Ptc1, which competes with Fus3 for FBD binding and dephosphorylates Ste5, failure of 
which (ptc1) prevents activation of Fus3 (149). 
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Within the context of G protein signaling, G subunits have been largely understood 
as membrane anchors for G subunits, and rarely have been studied in any other context. 
Phosphorylation of G12 has been shown to enhance the affinity of G for G subunits 
in vitro (186); and impact the activity of the G12 dimers toward specific effectors (187). 
Recently, we showed that G subunits across all eukaryotes harbor at least 2 
phosphorylation sites in their intrinsically disordered N-terminal tails, many of which have 
also been observed as phosphorylated in high throughput proteomics screens (188). Here, 
we show that the N-terminal tail of the yeast G subunit, Ste18, together with the 
Fus3/Ste5FBD docking interaction, constitute a negative regulatory system that 
synergistically controls the activation of Fus3 and Kss1 through a dynamic phospho-
inhibitory mechanism that prevents rapid and stable association of bulk Ste5 at the plasma 
membrane. Disruption of either side alone (by point mutation of Ste18Nt or Ste5FBD) results 
in minor but significant and reciprocal changes to the rate and amplitude of Fus3 activation 
and Ste5/PM recruitment, whereas combined disruption of both elements results in ultra-
rapid and robust Fus3 activation and Ste5/PM recruitment. We show that negative 
regulation is facilitated by weakened binding between G and Ste5 when both proteins 
are phosphorylated – a mechanism that may have emerged through co-evolution of the 
two distinct phospho-regulatory elements. Taken together, these data reveal a new way 




2.3 RESULTS  
2.3.1 The N-terminal tail of Ste18 is rapidly phosphorylated in response to GPCR 
activation  
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Like other G subunits throughout Eukarya, the terminal ends of Ste18, 
representing 20% of its residue content, are intrinsically disordered – most of which 
correspond to the N-terminal tail (Ste18Nt). This region in Ste18 (residues 1-13) harbors 
phosphorylation sites at Thr-2, Ser-3, and Ser-7, specifically (188,189). Phosphorylation 
of Ste18Nt produces a distinctive electrophoretic mobility shift in response to pheromone 
stimulation, which can be detected by SDS-PAGE and immunoblotting (188). Treatment 
with alkaline phosphatase eliminates the mobility shift in a manner that depends on the 
presence or absence of phosphatase inhibitors (Figure A.S1A). Moreover, phospho-null 
mutations (Ste18T2A, S3A, S7A; referred to here as Ste183A) and phospho-mimic mutations 
(Ste18T2E, S3E, S7E; referred to here as Ste183E) eliminate or restore the mobility shift, 
respectively (188). To determine a precise estimate of phosphorylation kinetics early and 
late after receptor activation, we surveyed the phosphorylation-dependent mobility shift of 
Ste18 in both long and short time course experiments (Figure 2.1A, A.S1B). We found 
that phosphorylation occurs almost instantaneously after receptor activation and is readily 
detectable within 30 seconds (Figure 2.1B, A.S1B). Maximum phosphorylation is achieved 
at ~80% of total Ste18 levels within 3 minutes with a t1/2 of 1.25 minutes (Figure 2.1B, 
inset). Phosphorylation remains stable for the duration of pheromone exposure up to 90 
minutes. Activation profiles for Fus3 and Kss1 MAPKs were consistent with their expected 











Surmising that Ste18 phosphorylation may depend on a kinase within the 
pheromone pathway, we monitored Ste18 phosphorylation in cells lacking single 
components of the pathway including: Ste20, Ste11, Ste7, Fus3, Kss1, in addition to the 
MAPK scaffold Ste5. We found that all kinases upstream of and including the scaffolded 
MAPK complex were necessary for robust phosphorylation of Ste18Nt in response to 
Figure 2.1. Ste18Nt is rapidly phosphorylated in response to GPCR 
activation. (A) Immunoblots of HA-Ste18, activated MAPKs (ppKss1 and 
ppFus3), and a protein loading control (LC) in wild type cells treated with 3M 
pheromone (-F) for the indicated time (long time course). (B) Quantification of 
pHA-Ste18 over short (black circles) and long (grey circles) time course periods 
in wild type cells. Data correspond to the percent abundance of phosphorylated 
HA-Ste18-Nt (pHA-Ste18) relative to total HA-Ste18 (mean ± S.D.; n=12). 
Short- and long-time course data were normalized to each other at 5 minutes. 
(C) MAPK activation profile in wild type cells from the long-time course 
experiment shown in A.  
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pheromone (Figure A.S1C, D). Kss1, which is rapidly phosphorylated after receptor 
activation but is not scaffolded by Ste5, is not required for pheromone-dependent Ste18 
phosphorylation. Since Ste18 phosphorylation should not be lost in fus3 cells if MAPKs 
upstream of Fus3 are responsible for phosphorylation, these data suggest that Fus3, but 
not upstream MAPKs are necessary. Other genes involved in the pheromone pathway 
that either regulate pheromone dependent kinase activation or are themselves 
pheromone-activated kinases had little to no effect when deleted from the genome (Figure 
A.S2). Taken together, these data demonstrate that Ste18 is rapidly phosphorylated in 
response to GPCR activation in a manner that requires Fus3.   
 
2.3.2 Phosphorylation of Ste18Nt and Ste5 function synergistically to delay Fus3 
peak activation in response to pheromone  
Considering that Ste18 is rapidly phosphorylated within seconds of receptor 
stimulation, we hypothesized that it must be a pre-requisite for proper pathway activation. 
Consistent with this hypothesis, we found that preventing phosphorylation of Ste18 
(Ste183A) resulted in a significant shift in peak activation of Fus3, which occurred twice as 
fast (15 minutes earlier) than in wild type cells (Figure A.S3 A,C). In contrast, activation of 
Fus3 and Kss1 in cells harboring the phosphomimic form, Ste183E, was no different from 
wild type cells, as would be expected if phosphorylation is a prerequisite feature required 
for normal pathway activation (Figure A.S3 A, B). Thus, Ste18 phosphorylation is required 
for delayed peak activation of the scaffolded MAPK Fus3 but has no effect on the 
activation of the un-scaffolded MAPK, Kss1.  
Negative feedback phosphorylation of Ste5, like phosphorylation of Ste18, occurs 
early/before the mating response and also requires Fus3. Therefore, we hypothesized that 
both elements may function in concert to delay Fus3 peak activation. This hypothesis was 
inspired, in part, by two points of indirect evidence that converge on Fus3 as a negative 
 40 
regulator of the pheromone response. First, rapid receptor-activated phosphorylation of 
Ste18Nt requires Fus3 (Figure A.S1), and activated Fus3 has been previously shown to 
counteract the stability of Ste5/PM association during the pheromone response (191). 
Second, Fus3-mediated negative feedback phosphorylation on Ste5 dampens the 
intensity of Fus3 di-activation in response to pheromone (190,192,193). Additionally, we 
considered as further evidence that stable Ste5/PM association is facilitated in part by the 
interaction of  the Ste5RING domain (Ste5138-214) with residues in Ste4 (Ste449-65) that are 
located in the coiled-coil structure formed by both G (Ste4) and G (Ste18) subunits and 
in very close proximity to where phosphorylation occurs in Ste18Nt (193).  
To test the hypothesis, we monitored phosphorylation of Ste18, Kss1, and Fus3 in 
cells that endogenously express different combinations of Ste18 phosphosite and Ste5FBD 
docking site mutants. Precise mutation of multiple sites within two essential binding 
surfaces (A and B) in the Ste5FBD (a.k.a. Ste5ND) prevents Fus3 docking, allosteric 
activation, and negative feedback phosphorylation of Ste5 (147). Interestingly, 
phosphorylation of Ste18Nt was unaffected by Ste5ND, suggesting that Fus3 docking to 
Ste5 is not necessary for Ste18 phosphorylation (Figure 2.2. A, B). As observed in 
previous experiments, peak activation of Fus3 occurred significantly early in Ste183A 
compared to Ste183E or wild type cells (Figure 2.2. C, E), whereas Kss1 activation was 
unaffected (Figure 2.2. C, D). In contrast, we found that peak activation of Fus3 (at 30 
min) and Kss1 (between 5-30 min) was significantly elevated but not early in Ste5ND cells 
harboring the wild type form of Ste18, an observation that is nearly identical with previously 
reported evidence (Figure 2.2. C-E) (190).  
We made several unique observations with yeast harboring both Ste18 and Ste5 
mutations in combination. First, peak activation of Fus3 occurs rapidly in Ste183A/Ste5ND 
cells, wherein neither protein can be phosphorylated (Figure 2.2. E, Table A.S2). 
Significantly, this response was 25 minutes earlier and nearly 1.5-fold greater in amplitude 
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than observed for Ste5ND alone and 3.6-fold greater than the response in wild type cells 
(Figure 2.2. E, Table A.S2). Neither this nor any other mutant showed abrupt differences 
in the pattern of pheromone-dependent Fus3 expression level compared to wild type cells, 
suggesting that differences in the intensity of activated Fus3 at early time points is due to 
Fus3 phosphorylation and independent of Fus3 expression (Figure A.S4A). Interestingly, 
Ste183A/Ste5ND, but not other cell types also exhibited morphological defects in the 
absence of pheromone, showing pronounced elongation in multiple cases (Figure A.S4B). 
Second, in cells harboring the combination of Ste183E and Ste5ND, Fus3 peak activation 
occurs early (15 min) and with no change in amplitude – nearly identical to the response 
in Ste183A/Ste5WT cells and indicative that phosphorylation restricted to either Ste18 or 
Ste5 is sufficient to elicit an equivalent outcome in Fus3 peak activation (Figure 2.2. E, 
Table A.S2). Complementary phos-tag analysis of Fus3 phosphorylation further suggest 
that either Ste18Nt phosphorylation or Ste5 phosphorylation (controlled by Fus3 docking 
on Ste5), can effectively inhibit the aberrant di-phosphorylation of Fus3 in the absence of 
pheromone (Figure A.S5). Moreover, preventing such control on both proteins together 
results in aberrant Fus3 di-phosphorylation in the absence of pheromone. Unexpectedly, 
activation of Kss1 was also affected by combined disruption of Ste18/Ste5. However, in 
contrast to Fus3, Kss1 becomes hyper-activated in Ste183E/Ste5ND cells (Figure 2.2. D). 
Further confirmation of these results was achieved by endpoint immunoblot assays 
conducted within the first 15 minutes of pheromone stimulation (Figure A.S4C-E).  
Evidence from MAPK activation analysis suggested that Ste18 and Ste5 
phosphorylation behave synergistically such that the combined effect of both produces an 
effect that is greater than the sum of their separate effects. Indeed, a quantitative test for 
synergy revealed that phosphorylated Ste18/Ste5 are synergistic in their control of Fus3 
peak activation time, but additive in their control of Fus3 peak amplitude, with an overall 
synergistic impact that is ~4x greater than the sum of effects contributed by Ste18 or Ste5 
 42 
alone (Table A.S2). Taken together, these data suggest that phosphorylation of Ste18 and 
MAPK docking/phosphorylation of Ste5 (heretofore referred to as the Ste18/Ste5 
phospho-inhibitory system) synergize to delay the activation and repress the amplitude of 














2.3.3 Together, Ste18/Ste5 phosphorylation delays bulk recruitment rate and 
reduces the duration of Ste5/PM association 
 Activation of Fus3 requires recruitment and stable association of Ste5 with the 
plasma membrane, and consequently, mutations that disrupt or enhance Ste5/PM 
association should be reflected by the kinetics and amplitude of Fus3 activation. To test 
this hypothesis, we monitored Ste5/PM association by fluorescence microscopy before, 
during, and after pheromone stimulation of yeast cells. We were unable to detect Ste5-
GFP at the PM in any cell that was not treated with pheromone (Figure 2.3. A, top). 
However, in as few as 23-26 minutes after pheromone stimulation, we observed robust 
PM accumulation of Ste5-GFP in all cell types – most noticeably in Ste183A/Ste5ND cells 
(Figure 2.3. A, bottom). Consistent with our hypothesis, preventing phosphorylation on 
both Ste18 and Ste5 (Ste183A/Ste5ND) resulted in robust accumulation of Ste5-GFP at the 
PM after 25 minutes of pheromone stimulation, reaching a level nearly 7-fold greater than 
that of wild type cells measured at the same time (Figure 2.3. B). However, no differences 
were observed in the protein levels of Ste5-GFP (Figure A.S6). Thus, the Ste5-GFP signal 
at the membrane reflects altered Ste5/PM accumulation rather than protein stability. 
Furthermore, these data suggest that the bulk recruitment rate of Ste5 to the PM – 
reflected in the number of Ste5-GFP molecules that accumulate at the PM per unit time 
Figure 2.2. Phosphorylation on Ste18 and Ste5 cooperate to prevent early 
and maximal Fus3 activation. Cells harboring the indicated combination of 
wild type or mutant versions of Ste18 and Ste5 were stimulated with 3M -F 
followed by quantitative immunoblot analysis of HA-Ste18 or activated Fus3 
and Kss1. (A) HA-Ste18 immunoblot in cells harboring wild type (WT/WT) or 
Ste5ND (WT/ ND). (B) Quantitative comparison of pHA-Ste18 from A (n=4) (C) 
Representative immunoblot for activated Kss1 and Fus3. (D) Quantitative 
comparison of activated Kss1 relative to wild type peak activation at 5 minutes 
from immunoblots shown in C. (E) Quantitative comparison of activated Fus3 
relative to wild type peak activation at 30 minutes from immunoblots shown in 
C.  (Mean ± S.D., n=12) (SE: short exposure, LE: long exposure, LC: loading 
control) 
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(i.e. total fluorescence intensity/time) – is significantly faster when phosphorylation on both 
proteins is prevented.  
To compare the relative rates and stability of Ste5-GFP/PM accumulation at the 
population level, we quantified the percentage of the cell population with Ste5-GFP 
localized at the PM as a function of time. Measured in this way, Ste5/PM accumulation 
data is more comparable to MAPK activation data, which is a population-based analysis. 
Preventing phosphorylation on both Ste18 and Ste5 (Ste183A/Ste5ND) significantly 
enhanced the rate at which the population of cells exhibited Ste5-GFP/PM accumulation, 
where 100% of the cells were responsive by 14 minutes (Figure 2.3. C, D). This effect was 
reverted to a wild type state in Ste183E/Ste5ND cells, mimicking the effects of reciprocal 
mutations on MAPK activation seen earlier. In contrast, Ste5ND cells exhibited an 
intermediate phenotype. As expected, mutations to Ste18 alone had mild average effects 
on Ste5-GFP/PM accumulation.  
Lastly, we also observed that Ste5/PM association was noticeably more stable in 
Ste183A/Ste5ND cells compared to all other strains, whereby the population of 
Ste183A/Ste5ND cells had maximal association for the longest time (141 minutes) 
compared to that of wild type or Ste183E/Ste5ND cells (Figure 2.3. E). In support of the 
hypothesis that this is promoted by more stable association between Ste4/18 and Ste5, 
co-immunoprecipitation (co-ip) experiments revealed significantly more (2-5x) Ste18 
immunoprecipitated with Ste5-GFP in Ste183A/Ste5ND cells compared to all other cell types 
(Figure 2.3. F, G). We conclude that rapid bulk recruitment of Ste5 to the PM and 
subsequent Fus3 activation in Ste183A/Ste5ND cells can be attributed in part to greater 
physical association between the two proteins in their non-phosphorylated states, and 
support evidence that phosphorylation of Ste18Nt and Ste5 together control bulk rate and 














Figure 2.3. Phosphorylation on Ste18/Ste5 regulates the rate and duration of 
Ste5 association at the plasma membrane. Cells expressing phosphorylation 
mutants of Ste18 with either Ste5-GFP or Ste5ND-GFP were treated with -factor to 
examine Ste5 localization by fluorescence microscopy (see Experimental 
procedures). (A) Representative fluorescent images showing cells with localized 
GFP signal at the membrane before (top) or 23-26 min post-pheromone treatment 
(bottom). (B) Quantification of total Ste5-GFP fluorescence at the shmoo tip in cells 
treated with pheromone.  (C) Time-resolved percentage of the cell population with 
Ste5-GFP localized at the plasma membrane in response to pheromone stimulation. 
(D) Zoomed view of the first 60 minutes from panel C. (inset) Time required before 
100% of all cells display Ste5-GFP at the shmoo tip. (E) Mean duration of Ste5-
GFP/PM association (at the site of an emerging or extant mating projection). (F) 
Immunoblot showing co-immunoprecipitation of HA-Ste18 with Ste5-GFP from 
pheromone treated cells. The lysate shown is 4% of the total lysate used for co-ip 
(see Experimental Procedures). (G) Quantitative analysis of immunoblots from co-ip 
in F.  Bars represent fold-enrichment of total HA-Ste18 relative to wild-type (Mean ± 
S.D., n=3). All microscopy data represents GFP signal scored in 8-14 cells with error 
bars depicting SEM in panel B.  
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2.3.4 Ste183E partially restores a switch-like mating response in Ste5ND cells  
Ste5 has been shown previously to be an important control point for the switch-like 
morphological response, which in wild type cells is controlled by competitive Ste5FBD 
docking by Fus3 and the phosphatase Ptc1 (149). Consequently, non-docking Ste5ND 
mutants, which cannot bind to either Fus3 or Ptc1, exhibit a graded morphological dose-
response. We hypothesized that Ste18 phosphorylation might also be involved in 
controlling the switch-like mating decision. To test this hypothesis, we performed 
microscopy-based dose-response experiments to quantify shmoo formation as a function 
of pheromone dose. Modeling the data with a sigmoidal dose-response curve with variable 
slope, we confirmed that wild type cells exhibit switch-like dose-responsiveness with a hill 
slope well above 1 (nHWT = 6.2) (Figure 2.4. A & Table A.S3). Similarly, Ste183A and 
Ste183E cells were also switch-like (nH3A = 6.3; nH3E = 3.7). We observed that Ste5ND cells 
are graded rather than switch-like (nHND = 0.97), consistent with previous reports (116,149) 
(Figure 2.4 B & Table A.S3). Disabling both regulatory elements (Ste183A/Ste5ND) 
produced a slightly more graded response (nH3A/ND = 0.85), exhibiting a hillslope lower than 
Ste5ND. Not surprisingly, Ste183A/Ste5ND cells also exhibited an elevated basal response 
that was ~3-fold greater than that of wild type cells, consistent with earlier results showing 
elevated Fus3 activation in these cells (Figures 2.2, A.S4B,C, A.S5). Expression of the 
phosphomimic form of Ste18 in the Ste5ND background (Ste183E/Ste5ND) resulted in a 
reversion of the analogue response in Ste5ND cells back to a switch-like state (nH3E/ND = 
2.7) (Figure 2.4. B & Table A.S3). Taken together, these data suggest that phosphorylation 
on Ste18 regulates the morphological mating switch in cells when Ste5 is incapable of 
docking with Fus3. Furthermore, these data suggest that Ste18/Ste5 phosphorylation 











2.3.5 Phosphorylation of the G subunit and MAPK docking on Ste5 appear 
simultaneously in the phylogeny of yeasts 
Figure 2.4. The switch-like morphological response to pheromone is 
regulated by Ste18-Nt phosphorylation when Fus3 cannot bind to Ste5. 
The morphological dose-response to mating pheromone represented by the 
cellular formation of a mating projection (i.e. shmoo) was quantified as a 
percentage of total cells in a population by DIC microscopy. Data were fit to a 
sigmodal dose-response curve with variable slope. (A) Effect of individual 
Ste18Nt phosphorylation mutations on the mating response. (B) Effect of 
Ste18Nt phosphorylation mutations in strains exclusively expressing the Fus3 
non-docking mutant Ste5ND. Error bars represent SEM across ≥ 200 cells per 
experiment. 
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Recent phylogenetic and experimental evidence has revealed that the Ste5 FBD 
domain arose ~130 million years ago and is almost exclusively found in the clad to which 
Saccharomyces cerevisiae belongs, but is also partially extant in V. polyspora  species, 
which contain a partial FBD that is moderately active (116). Having determined that the 
phosphorylation of the N-terminal tail of Ste18 and the Ste5FBD function synergistically to 
control signaling, we asked whether these two structural elements may have co-evolved. 
Comparison of the phylogeny of Ste18 and Ste5 fungal orthologs revealed compelling 
evidence in support of this hypothesis. Indeed, the appearance of the phosphorylation 
sites in the Ste18 intrinsically disordered region (phospho-IDR) coincides with the 
appearance of Ste5FBD (Figure 2.5 A, A.S7A). Furthermore, all extant members of the clad 
retain nearly 100% identity for sites of phosphorylation and MAPK binding that are 
essential to either element (Figure 2.5 B). A somewhat similar putative phospho-IDR was 
also found in the Ste18 ortholog from S. castellii and the distantly related Y. lipolytica, both 
species of which harbor 2 of the 3 phosphosites observed in S. cerevisiae, but exhibit 
dramatically different N-terminal IDR lengths (Figure A.S7B). When looking strictly within 
the phylogeny of Ste5-containing yeast species (excluding A. gossypii, which harbors an 
extraordinarily long N-terminal IDR), we observed a progressive lengthening over time of 
the N-terminal IDRs of Ste18 orthologs, culminating in a dramatic increase of 8-10 amino 
acid residues that appeared coincidently with the Ste5FBD (Figure A.S7C). Taken together, 
these data suggest that Ste18 and Ste5 phospho-regulatory elements arose at similar 











Figure 2.5. Coordinated phospho-regulation of Ste18 and Ste5 
evolved at the same time.  (A) Bootstrapped phylogenetic tree of Ste18 
orthologs from the Ascomycota phylum showing the evolutionary co-
occurrence of regulatory phosphorylation sites on the N-terminal tail of 
the G subunit and the FBD of orthologous Ste5 scaffolds. The presence 
of Ste5 orthologous proteins, functional Ste5-like FBDs, and N-terminal 
G phospho-regulatory intrinsically disordered regions (IDRs) are shown 
next to yeast species harboring each element. (B) Species that contain 
the synergistic regulatory element (Ste18Nt and Ste5FBD) are nearly 100% 
identical at phosphorylation site alignment positions in Ste18 and MAPK 
binding sites reported previously in Ste5 (Coyle et al., 2013). 
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2.4 DISCUSSION 
G subunits are recognized as having limited function as membrane anchors for 
G subunits in heterotrimeric G protein signaling systems (35,161,162). As such, their role 
in signal transduction beyond this function is generally perceived as benign. We previously 
revealed that G N-terminal tails are prominent targets of phosphorylation, indicating that 
they might also possibly be important signal regulators (188). Here we have demonstrated 
that phosphorylation of the G subunit in yeast regulates G protein signaling through a 
feedback phosphorylation mechanism that synergizes with MAPK docking-dependent 
phosphorylation on the protein scaffold Ste5.  
 
2.4.1 New insights into the regulation of Ste5/PM association and MAPK activation.  
For good reason, understanding the mechanism by which Ste5 coordinates mating 
pathway output has been a longstanding endeavor with many revisions over the last 10-
15 years. The primary function of Ste5 is to properly translate stimulus dose to MAPK 
response signals – a function that is facilitated by scaffolding of the MAPK cascade module 
(MAPKKK Ste11, MAPK Ste7, and MAPK Fus3). In resting cells, Ste5/MAPK and Ste5 
inter-domain interactions as well as phosphorylation prevent signaling from occurring 
spontaneously. Under such conditions Ste5 is distributed between the cytoplasm and the 
nucleus – a phenotype that is cell cycle regulated in part (194,195). Cytoplasmic Ste5 can 
still interact with all three components of the MAPK cascade module (151). However, Ste5 
is incapable of facilitating MAPK activation in this state due to inter-domain binding 
between Ste5PH and Ste5VWA domains (150) as well as inhibitory phosphorylation 
mediated by Fus3 and Ste5FBD interactions (147). Relief of inter-domain binding inhibition 
is mediated by pheromone-dependent accumulation of PIP2 in the PM, which, when 
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stimulated, promotes Ste5PH/PM association and de-inhibition of Ste5VWA allows for a 3-
fold increase in Fus3 phosphorylation over the inhibited state in vitro (150).  
Our evidence suggests that Ste5/PM association is also modulated by 
phosphorylation on Ste18 in addition to Ste5, both of which function synergistically to 
control Fus3 activation output. In a wild type cell, phosphorylation of both proteins slows 
the rate and restricts the amplitude of Fus3 activation, resulting in 30 minute peak 
activation (Ste18WT/Ste5WT). Engaging either only one element (Ste183E/Ste5ND) or the 
other (Ste183A/Ste5WT) produces an equivalent enhancement in peak activation and 
amplitude that is 2 times faster and 1.5 to 2 times more intense than in wild type cells 
(Figure 2.2. E). Disabling both elements (Ste183A/Ste5ND) results in ultra-fast and intense 
Fus3 activation that is 6 times faster and 3-4 times greater than the wild type response. 
We show further that the response in MAPK activation for these mutants correlates very 
well with the bulk rate and duration of Ste5/PM association, indicating that it is the 
dominant control factor for Fus3 activation profiles observed in each mutant.  
Considering our body of evidence in light of previous work by others, we propose 
a model in which the activation/deactivation of the Ste18/Ste5 phospho-inhibitory system 
is regulated differentially (Figure 2.6A). In a pre-stimulated state, Fus3 is mono-
phosphorylated and in this state is capable of phosphorylating Ste5 at up to 4 positions 
near Ste5FBD (Figure A.S5) (149), while Ste18 is also basally phosphorylated (Figure 2.1. 
& A.S1). This suggests that inhibition is partially engaged even before a pheromone 
stimulus. Upon addition of pheromone, the Ste18/Ste5 inhibitory elements become fully 
activated as both Ste18 and Ste5 become hyper-phosphorylated – demonstrated herein 
directly for Ste18 (Figure 2.1.), and presumed by an in vitro Fus3 kinase assay with Ste5 
(see supplemental figure 9 in  (149)). We propose that this constitutes the fully activated 
inhibitory element that is responsible for bulk inhibition of Ste5/PM association early in the 
pheromone response, as determined from the relative amounts of Ste5-GFP/PM 
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accumulation observed in Ste183A/Ste5ND compared to other cells (Figure 2.3.). 
Simultaneously, pheromone stimulates recruitment of Ptc1 phosphatase to Ste5FBD, which 
outcompetes Fus3 binding within 2 minutes post-stimulus and dephosphorylates the 
inhibitory feedback phosphosites on Ste5 (see supplemental figure 18 in (149)). Since as 
few as one occupied Ste5 phosphosite leads to inhibition of Fus3 di-phosphorylation (149), 
it is presumed that all four sites must be completely dephosphorylated. We propose that 
this constitutes a release by partial de-inhibition of the Ste18/Ste5 inhibitory element, 
which leaves the Ste18 element in-tact (phosphorylated), as can be seen by the fact that 
Ste18 phosphorylation remains unchanged during this time (Figure 2.2. B). We propose 
that as a consequence of having one phospho-inhibitory element still intact (phospho-
Ste18), the bulk recruitment of Ste5 to the membrane is permitted but relatively slow and 
the activation of Fus3 is delayed – not reaching peak amplitude until ~30 minutes post-
stimulus (Figure 2.1. C, 2.2. E, 2.3). This half-activated state of the Ste18/Ste5 system 
also controls the degree to which Ste18 co-immunoprecipitates with Ste5 and the degree 
to which Ste5/PM association occurs (Figure 2.3. G) – observations that correlate very 













In preventing phosphorylation on Ste18 and Ste5 (Ste183A/Ste5ND), we show that 
this system is necessary to delay what is otherwise ultra-fast and intense Fus3 activation 
(Figure 2.6. B). Consequently, Fus3 activation in this state appears to match the profile of 
Kss1 activation, which is not scaffolded (Figure 2.2. D/E). Again, the rapid bulk recruitment 
of Ste5 under these conditions (Figure 2.3), can explain this effect since rapid Ste5/PM 
Figure 2.6. Phosphorylated Ste18Nt and Ste5FBD constitute a dynamic 
phosphoregulatory system for pheromone signaling. (A) In response 
to pheromone, Ste18 is rapidly phosphorylated at its N-terminal tail (P-
lollipop). Ste5 is simultaneously phosphorylated via negative feedback 
controlled by Fus3/Ste5FBD docking (P-lollipops). Together, this constitutes 
a phospho-inhibitory system that prevents otherwise rapid Ste5/PM 
association. While not shown outright here, previous work implicates 
pheromone-stimulated expression of Ptc1 phosphatase and removal of 
inhibitory phosphorylation on Ste5 as the inhibition release (149) (dashed 
orange box). Consequently, the mating pathway is activated with a kinetic 
delay as evident by the slower rate of Ste5 association at the membrane 
and delayed peak activation of Fus3. (B) Cells engineered to prevent 
activation of the Ste18/Ste5 system (Ste183A/Ste5ND) respond ~6 times 
faster with ~4 times greater intensity than observed in wild type cells – a 
response that demonstrates synergy between the two phospho-regulatory 
elements (phosphorylated Ste18 and Ste5) in the system. 
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association is known to drive rapid de-inhibition of the Ste5VWA domain by promoting the 
association of Ste5PH with the plasma membrane – a mechanism that has been 
demonstrated previously by the Lim lab as an essential step to drive phosphorylation of 
Fus3 by Ste7 (150). Switch-like behavior of the pathway is also modulated in part by the 
Ste18/Ste5 phospho-inhibitory system, which controls Ste5/PM association – an 
observation that is consistent with previous reports demonstrating that Ste5FBD and 
Ste5/PM association regulate hillslope (116,151).  
Several pieces of evidence, both from our work and others, suggest that Fus3 is 
the major (if not primary) kinase for activating the phospho-inhibitory system. Fus3 
phosphorylates proline +1 sites on Ste5 (147), and on Ste18Nt (Figure. A.S3 C,D) – both 
sites of which emerged at the same time in the evolution of budding yeast (Figure 2.5). 
Second, Ste5/PM association is enhanced in fus3 compared to FUS3 cells treated with 
pheromone (196) – a phenotype that we also observe for the phospho-null mutant 
Ste183A/Ste5ND (Figure 2.3). Third, inhibition of an analog-sensitive form of Fus3 (fus3-
as2) serves to stabilize Ste5/PM association upon pheromone stimulation (191). 
Consequently, a Fus3-specific phosphatase such as Msg5, which has been suggested to 
synergize with Ste5 to repress Fus3 activation (197), will alter the ability of Fus3 to function 
as an activator of the system. Indeed, deletion of the Msg5 phosphatase in Ste5ND cells 
(Ste5ND/msg5) results in more intense, but not faster, Fus3 activation compared to wild 
type or either mutation alone (197), consistent with longstanding evidence that deletion of 
Fus3-specific phosphatases permits intense and prolonged Fus3 activation (198). Thus, 
modulation of Fus3 activity necessarily imparts both positive (gene transcription) and 
negative (Ste18/Ste5) feedback on the pheromone pathway, which will be affected by 
inhibition or deletion of the kinase.   
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2.4.2 G N-terminal tails as regulators of G protein signaling – from yeast to humans 
 Our data reveal the potential for G subunits to play more intricate roles in 
regulating G protein signaling – affective through PTM-altered protein interactions. As 
stated earlier, most eukaryotic G subunits are phosphorylated in their N-terminal tails, 
and all G subunits have the potential to be phosphorylated since serine and threonine 
are ubiquitous in eukaryotic G subunit N-terminal tails (based on data curated and 
reviewed by UniProt) (188). In yeast, we find that phosphorylation plays a major role in 
effector recruitment, but we do not observe evidence that it impacts heterotrimer 
association, which can be sensitively detected by monitoring Fus3 activation in yeast. This 
is consistent with previous reports that negative feedback by Fus3 does not impact 
heterotrimeric G protein dissociation (191). Thus, functional, GPCR-activated 
phosphorylation of G N-terminal tails is not a process restricted to yeast, and as we have 
shown here, can regulate G protein signaling output by modulating G effector binding.  
 
 
2.5 EXPERIMENTAL PROCEDURES 
Yeast strains and plasmids – Standard methods for cell growth, maintenance, and 
transformation of yeast, and for the manipulation of DNA were used throughout. Strain 
BY4741 (MATa leu2 met15 his3 ura3) and BY4741-derived mutants were used. 
Details of strainsused are listed in Table A.S1. Strains were constructed using the two-
step dellitto perfetto mutagenesis method (199) and confirmed by dideoxy sequencing. 
LRB341 and LRB345 strains harboring yck1 and temperature-sensitive yck2ts alleles 
were graciously provided by Dr. Lucy Robinson (200). Plasmids used in this study for 
kinase deletion screening (pRS316-CUP1-HA-STE18), were graciously provided (gift from 
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T. Chernova). Detailed method of strain construction is provided as Supplemental 
Information.  
Yeast cell culture and treatments – Yeast Strains were grown in YPD growth medium 
(Yeast Extract, Peptone, 2% Dextrose media) unless otherwise noted. All experiments 
were conducted with log phase cells between OD600 0.75-0.85 and stimulated with -
factor peptide hormone (Genscript) at 3µM final concentration, if required. Cells were 
harvested with trichloroacetic acid (5% final vol/vol) and frozen at -80C.   
For kinase screening, deletion strains carrying the pRS316-CUP1-HA-STE18 
plasmid were grown in synthetic media lacking uracil and other appropriate amino acids 
as necessary. Expression of HA-STE18 was induced by 100µM copper sulfate and cells 
were stimulated as described earlier. Detailed procedure is provided as Supplemental 
Information.   
Cell extracts and immunoblotting – Proteins were extracted by glass bead lysis in TCA 
as previously described (201). Protein concentration was determined by DC protein assay 
(Bio-Rad Laboratories). Protein extracts were resolved by 7.5% or 12.5% SDSPAGE and 
immunoblotted with epitope-specific antibodies (see entire list in Supplemental 
Information). Note that the current lot of Phospho-p44/42 MAPK antibody (Cell Signaling 
Technologies Cat # 9101) exhibits reduced detection sensitivity for activated Fus3 
compared to activated Kss1, which affects the ability to detect Fus3 activation in the very 
early stages of a pheromone response (i.e. before 1 minute). HRP conjugated secondary 
antibodies (goat-anti-rabbit, goat-anti-mouse or rabbit-anti-goat) were used for detection 
of reactant bands by chemiluminescence with ECL reagent (Perkin Elmer Cat #NEL 
104001EA). Immunoblots were quantified by high-resolution scanning and pixel 
densitometry using Image J software (202).  
Morphological response assay – The morphological response of STE18/STE5 mutants 
to -factor was measured as described previously (116,149) and detailed in Supplemental 
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Information. The morphology of the cells was determined, 3h post- pheromone stimulation, 
by differential interface contrast (DIC) confocal microscopy using a PerkinElmer 
UltraVIEW spinning disk confocal microscope. Number of cells with mating projections 
were counted as a percentage of total.  
Ste5-GFP localization assay – Live cells endogenously expressing either Ste5-GFP or 
Ste5ND-GFP were visualized by microscopy. To ensure visibility across all strains, we 
exposed cells to 10 M -factor followed immediately by deposition onto agar pads 
saturated with 30M -factor. Once deposited, cells were monitored by PerkinElmer 
Ultraview VoX spinning disk confocal microscope. Detailed procedure for image 
acquisition and quantification is provided as Supplemental Information.  
Co-immunoprecipitation – Cells endogenously expressing different combinations of 
wild type or mutant HA-STE18 and STE5-GFP were treated with 10M pheromone for 
20 mins followed by cell lysis and co-ip using anti-GFP mAb-agarose (MBL, #D153-8). 
Eluted proteins were separated by SDS-PAGE and immunoblotting with anti-GFP 
(Invitrogen, A11122) and anti-HA (Supplemental Information). 
Phylogenetic analysis – Ascomycota protein sequences were retrieved from the Broad 
Institute Fungal Orthogroups Respository 
(https://portals.broadinstitute.org/regev/orthogroups/). Multiple sequence alignments were 
achieved using MUSCLE with default parameters (203), 2004). Phylogenetic and 
graphical analysis of Ste18 and Ste5 sequence alignments were achieved using Unipro 
UGENE software (204). Bootstrap consensus trees were prepared using 100 (shown) and 
500 (not shown) iterations. Presence or absence of Ste5 or the Ste5FBD were determined 
from a combination of sequence alignment homology as well as previous phylogenetic 
analyses of Ste5 (Coyle et al., 2013).  
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Statistical analysis – Statistical analysis for quantifying immunoblots and microscopy 
data was achieved using Prism software version 6/7 (GraphPad Software Inc.). Statistical 
significance was determined by ANOVA tests.  
Supplemental Information in Appendix A 
Document S1. Supplemental Results, Discussion and Experimental Procedures; Table 
A.S1-A.S3 and Figures A.S1-A.S7.  
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Interrogating phosphorylation of the N-terminal tail of the G protein gamma subunit, 
Ste18, in response to multiple conditions 
Running title: Identification of Ste18 as a potential phospho-regulatory module for cross-





Ste18 is the G gamma subunit of the heterotrimeric G proteins in yeast 
Saccharomyces cerevisae and is critical for the mating pathway.  Like mammalian G 
subunits, Ste18 is commonly thought to have limited functionality as a membrane anchor 
for its obligate heterodimer partner, Ste4 (yeast G subunit).  Previously, we demonstrated 
a novel role of Ste18 in the regulation of G protein signaling. In this role, Ste18 required 
phosphorylation of the unstructured N-terminal tail of Ste18 (Ste18-Nt), a disordered 
region conserved in all G subunits. Phosphorylated Ste18-Nt along with Fus3 docking on 
the scaffold protein Ste5, mediated the negative feedback regulation of the mating 
pathway activation kinetics.  Here, we show that Ste18-Nt is phosphorylated under two 
independent conditions including cell-cycle progression, and osmotic stress- suggesting 
the role of multiple kinases. Interestingly, the dynamics of phosphorylation were distinct 
for each stimulus, and had no resemblance to the previously described GPCR activation 
dependent phosphorylation of Ste18-Nt (Chapter 2; (205)). These results suggest that 
Ste18-Nt may serve as a communication node between the mating pathway, cell cycle 
regulation, and osmotic stress; and may prevent activation of the mating pathway under 
sub-optimal conditions, probably through the Ste18/Ste5 inhibitory module described 
previously (Chapter 2; (205)). More broadly, these data provide additional evidence that 
 60 
G subunits – and their intrinsically disordered N-terminal tails – serve as PTM regulatory 




Heterotrimeric G-proteins composed of G, G, and G protein subunits are a 
family of signal transducing proteins that couple an enormous number of G-protein 
coupled receptors (GPCRs) to intracellular effector proteins (11). Together these proteins 
mediate a vast number of physiological responses, and dysregulation of these pathways 
contributes to many diseases, including blindness, cardiac disease, endocrine disorders, 
and cancer (2,5,54,55,206). G-protein signaling is initiated by the binding of an 
extracellular agonist such as neurotransmitters, hormones, chemokines, lipids and many 
more to GPCRs (11,12). Agonist-bound GPCRs act as guanine nucleotide exchange 
factors (GEF) that promotes the release of bound GDP by G subunit. The nucleotide free 
Gα-subunit then binds GTP, undergoes conformational changes within its switch region, 
and subsequently dissociates from the G-dimer, enabling both molecular entities to 
regulate the activity of their specific effectors. The intrinsic GTPase action of G subunit 
coverts GTP to GDP, facilitating the reassociation of G and G subunits, and 
subsequent deactivation of the G-protein signaling pathway(11,207). Regulators of G-
protein signaling (RGS) proteins accelerate inactivation by increasing the rate of G-
catalyzed GTP hydrolysis (208,209).  
Although the classical paradigm of G-protein signaling pathway is rather linear and 
sequential, accumulating evidences have revealed signaling via GPCRs is coupled with 
many other cellular pathways. These interconnections allow the cell to integrate multiple 
signals and generate appropriate response based on the net status of the pathway (210–
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212). This pathway interaction is called cross-talk and is crucial for shaping the 
controllability of the signaling networks. Misregulation of cross-talk between signaling 
pathways can lead to various diseases, such as Alzheimer’s disease (213,214), head and 
neck squamous cell carcinoma (215), and cardiac arrhythmia (216,217), to name a few. 
A prototypic experimental model used for studying cross-talk between signaling 
pathways is Saccharomyces cerevisae, specifically between the mating pathway, and 
stress-response pathways such as high osmolarity glycerol (HOG) pathway, filamentous 
growth pathway, as well as cell-cycle phase (88,139,218,219). Mating is the process by 
which two opposite mating types-MATa and MAT, fuse to form an a/ diploid cell and is 
controlled by G-protein signaling system (173). As in mammalian cells, receptor activation 
by the binding of stimuli (pheromone) causes dissociation of Gα (Gpa1) and G 
(Ste4/Ste18) subunits. In yeast, free Gpa1 serves to sequester Ste4/Ste18, which is 
responsible for activating a scaffolded protein kinase cascade consisting of Ste20 (p21 
activated kinase, PAK), Ste11 (MAPKKK), Ste7 (MAPKK), Fus3 (MAPK), and Kss1 
(MAPK) (173). Direct interaction between Ste4/Ste18 and the MAPK scaffold protein Ste5 
organizes each kinase into a protein complex that drives the phosphorylation cascade 
(220,221) culminating in dual phosphorylation and activation of Fus3 – a highly conserved 
ortholog of the human MAPK Erk1/2, and the primary pheromone-responsive MAPK in 
yeast. Full scale activation is switch-like in its response, due in part to the interaction of 
Fus3 at two distinct positions on Ste5: a productive but weak binding site distal to the G 
binding surface that enables full activation of the MAPK; and a non-productive strong 
binding site, proximal to the  G binding surface (147,185). Recently, we discovered that 
Fus3-dependent phosphorylation of G (Ste18) at its N-terminal tail and of Ste5 at 4 MAPK 
phosphorylation sites near the proximal binding site synergistically controls the rate at 
which the Ste4/Ste18/Ste5 complex is formed at the plasma membrane. Thus, unearthing 
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a novel role of phosphorylated G in negative feedback inhibition of the pathway (Chapter 
2; (205)). 
Yeast in which cell cycle progression is un-coupled from pheromone signaling 
results in aneuploidy, and strongly favors the fusion of cells during G1 phase when a single 
copy of each haploid genome is present (139). Similarly, yeast in which the hyperosmotic 
stress and pheromone pathways have been un-coupled undergo fewer successful mating 
events, illustrating the evolved capacity of yeast to avoid energy expenditure towards 
mating when they encounter stressful environments (118,222). Indeed, mechanisms that 
coordinate the mating pathway with the cell cycle have been discovered previously, 
including the cell cycle-dependent nuclear export and protein stability of the Ste5 scaffold 
(132), the phosphorylation-dependent ubiquitination of Gpa1 (88), the phosphorylation 
and activation of Ste20 (PAK) (219,223) and the prominent effect of cell cycle arrest at 
START by the cyclin-dependent kinase (CDK) inhibitor, Far1, itself a cell cycle-regulated 
protein (139,153).  Likewise, an altogether separate mechanism prevents yeast mating in 
the presence of hyperosmotic stress, whereby the osmo-sensitive MAPK, Hog1, 
phosphorylates Ste50, a MAPKKK-interacting protein, that blocks the pheromone-
dependent phosphorylation cascade necessary for a mating response (118,119). Yet 
another pathway coordinates mating with nutrient stress, promoting pseudohyphal or 
invasive growth that may serve as a way for starving yeast to forage for a food source 
(157,222). In all cases, these stress response pathways mediate the phosphorylation of 
several components in the mating and other pathways, which prevent yeast cells from 
mating under sub-optimal conditions. 
As with the GPCRs, the heterotrimeric G-proteins represent an ancient protein 
family that has been highly conserved over evolution. 23 G 5 G, and 13 G protein 
subunits have been identified in humans, resulting in large number of potential 
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heterotrimeric G protein complexes(30). While the signaling roles of G subunits are 
precisely ascribed, those of G and G are rarely distinguished independently due to their 
obligate heterodimeric interaction (16,224–227). G and G subunits form an obligate 
heterodimer and act as a stable structural and functional monomer (16,228). The structure 
of G shows that G forms a seven bladed propeller structure consisting of seven WD40 
repeats, while the N-terminus forms an -helix; G subunit consists of two -helices that 
extensively interacts with the -helix as well as several of the WD40 repeats of G subunit. 
The protein-protein interactions that drive G function are thought to be primarily provided 
by G subunits (123,130,193,229–231).  In contrast, the primary function of G subunits 
is to anchor G subunits to the plasma membrane (232). Indeed, all eukaryotic G subunits 
are prenylated at their C-terminus, which is essential for membrane anchoring of the G 
heterodimer (161,162), but has also been shown to be involved in controlling the 
interaction of G with G subunits (233), GPCRs (35,234), and downstream effectors 
(227). Beyond this role, any additional signaling attributes of G subunits have remained 
somewhat elusive.  
We recently revealed that all proteins in the G subunit family, including the yeast 
G subunit Ste18, contain an intrinsic disordered region (IDR) through the first 8-15 
residues of their N-termini (G-Nt) (188). Much like the C-terminal IDRs of GPCR C-
terminal or histone N-terminal tails (235–237), G-Nt is a predominant site of PTMs. 
Indeed, 41% of all G PTMs, 56% of which correspond to phosphorylation, are clustered 
within G-Nt (188). In Choudhury et. a. 2018, we showed that phosphorylation of G-Nt 
coupled with phosphorylation of G effectors can prevent binding and inhibit MAPK 
signaling in the eukaryotic model organism, Saccharomyces cerevisae (Chapter 2; (205)). 
Thus, G subunits, besides acting as anchors for their obligate G subunits by virtue of 
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their C-terminal prenylation, also mediates negative feedback regulation of G protein 
signaling via phosphorylation of its N-terminal tail (Chapter 2; (205)).  
Phosphorylation events which occur on intrinsically disordered regions of proteins 
often serve as hubs in the signal flow allowing a rapid method for signaling pathways to 
cross-talk with each other and have functional consequences on downstream signaling 
(238). Thus, identification of phosphorylation on proteins with the potential to regulate 
integration of multiple stimuli or cross-talk between signaling pathways is critical. Here, we 
investigated whether the N-terminal tail of yeast G, Ste18, is phosphorylated in response 
to stress conditions such as nutrient stress and osmotic stress, as well as cell cycle phase; 
and thus, could potentially act as hub for cross-talk mediated regulation of G-protein 
signaling. We show that Ste18 is indeed phosphorylated within its N-terminal IDR in 
response to multiple independent stimuli such as cell-cycle progression and osmotic 
stress. Surprisingly, a systematic screen for phosphorylation-deficient genetic mutants 
revealed that Hog1 and other kinases in the osmotic pathway are dispensable for 
phosphorylation of Ste18-Nt under osmotic stress. Thus, further work is required to identify 
the underlying osmotic stress kinase and cell cycle regulated kinase. Taken together with 
evidence for the synergistic inhibitory phosphorylation of Ste5 and Ste18 that mediates 
negative feedback regulation of G-protein signaling (Chapter 2; (205)), we propose a 
similar mode of action for cross-talk mediated regulation.  
 
 
3.3 Results  
3.3.1 The N-terminal tail of Ste18 is transiently phosphorylated in response to 
osmotic stress but not nutrient stress 
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Like other G subunits throughout Eukarya, the terminal ends of Ste18, 
representing 20% of its residue content, are intrinsically disordered – most of which 
correspond to the N-terminal tail (Ste18-Nt). This region in Ste18 (residues 1-13) also 
harbors phosphorylation sites at Thr-2, Ser-3, and Ser-7, specifically (188). We 
demonstrated previously that phosphorylation of Ste18-Nt produces an electrophoretic 
mobility shift in Ste18, which can be detected by SDS-PAGE and immunoblotting (Chapter 
2; (205)). Previously, we observed that rapid and prolonged phosphorylation of Ste18-Nt 
is stimulated in response to -factor pheromone GPCR activation (Chapter 2; (205)). Here 
we show that phosphorylation of Ste18-Nt occurs in response to osmotic stress but is 
insensitive to glucose limitation stress (Figure 3.1). Whereas the phosphorylation 
response to pheromone is prolonged (Chapter 2; (205)), the response to osmotic stress 
is robust but short-lived – nearly matching the kinetic profile of high osmolarity glycerol 
(HOG) pathway activation of the p38 MAPK ortholog, Hog1 (Figure 3.1 A-C). Interestingly, 
the phosphorylation of Ste18-Nt was independent of Hog1(Figure B.S1), which is the key 
kinase reported to inhibit cross-talk between HOG pathway and mating pathway  (117–
119). Indeed, elimination of any of the kinase directly involved in the pathway were 
dispensable for Ste18 phosphorylation (Figure B.S1). Thus, further work is required to 













3.3.2 Cell-cycle dependent phosphorylation of Ste18-Nt  
 
We next asked whether phosphorylation could be promoted by cell cycle 
dependent transitions in the absence of pheromone. We synchronized cells in G2/M phase 
with nocodazole and monitored phosphorylation of Ste18-Nt after release into fresh 
medium. To validate the arrest and release protocol, we monitored the abundance of the 
mitotic cyclin Clb2, which exhibits peak expression in G2/M phase and is rapidly degraded 
by the anaphase-promoting complex upon exit into G1 phase (239). Consistent with the 
hypothesis, we observed a slow, cell cycle-dependent increase in Ste18-Nt 
phosphorylation, reaching a maximum level at 75 minutes post-release and gradually 
Figure 3.1. Ste18-Nt is phosphorylated in response to osmotic stress. 
Cells were exposed to either 0.75M KCl (A-C), or 0.05% dextrose (D-F) for the 
indicated times. (A) Representative immunoblots of HA-Ste18, activated 
MAPKs (pKss1, pFus3 and pHog1), and a protein loading control in response 
to osmotic stress. (B, C) Averages and standard deviations of HA-Ste18 
phosphorylation percentage (%pHA-Ste18) and activated MAPKs (relative to 
maximum), representing three independent colonies/experiments quantified 
from (A). (D- F) Immunoblots and quantitative graphs showing the 
phosphorylation of Ste18 in response to glucose depletion. 
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decrease thence after (Figure 3.2). This trend was inversely related to Clb2 abundance, 



















As expected, neither Kss1 nor Fus3 MAPKs were activated as a consequence of 
the arrest or release conditions (Figure 3.2), and are therefore unnecessary for cell cycle 




Despite their essential role in G-protein signaling, G subunits have been largely 
overlooked for their potential to regulate G protein signaling. While considerable evidence 
Figure 3.2. Ste18-Nt phosphorylation is cell cycle regulated and G1-phase 
specific. Cells were synchronized in G2/M phase by treatment with 
Nocodazole followed by release into fresh medium and time course sampling 
for 3 hours. (A) Representative immunoblots showing the phosphorylation of 
HA-Ste18-Nt in asynchronous log-phase cells (AS), nocodazole-synchronized 
cells (S), and at different time points after release. Each sample was also 
blotted for Clb2, activated MAPKs pKss1 and pFus3, total Kss1 and Fus3, and 
loading control (LC). (B) Quantification from three independent experiments 
showing the average and standard deviation of pHA-Ste18 phosphorylation 
percentage (left axis) in each sample. Clb2 abundance is shown as a 
percentage relative to the maximum signal achieved in the synchronous cell 
culture (right axis). 
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supports the functional significance of PTMs on G and G subunits (174,175,177–179), 
G subunits are recognized as having limited function as membrane anchors for G 
subunits (161,162). We previously demonstrated that all eukaryotic G subunits contain a 
structurally conserved, intrinsically disordered N-terminal tail (G-Nt) that is enriched with 
phosphorylation hotspots predicted to have a high probability of biological impact on G 
protein signaling (188). Using yeast as a model organism, we further showed that 
phosphorylation in the intrinsically disordered region of G subunit (Ste18) participates in 
the negative feedback regulation of G-protein signaling. In this role, Ste18-Nt and the 
scaffold protein, Ste5, is phosphorylated by the MAPK, Fus3. Together, phosphorylated 
Ste18-Nt and Ste5, synergistically inhibit G-protein signaling (Chapter 2; (205)). In this 
study, we extend the array of stimuli that regulate Ste18-Nt phosphorylation Taken 
together, we propose that the N-terminal tails of G subunits are likely to have regulatory 
function in mammals and other eukaryotic G-protein signaling systems. 
 
3.4.1 N-terminal tail of yeast G, Ste18 is phosphorylated under multiple conditions 
We have found that phosphorylation of Ste18-Nt is regulated under three 
independent conditions, (i) GPCR activation (Chapter 2; (205)), (ii) cell cycle progression 
(G1 phase), (Figure 3.2) and (iii) hyperosmotic stress (Figure 3.1A, B). Previously we had 
shown that the GPCR activation mediated phosphorylation of Ste18 required Fus3 (see 
Figure A.S1 C-D in Chapter 2; (205)). However, phosphorylation of Ste18-Nt observed in 
hyperosmotic stress conditions and in G1 phase of the cell-cycle, despite the evident 
absence of activated Fus3 kinase (Figure 3.1A and 3.2), highly suggests the role of 
conditionally-dependent multiple kinases. In yeast, the cyclin-dependent kinase Cdc28 is 
the central coordinator of cell-cycle progression. It does so by associating with specific 
cyclins at different cell-cycle phase, including Cln1/2 at G1 phase of cell-cycle (240). In 
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fact two proteins in the mating pathway, Ste20 and Ste5, are phosphorylated by Cdc28 
only when it is  associated with G1 specific cyclins Cln1/2 (152,194,241). This cyclin 
specificity is conferred by the presence of Cln1/2 docking motif LxxPx (where x is any 
amino acid and  is a hydrophobic amino acid) on both Ste20 and Ste5 (241). Interestingly, 
survey of the primary sequence of Ste18 highlighted the presence of a stretch of amino 
acids in the N-terminus region which partly resembled the Cln1/2 docking motif. This 
stretch of 16 residues (LQQPQEQQQQQQQLSL) has the LxxP and the x (LSL) 
residues interrupted by a stretch of hydrophilic residues. Although sequence variability in 
the docking motif has been previously shown in the case of Ste20, Ste5 as well as other 
Cdc28 substrates, such as Sic1, Bem3 to name a few (241), whether the sequence in 
Ste18 binds Cln1/2 needs to be experimentally determined. Based on this reasoning, we 
speculate the cell-cycle dependent phosphorylation of Ste18-Nt to be mediated by the 
Cdc28, though the specificity for Cln1/2 is uncertain.  
In conditions of hyperosmotic stress, we found the kinases involved in the 
activation of the HOG pathway dispensable for Ste18-Nt phosphorylation (Figure B.S1). 
This is in contrast to previous studies that have shown components of G-protein signaling 
pathway, such as Ste50 and Gpa1, to be phosphorylated in a Hog1-dependent manner, 
either directly or indirectly (117–119). However, many physiological changes including 
glycerol production, cell-cycle pause, changes in cell wall integrity, and a pause in protein 
translation occurs within seconds after exposure to hyperosmotic shock (242–245). 
Kinases involved in such processes could potentially play a role in phosphorylating Ste18-
Nt. Further screening of the yeast kinome deletion is required to determine the putative 
kinases of Ste18-Nt.  
In yeast, the mating pathway is well coordinated with other cellular events such as 
cell cycle (139,153,159,246,247) and hyperosmotic stress response (118). Indeed, 
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several components in the mating pathway are known to be phosphorylated in response 
to stress conditions and cell-cycle stage, providing a mechanism for pathway 
regulation(88,118,175,219,223,248,249). Consequently, we envision that the dynamic 
phosphorylation of N-terminal tail of Ste18 under various conditions, serves to coordinate 
the mating, cell-cycle, and osmotic stress pathways. Indeed, post-translationally modified 
intrinsically disordered tails acting as regulatory hub for various pathways is a common 
theme in cellular signaling and regulation (235,236). The ability to interact with different 
PTM “writers” (kinases in this case) is yet another characteristic of intrinsic disordered tails 
that serve as “regulatory handle”, further reinforcing the regulatory relevance of the N - 
terminal tail of Ste18 (235,236).  
 
3.4. 2 Phosphorylation of Ste18 may serve an inhibitory function to delay G-protein 
signaling under suboptimal condition. 
Earlier we had shown that phosphorylation of Ste18-Nt and Ste5 synergistically 
inhibit the mating pathway. Ste5 harbors four MAPK sites (T267, S276, T287, and S329) 
that are phosphorylated by Fus3, very close to a Fus3 binding site and proximal to the 
binding site for G[Ste4/18] (147). The inhibitory phosphorylation at Ste5 is presumably 
short lived due to the action of the phosphatase, Ptc1, which competes with Fus3 for 
access and de-phosphorylates the inhibitory sites, enabling complete pathway activation 
(149). Similarly, Ste18-Nt is phosphorylated in a Fus3-dependent manner. However, 
unlike Ste5, Ste18 phosphorylation is retained during this time and is therefore not likely 
the target of de-phosphorylation. When both substrates are phosphorylated, productive 
association of the scaffolding MAPK complex with the G subunit at the plasma 
membrane is disfavored due to charge repulsion (Chapter 2; (205)). The inhibition 
presumably remains unless Ste5 is dephosphorylated by Ptc1 to relieve charge repulsion.  
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The osmoregulatory or HOG pathway represses activation of the mating pathway 
and this repression requires the catalytic activity of Hog1 (117–119). Costimulation of 
yeast cells with pheromone and osmolyte (0.75M KCl) results in a delayed and dampened 
(i) activation of the mating pathway specific MAPK (Fus3), (ii) transcription of mating 
related genes, and (iii) morphological response such as shmoo formation (118). This 
Hog1- dependent repression of mating pathway occurs through two mechanisms. One 
way is by the negative feedback phosphorylation of Ste50, a shared component between 
HOG and mating pathway, required for activation of Ste11 (118,119). As a consequence 
of Ste50 phosphorylation, the activation of MAPKs in the mating pathway (Fus3 and Kss1) 
is attenuated (118). Additionally, cross-inhibition of mating pathway by Hog1 is mediated 
through phosphorylation and activation of Rck2, the negative regulator of translation. 
Activated Rck2 phosphorylates the yeast elongation factor EF2, and thus transiently 
represses translation (118). Interestingly, the function of Hog1 in limiting the mating 
pathway were only seen at later time points (30 mins onward) of co-stimulation; whereas 
the repression at early time points was Hog1-independent (see Figure 4 in (118)), hinting 
at the presence of another repression mechanism which operates at early time points.  
Here, we observed that Ste18-Nt is phosphorylated rapidly after salt stress, with 
phosphorylation of Ste18-Nt peaking at 15 minutes post osmotic stress. Although the 
kinetic of Ste18-Nt phosphorylation mimicked Hog1 activation, surprisingly Ste18-Nt 
phosphorylation was independent of Hog1. Thus, it could be possible that the Hog1-
independent repressive effect of salt seen at early time points (5 and 15 min) could be 
mediated through Ste18-Nt. Whether Ste5 participates in this inhibition is unknown. If the 
Ste18/Ste5 phospho-inhibitory mechanism (described earlier in chapter 2; (205)) did exist 
under stress condition, it will be short-lived since Ptc1 is expressed during osmoadaptation 
to prevent hyperactivation of Hog1 (250). The Ptc1 expressed during osmoadaptation 
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could also mediate de-phosphorylation and hence removal of inhibition from Ste5. 
However, these speculations will require further validation.  
 
3.4.3 Phosphorylated Ste18 may serve as a node to integrates pheromone and cell-
cycle cues.  
We have shown that Ste18 is a target of cell cycle dependent phosphorylation in 
G1 phase – independent of pheromone stimulation. Similar observations have been made 
for Ste5, as well as Ste20, both of which harbor cyclin docking sites that are essential for 
phosphorylation by the primary CDK in yeast, Cdc28 (241). In particular, Ste5 harbors 8 
CDK sites at its N-terminus, which flank a plasma membrane targeting domain that is 
essential for regulating the proximity of Ste5 to the G proteins and for activation of the 
pathway (194,251). Phosphorylation of these sites depends on G1 cyclin and occurs 
independently of MAPK binding to Ste5 (194). Phosphorylation at these sites disrupts Ste5 
membrane localization and restricts pheromone arrest to G1 cells; thus preventing 
inappropriate mating pathway activation in cells that have passed the Start check-point 
(158). 
Ste18 is also a target of G1 cyclin-dependent CDK phosphorylation and could 
potentially participate in cell cycle-regulated signaling competence in the presence and 
absence of other regulatory phosphorylation events on Ste5 and Ste20. An attractive but 
speculative possibility is that Ste5 is potentially phosphorylated at the 4 MAPK/Cdk sites 
proximal to the RING domain (currently unknown), which along with phosphorylation of 
Ste18 disrupts (Ste4/Ste18)/Ste5 binding. This inhibitory mechanism could synergize with 
the previously known inhibition mediated via phosphorylation of 8 sites flanking the PM 
domain, resulting in substantial accumulation of negative charge which is unconducive for 
Ste5/plasma membrane association (71). Interestingly, the Cdc28 docking site on Ste5 
shares multiple similarities with FBD- both Cdc28 docking motif and FBD lie in the same 
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interdomain region of Ste5, are proximal to the four inhibitory phosphorylation sites (T267, 
S276, T287, and S329), and show competitive binding with Ptc1 (72). However, cell-cycle 
regulated phosphorylation at these sites, even though these have the S/T-P Cdc28 
consensus sequence, needs to be determined for this speculation to hold true. Other 
possibilities include (i) inhibition of the (Ste4/Ste18)/Ste5 binding due to steric hindrance 
mediated by the docking of Cln1/2-Cdc28 on Ste5 in close proximity to the RING domain, 
and consequent inhibition of Ste5/plasma membrane association, or (ii) phosphorylated 
Ste18 may act in conjugation with phosphorylation of the 8 sites in the N-terminus region 
of Ste5 to prevent mating pathway activation. Further work is required to determine the 
precise role of phosphorylated Ste18 in cell-cycle regulation of the mating pathway. 
In conclusion, we have demonstrated multi-conditional phosphorylation of the N-
terminal tail of G subunit - a well conserved, but previously overlooked region of G. 
Previously, we had reported that phosphorylated G is inhibitory for mating pathway 
activation (Chapter 2; (205)). Here, we propose that the intrinsically disordered N-terminal 
tail of G subunit could potentially act as a phospho-regulatory hub for cross-talk between 
G-protein signaling pathway, stress response pathway and cell-cycle regulation. Thus, 
expanding the functional significance of G subunits in G-protein signaling, besides its 
well-known critical role as a membrane anchor for G subunit. Recent studies have also 
implicated the deletion of specific G subunits with various diseases (37,252–255).  Thus, 
the identification of new pathway regulators in yeast, which affect the basal activation 
and/or agonist efficacy, could not only facilitate our understanding of G protein signaling 
in mammalian cells but also reveal potential new drug targets. 
 
 
3.5 EXPERIMETAL PROCEDURES 
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Yeast strains and plasmids- Standard methods for cell growth, maintenance and 
transformation of yeast and for the manipulation of DNA were used throughout. Previously 
described BY4741 (MATa leu2 met15 his3 ura3) -derived mutant strain YMT 235 
endogenously expressing HA-Ste18WT was used. pRS316-CUP1-HA-STE18 and yeast 
knock-out (YKO) collection from open biosystems used for kinase deletion screen was 
graciously provided by Dr. Tatiana Chernova and Dr. Kirill Lobachev, respectively. 
Yeast cell culture and treatments - Yeast Strains were grown in YPD growth medium 
(Yeast Extract, Peptone, 2% Dextrose media) unless otherwise noted. Cells were grown 
at 30C with shaking at 250 rpm and cell culture density was determined by absorbance at 
600 nm. All experiments were conducted with log phase cells at OD 0.8-1.  Cells were 
then treated as per experimental requirement. 10 ml aliquots of treated cells were 
harvested with 0.5 ml trichloroacetic acid (TCA) on ice and centrifuged at 3724 x g in 
Allegra X-14R Beckman Coulter Centrifuge. Cells were then washed with 10 ml Mili-Q 
water, followed by transfer to microcentifuge tubes that were immediately frozen at -80C. 
Treatment conditions- GPCR activation- In order to activate the G protein signaling 
system, log-phase cells were treated with -factor peptide hormone (Genscript) at 3M 
final concentration. Cells were harvested as per standard protocol. 
Synchronization of cells with nocodazole-   Log phase yeast cells were pre-treated with 
1% dimethyl sulfoxide (DMSO) for 30 min at 30C. Nocodazole (100X stock solution- 
1.5mg/ml in DMSO) was then added to the cells at 15 g/ml final concentration. Cells were 
allowed to synchronize at G2/M phase for 3 h.  The synchronized cells were then released 
by washing the cells twice with MiliQ-water followed by resuspension in fresh medium to 
an A600 nm of 0.7 and growth at 30C (256). 
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Nutrient Stress- Log-phase cells grown in YPD containing 2% (w/v) D-glucose were 
centrifuged. Nutrient stress was achieved by washing the cells with YP medium containing 
0.05% (w/v) D-glucose and resuspending in 0.05% glucose medium for 15 min (175). 
Osmotic Stress- Cells were grown in synthetic complete media with 2% w/v D-glucose till 
A600 nm of 0.8-1. Osmotic stress was achieved by centrifuging the cells and resuspending 
in synthetic complete media with 0.75M KCl for the desired amount of time (118). 
Cell extracts and immunoblotting- Proteins were extracted by glass bead lysis in TCA 
as previously described (257). Protein concentration was determined by DC protein assay 
(Bio-Rad Laboratories). Protein extracts were resolved by 7.5% or 12.5% SDS-PAGE and 
immunoblotting with HA antibodies (Cell Signaling Technology, Cat # 3724) at 1∶5000, 
Phospho-p44/42 MAPK antibodies (Cell Signaling Technology, Cat # 9101) at 1∶500, Fus3 
antibodies (Santa Cruz Biotechnology, Inc., Cat # sc-6773) at 1∶500, Kss1 antibodies 
(Santa Cruz Biotechnology, Inc., Cat # sc-28547) at 1:1000, phospho-p38 MAPK 
antibodies (Cell Signaling Technology, Cat # 9216) at 1∶500, Clb2 antibodies (Santa Cruz 
Biotechnology, Inc., Cat # sc9071) at 1∶350,  Phospho-AMPK alpha (Snf1) antibodies 
(Santa Cruz Biotechnology, Inc., Cat # 4188) at 1:2000, and glucose-6-phosphate 
dehydrogenase (G6PDH) antibodies (Sigma-Aldrich, Cat #A9521) at 1∶50,000. HRP 
conjugated secondary antibodies (goat-anti-rabbit, goat anti mouse or rabbit anti goat) 
were used for chemiluminescent detection using ECL reagent (Perkin Elmer Cat # NEL 
104001EA). Immunoblots were quantified by high-resolution scanning and pixel 
densitometry using Image J software (202). 
Statistical analysis- Statistical analysis for quantifying immunoblots was achieved using 
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G-protein signaling system composed of G-protein coupled receptors (GPCRs), 
heterotrimeric G proteins (G), and downstream effectors mediate response to a 
tremendous variety of stimuli, such as light, hormones, neurotransmitters and many more 
(11,165,258). Aberration in G-protein signaling has been associated with a number of 
malignancies; and components of this pathway, especially GPCRs, represent the most 
important targets in modern pharmacology (1,3–6,259,260). Thus, G-protein signaling is 
one of the most exhaustively studied cellular process, with increasing efforts made to 
understand the intricate regulation of the G-protein signaling system through various 
mechanisms, including post-translational modifications (PTMs). 
As G-protein signaling system is conserved among species, molecular and 
systems-biology studies of this process in yeast have great relevance to human biology. 
Indeed, the baker’s yeast, Saccharomyces cerevisae, have had a long history of success 
for finding new pathway regulators, including regulators of G-protein signaling (RGS) and 
many PTM-based regulators (49,80,87,163,174,256,261).  
In yeast, mating pheromones activate G-protein signaling by initiating dissociation 
of the heterotrimeric G proteins (G) to G (Gpa1) and G (Ste4/Ste18), and 
transduction of signal from the released G (Ste4/Ste18) to downstream effector proteins 
(reviewed in (173)). The G effector protein, Ste5, which scaffolds the three members of 
the MAPK cascade – MAPKKK Ste11, MAPKK Ste7, and MAPK Fus3, but not MAPK 
Kss1- is an important factor in mediating signaling efficiency and specificity (185,262–
264). Upon pheromone stimulation, Ste5 is recruited to the plasma membrane through 
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collective stabilizing effect of three interactions- binding of Ste4/Ste18 to the RING domain 
of Ste5 (134,135,265–267), association of the N-terminal basic PM domain with the acidic 
phosphoinositides at the plasma membrane (158), and interaction of PH domain with PIP2 
in the membrane (136)- resulting in conformational activation of the VWA domain, a 
phenomenon that positively regulates cascade activation. Consequently, the activated 
Fus3 translocate to the nucleus where it activates the transcription factor, Ste12, that 
triggers the expression of mating specific genes, which leads to cell-cycle arrest and 
eventually mating (reviewed in (173)).  
Full-scale activation of the mating pathway is switch-like in its response and is 
regulated by another domain of Ste5- Fus3 binding domain (FBD). This domain is also 
involved in the inhibition of mating pathway activation (147,149,185). Ste5FBD allosterically 
mediates autophosphorylation of Fus3 to a monophosphorylated form (pFus3), which 
promotes Ste5 phosphorylation at four sites proximal to the RING domain, and through a 
previously unknown mechanism decreases the pathway output (147,185,268). 
Additionally, the phosphatase Ptc1, competes with Fus3 for binding to FBD domain, 
thereby regulating the overall phosphorylation status of Ste5 at the four sites (149). 
Interestingly, this Fus3-Ste5-Ptc1 circuit also regulates the switch-like mating process, 
wherein “non-docking” mutations of Ste5 which abrogate Fus3 binding to the FBD domain 
confers a graded mating response (149). However, the molecular mechanism underlying 
the negative feedback regulatory role of Ste5 was unknown. 
Similarly, little is known about the function of Ste18 (G subunit in yeast), besides 
its role as an anchor for Ste4 (G) by virtue of prenylation of the C-terminal region of Ste18 
(41). This scarce understanding about the functional relevance of G subunit is not 
restricted to yeast G but is the case with all eukaryotic G subunits, including the ones in 
human. Recently, we had showed that all eukaryotic G subunits possess an intrinsically 
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disordered N-terminal tail which harbors at least two phosphorylation sites (160). 
Moreover, the analytical component of our in-house PTM prioritization tool, SAPH-ire, had 
highly ranked these phosphorylation sites to have a potential function (160). However, the 
functional significance of these phosphorylation sites was still a mystery. 
This study aimed to determine the role of the phosphorylated G subunit in the 
regulation of G-protein signaling (if any). Using a yeast model system, this study 
demonstrates that the MAPK Fus3 phosphorylates Ste18 in a rapid and robust manner in 
response to GPCR activation, and this phosphorylation occurs in the N-terminal tail of 
Ste18. Interestingly, genetic mutants in which phosphorylation of Ste18-Nt was prevented 
(phospho-null Ste18, Ste183A) showed earlier activation of Fus3. Thus, phosphorylated 
Ste18 served as a negative feedback regulator of Fus3.  This study further shows that the 
phosphorylated Ste18 acts in synergy with phosphorylated Ste5 to regulate G protein 
signaling. Several findings corroborated this conclusion. First, mutants in which 
phosphorylation on both Ste18 and Ste5 was abolished (a dual mutant expressing 
phospho-null Ste18, Ste183A with the “non-docking” Ste5, Ste5ND), i.e. Ste183A/Ste5ND, 
showed augmented Fus3 activation which peaked 6 times faster and 4 times higher. 
Whereas, disruption of either inhibitory element alone (Ste183A/Ste5WT or Ste183E/Ste5ND) 
relieves partial inhibition resulting in minor change in the rate and amplitude of Fus3 
activation. Second, removal of phosphorylation from Ste18 and Ste5, through genetic 
mutations, led to greater interaction between Ste4/Ste18 and Ste5 as depicted by co-
immunoprecipitation assay. Third, as a consequence of the stronger interaction between 
Ste4/Ste18 and Ste5, yeast cells expressing Ste183A/Ste5ND displayed rapid and stable 
association of bulk Ste5 at the plasma membrane. Fourth, phylogenetic analyses of Ste18 
and Ste5 fungal orthologs revealed that the two phospho-regulatory elements (phospho-
Ste18 and phospho-Ste5) have co-evolved. Additionally, data presented in this work 
showed that this Ste18/Ste5 module controls the switch-like mating response to increasing 
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concentration of pheromone as well as the differential activation of Kss1. In conclusion, 
this study provides insights into the mechanism involved in feedback regulation of G-
protein signaling which proceed via synergy between the inhibitory phosphorylation of the 
N-terminal tail of Ste18 with the previously identified inhibitory phosphorylation of Ste5.  
Besides feedback mediated regulation of G-protein signaling, mating pathway in 
yeast is also subject to cross-inhibition during stress conditions and inappropriate cell-
cycle phase (117,118,127,158,159,219,222,249,256,269–273). Environmental stresses, 
such as high osmolarity and depletion of glucose to name a few, inhibit activation of the 
mating pathway in response to pheromone until the cell has adapted to stress (117–
119,222,271,272,274). Similarly, mating is prohibited in cells that have passed the START 
check-point (127,158,159,219,256,269,270,273). Several components of the mating 
pathway, including Ste50 (118,249), Rck2 (118), and Gpa1 (117) is phosphorylated during 
osmotic stress; while Ste20 (219), Far1 (153), and Ste5 (158) is phosphorylated in a cell-
cycle dependent manner. These phosphorylation events serve to inhibit activation of the 
mating pathway. In this study, we have identified Ste18-Nt as a target of cross-inhibition 
mediated phosphorylation during osmotic stress and G1 cell-cycle phase, but not during 
glucose depletion. We further speculate that the phosphorylated Ste18 could mediate 
inhibition of the mating pathway under sub-optimal conditions through a similar 
phosphorylated Ste18/Ste5 regulatory mechanism described above. 
Together, this study shed light on the previously unknown regulatory role of G 
subunits in G-protein signaling. In this role, the N-terminal intrinsically disordered tail of G 
acts as a PTM-based regulator to modulate the G/effector binding, consequently 
controlling the pathway output. Thus, the work done in this study has successfully 
expanded the relevance of G subunits in G-protein signaling, beyond its most appreciated 
role as an anchor for its obligate partner, G subunit (41). In fact, prior to this work, 
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functional attributes of G and G subunits were rarely distinguished independently; 
instead in most cases either G was considered as a functional monomer or G subunit 
was suggested to be the key player amongst the two proteins (4,275). Furthermore, this 
work suggests that the intrinsically disordered tail of G subunit could potentially act as a 
node for cross-talk between G-protein signaling pathway and other pathways. 
 
The conclusion from this study have been summarized below. 
1. G subunit in yeast, Ste18, is phosphorylated in response to GPCR activation 
by mating pheromone. This phosphorylation occurs in the intrinsically 
disordered N-terminal tail of Ste18. 
2. The mating-specific MAPK, Fus3, is necessary for pheromone-dependent 
Ste18 phosphorylation. 
3. Phosphorylation of Ste18, together with phosphorylation of the scaffold protein 
Ste5, synergistically mediate negative feedback regulation of Fus3 activation. 
4. The inhibitory effect of Ste18/Ste5 regulatory module is mediated through 
regulation of the rate and stability of Ste5 at the plasma membrane. 
5. The Ste18/Ste5 phospho-inhibitory module also regulates the switch-like 
morphological response to increasing concentration of pheromone. 
6. The Ste18/Ste5 phospho-inhibitory module co-evolved in fungal phylogeny. 
7. Ste18-Nt is phosphorylated in Fus3 and Hog1-independent manner when 
yeasts cells are exposed to osmotic stress. 
8. In the absence of pheromone, Ste18-Nt, like Ste5, is phosphorylated in cell-
cycle dependent manner, with maximum phosphorylation seen at G1 cell-cycle 
phase. Activated Fus3 is dispensable for this cell-cycle dependent 
phosphorylation. 
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9. Since the presence of an intrinsically disordered N-terminal tail with at least 
two phosphorylation sites is a conserved trait in all eukaryotic G subunits, this 
work can serve as a pioneer study for similar mechanisms in higher 
eukaryotes. 
 
4.2 FUTURE DIRECTIONS 
This study has provided an insight into the novel role of G subunit as a 
phosphorylation-dependent regulator of the G-protein signaling. Simultaneously, several 
research directions that might further our in-depth understanding of this novel regulatory 
unit, have opened up as a consequence of this study. Few of such questions have been 
discussed below. 
 
What is the design of Ste18-Nt phosphorylation? How does it affect the impact of 
the regulatory element?  
The intrinsically disordered N-terminal tail yeast G subunit, Ste18-Nt, harbors 
three phosphorylation sites (T-2, S-3, and S-7); thus, may exist in one of the 23 
phosphoforms, each corresponding to a particular pattern of phosphorylated sites. 
Moreover, the scope of regulation provided by each site may not be equal. Thus, 
identification of the phosphorylation site(s) is important to understand its mechanistic 
impact on the protein behavior.  
Analysis of the primary sequence of Ste18 revealed that S-7 but not T-2 and S-3 
has the signatory sequence S/T-P which promotes phosphorylation by MAPK/CDK. Using 
a genetic approach, our preliminary data shows that pheromone-dependent 
phosphorylation of Ste18-Nt occurs at a single site, S-7 (data not shown). Furthermore, 
the mobility shift of phospho-Ste18-Nt triggered in response to osmotic stress and cell-
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cycle phase is equivalent to the pheromone-dependent electrophoretic profile of Ste18. 
Thus, we propose that Ste18 is phosphorylated on serine-7 under these conditions as 
well; although experimental validation is still needed. Since, all eukaryotic G subunits 
contain two phosphorylation sites in their N-terminal region (160), an interesting question 
is whether T2 and/or S3 sites are amenable to phosphorylation in other (currently 
untested) condition(s)? Furthermore, investigating the contribution of each phospho-site 
in the regulatory mechanism depicted in this study might further our understanding of the 
regulatory role of Ste18.  
 
Does phosphorylated Ste18-Nt participate in cross-talk mediated inhibition of the 
mating pathway? 
It is well established that the mating process in yeast is coordinated with 
extracellular cues such as hyperosmotic stress, as well as intracellular cues such as cell 
cycle phase (118,119,222,271–273). Several components of the mating pathway are 
phosphorylated to limit the activation of the mating pathway when conditions are 
unfavorable (117,118,158,219,249,256). This work laid the foundation for the N-terminal 
tail of Ste18 as a phospho-regulator of G protein signaling. In this role, phosphorylated 
Ste18 synergizes with the scaffold protein, Ste5 to mediate negative feedback regulation 
of MAPK activation. In this study, we determined that Ste18 is phosphorylated in a cell-
cycle dependent manner and in response to osmotic stress. However, whether and how 
Ste18 phosphorylation contributes to the regulation of cross-inhibition of the signaling 
dynamics of the mating pathway in the presence of osmotic stress and G1 phase is yet to 
be determined.  
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Does similar phosphorylation dependent G/effector regulatory system occur in 
higher eukaryotes? 
The G-protein signaling system is one of the main signaling pathways in 
eukaryotes, ranging from the simplest eukaryotic organisms, such as the budding yeast 
S. cerevisiae, to much more complex eukaryotes, such as human (reviewed in (276)). The 
overall build of the system is similar, consisting of GPCRs, heterotrimeric G proteins, 
effector proteins and RGS proteins (reviewed in (276)). Both yeast and human utilize G 
proteins to respond to ligand binding by receptors that detect environmental cues. 
However, compared to yeast, which employs a single heterotrimeric G protein complex to 
transduce pheromone-dependent signals through a scaffolded MAPK complex (reviewed 
in (180)), G-protein signaling in humans, in which there are approximately 800 GPCRs, 
23 G, 5 G,13 G, multiple effectors, and 30 RGS proteins encoded by the genome, is 
much more complex (reviewed in (276)). Moreover, unlike in yeast, where G is the 
primary transducer of signal; both G and G are important transducers of signal in 
human (reviewed in (276)). As a result, discovering molecular mechanisms of G protein 
signaling and regulation is a comparatively simpler endeavor in the yeast model system; 
and the translation of such discoveries to other organisms may be more challenging in 
some cases and require special attention.  
Using yeast as a model organism, I discovered a novel regulatory role of G 
subunit in G-protein signaling. In this role, phosphorylated G (Ste18 in yeast) together 
with the phosphorylated G effector protein (Ste5) mediates inhibitory regulation of the 
activation kinetic of the MAPK (Fus3). The inhibition of MAPK activation is accomplished 
by disrupting the interaction between G (Ste4/Ste18) and a G effector (Ste5), by 
phosphorylation that occurs proximal to the binding sites on both proteins. Specifically, 
Ste18 is phosphorylated in its N-terminal intrinsically disordered tail, a region close to the 
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helical region of G which forms a coiled-coil structure with G that participates in the 
interaction between Ste4/18 and Ste5. Simultaneously, Ste5 is phosphorylated close to 
the RING domain serves as a G binding site. As a result of the reduced interaction 
between Ste4/Ste18 and Ste5, bulk recruitment of Ste5 to the plasma membrane is 
hampered, which leads to diminished and delayed Fus3 activation. At a fundamental 
level, I have identified a phosphorylation dependent G/effector regulatory system 
that inhibits pathway output in yeast. Hence, the most intriguing question that remains 
unexplored is whether a similar phospho-regulatory system exists in humans, wherein 
both G and effector protein phosphorylation inhibits/regulates G-protein signaling.  
In humans, multiple isoforms of G and G subunits combine to form specific 
combinations of G that associate with different G subunits and receptors, which in turn 
dictates the specificity of effector interaction and activation (277,278). The unique 
propeller structure of G confers interaction with various effector proteins such as adenylyl 
cyclase (isotypes I, II, IV, V, and VI), phospholipase C-  (PLC-), G-protein regulated 
inward rectifier K+ channels (GIRK), voltage gated calcium channels, and many more 
(reviewed in (4,275)). Besides the binding site on the propeller structure of G, other 
secondary binding sites have been suggested to occur on G that are used by certain 
effectors (reviewed in (4,275)). For example, the N-terminal region of G is one such 
secondary site important for interaction with adenylyl cyclase isotype II, GIRK1, and PLC-
2 (279,280). Thus, it is possible that phosphorylation of the N-terminus of G impacts 
activation of effectors. In fact, human G12 subunit when phosphorylated in its N-terminal 
region by protein kinase C negatively regulates activation of adenylyl cyclase II and cAMP 
production (91,187). This observation suggests that phospho-regulation of G-Nt is not 
restricted to the yeast G protein system. Furthermore, since most eukaryotic G subunits 
have the potential to be phosphorylated in at least two phosphorylation sites in their N-
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terminal tails (160), the phospho-regulatory role of G subunit could be a general rule 
which holds true in both yeast and humans. 
Several important questions should be explored to fully comprehend the role of G 
phosphorylation in humans. First, is to ask what are the dynamics of phosphorylation of G 
gamma isotypes in humans? Of the 13 isotypes of G, phosphorylation has been reported 
at one or more serine and/or threonine residues in the N-termini of G 2, 3, 4, 5, 7, 10, and 
12 (281–287). These phosphorylation sites were identified by high-throughput mass-
spectrometry based phospho-proteomic studies done in melanoma cell line (G2, 5, and 
10) (282), neurodegenerated brain (G3) (281), breast cancer cells (G5, and 10) (284), 
pancreatic and lung cancer cells (G12) (285,286), and in human epithelial cells treated 
with angiotensin (G12) (287). However, whether or not these G isotypes are 
phosphorylated in a GPCR activation dependent manner is yet to be determined. 
Additionally, the time and condition dependent dynamics of G phosphorylation as well as 
the underlying kinases should also be explored. For example, the phosphorylation 
dynamics of G12 can be determined in response to a time course stimulation of human 
endothelial cell lines expressing the angiotensin sensitive GPCR, such as the Mas. 
Additionally, in vivo strategies that employ screening of a deletion library of kinase to 
identify the kinase, followed by in vitro confirmation of the sufficiency of the kinase can be 
utilized to determine the kinase. As protein kinase C has previously been shown to 
phosphorylate G12 in vitro (187), any role of protein kinase C in the angiotensin 
dependent G12 phosphorylation can be investigated.  
The second major question to be explored should be, how does G 
phosphorylation affect interaction with other proteins? G subunits participate in either 
direct or indirect interactions with receptors, G subunit, G subunit, and effector proteins 
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(278–280,288–290). As an obligate partner of G, G interacts extensively to form the 
heterodimer G, wherein the N-terminal -helix of G is involved in a coiled-coil 
interaction with the N-terminal -helix of G and the C-terminal -helix of G extensively 
interacts with the base of the G propeller structure (reviewed in (4,275)). The N-terminal 
region of G also impart specificity to effector interactions (278–280,288,290). Moreover, 
specific G interaction with receptors also regulates guanine nucleotide exchange in the 
G subunit (289). Thus, phosphorylation of the N-termini of G subunits could affect the 
specificity and strength of interaction with receptors, G subunits, and effector proteins, 
and may also regulate conformational changes in the interacting proteins. Indeed, 
phosphorylation of the N-terminus of G12 has been reported to negatively control adenyl 
cyclase II (187). Thus, it will be interesting to test by an immunoprecipitation experiment, 
in vitro binding assay, and/or FRET based assay whether phosphorylation of G12 affects 
interaction with adenylyl cyclase II Interestingly, the activation of certain isotypes of 
adenylyl cyclase, such as type III and V, are inhibited in a phosphorylation dependent 
manner (291,292). Moreover, phosphorylation of human adenylyl cyclase type II has been 
demonstrated through high-throughput proteomic studies done in tumor samples 
(283,284,293), and has been implied to be phosphorylated by protein kinase C in rat (294). 
However, the regulatory effect of phosphorylation on the activation of adenylyl cyclase is 
unknown. Interestingly, three phosphorylation sites (Y452, S472, Y584) lie in the catalytic 
domain of adenylyl cyclase type II; and are close to the region (amino acid region 493-
509) that is important for interaction with G (295). Thus, another interesting question to 
probe is whether adenylyl cyclase type II is phosphorylated in a GPCR activation 
dependent manner in humans; and if so, whether it regulates binding and activation by 
G (similar to our findings in yeast).  
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 A third major question to be explored is whether G phosphorylation affects G-
protein signaling pathway output in mammals? The most important question is whether 
phosphorylation of G has any regulatory effect on the pathway output. Additionally, since 
G-protein signaling has major implications in health and disease (8,54,55,57) and 
phosphorylation of many G isotypes were identified in cancer cells or diseased cells 
(281–286); identification of the regulatory role of G (if any) in G-protein signaling can offer 
scope for new druggable targets. For example, angiotensin mediated activation of the 
GPCR, Mas, has important biological role in the pathophysiology of renal inflammation 
(296). Additionally, G12 has been shown to be phosphorylated in endothelial cells treated 
with angiotensin (287). Thus, it will be interesting to test if there is any regulatory effect of 
phosphorylated G12 in the activation of the pathway and eventually on renal 
inflammation.  
The fact that an intrinsically disordered structure has been retained throughout the 
evolution of G subunits further suggests that this feature is beneficial not only for yeast 
but also for other organisms. Intrinsically disordered regions (IDR) have continued to 
emerge as an important structural feature of N and C-terminal PTM regulatory elements, 
with classic examples such as the N-terminal tails of histones as well as the C-terminal 
tails of GPCRs, tubulin, and others (297–301). Further experimental evidence will help to 
determine whether not only the structure, but also aspects of function are conserved in G 
protein signaling systems in other organisms – for which there is considerable 
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Posttranslational modifications (PTMs) are covalent modifications of proteins 
following protein biosynthesis. One such modification, citrullination – deimination of 
arginine to citrulline by peptidyl arginine deiminases (PADs) - has recently received 
significant interest in biomedicine. Indeed, citrullination of the extracellular matrix (ECM) 
protein, fibronectin (Fn), is a common hallmark for the pathogenesis and detection of 
rheumatoid arthritis (RA), fibrosis and cancer metastasis. Nevertheless, the fundamental 
characterization of citrullination sites on Fn and its implication on physiological cell 
behaviors such as adhesion, migration and differentiation remain ill-defined. Here, we 
used high-resolution mass spectrometry to determine the site-specific citrullination status 
of Fn, catalyzed in vitro by PAD isotypes 2 and 4 – the most prevalent PADs in the 
pathophysiology of RA and fibrosis. We successfully identified 24 citrullination sites 
spanning the entire length of Fn, with maximum citrullination (7 sites) observed in the 
primary cell-attachment regions of the protein. Citrullination was specific in varying degree 
to the enzymatic activity of individual PADs. Interestingly, five citrullination sites (R1410, 
R1434, R1479, R1476, R1452) were in or near the canonical sites responsible for integrin 
binding (RGD and PHSRN). Additionally, cellular and biochemical analysis conducted by 
Stefanelli et.al. revealed that citrullination of Fn enhanced cell attachment and migration. 
This change in cell behavior was due to altered Fn-integrin binding dynamics, a switch in 
the integrin profile of a cell, and concomitant change in the activation of FAK-Src and ILK-
GSK signaling. Furthermore, they showed that citrullination of Fn represents a significant 
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means for recording inflammatory memories. Together, our collaborative effort has not 
only highlighted the impact of citrullination on cell behavior; but as the most 
comprehensive report of identification of citrullination sites in Fn, our study provides a 






Posttranslational modifications (PTMs) are covalent and enzymatic modifications 
of amino acid side chains or termini of proteins, resulting in a change in the function, 
localization, and/or interaction profile of proteins. Thus, by altering various properties of 
proteins, PTMs play central role in cellular physiology- an area of research that is 
becoming increasingly appreciated (reviewed in (302–304)). Indeed, the global analysis 
of type, dynamics, and function of PTMs of proteins are important goals in cell biology.  
Among different approaches to study PTMs, mass spectrometry (MS) – an 
analytical technique that accurately measures the masses within an ionized sample based 
on their mass-to-charge ratio- has been extensively used in the past few decades to 
identify proteins modified by a particular PTM (305–308). In particular, tandem mass 
spectrometry (MS/MS), which involves multiple steps of mass spectrometry selection and 
fragmentation of selected ionized samples, is used to determine the identity of modified 
residue. The traditional approach to detect PTMs is by measuring the mass of peptides 
derived from the proteolytic digestion of proteins (“bottom-up MS”), rather than of the entire 
protein (“top-down MS”) as mass differences between modified and unmodified forms of 
large proteins are difficult to measure. Broadly, a typical workflow consists of separation 
of protein on a SDS-PAGE gel, excision of gel pieces corresponding to unique protein 
bands, and subjecting the protein in the gel pieces to a series of chemical reactions, 
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including cleavage of disulfide bonds by a reducing agent, the capping of free thiol groups 
by an alkylating reagent, and finally the enzymatic cleavage of peptide bonds to generate 
peptides (309). The peptides mixture then undergoes high throughput liquid 
chromatographic separation and subsequent MS analysis (LC-MS). Characteristic mass 
shifts in fragmentation MS/MS spectra often allows specific detection of the post-
translationally modified amino acid residues. Indeed, recent advances in bottom-up MS 
have dramatically propelled the identification of PTM sites on large number of proteins, 
with phosphorylation being the most widely identified PTM (305–308).  In contrast, 
citrullination of arginine residues, a PTM catalyzed by the enzymatic action of peptidyl 
deiminase (PAD), is far less characterized.  
Citrullination involves removal of the positively charged imino moiety from the side 
chain of arginine and converting arginine to an uncommon amino acid, citrulline (reviewed 
in(310,311)). As a consequence of the hydrolytic reaction, the resulting citrulline shows 
1Da reduction in mass and is a neutral amino acid. The enzyme, PADs, which catalyze 
the deimination reaction, exist in 5 isoforms- PAD1, PAD2, PAD3, PAD4, and PAD6 and 
are expressed in a tissue-specific manner. Under physiological conditions, PADs function 
in gene regulation by citrullinating histone proteins. Additionally, PADs 2 and 4 are 
involved in apoptosis and inflammatory immune responses, such as rheumatoid arthritis 
(RA) and fibrosis. Since citrulline is not a natural amino acid in proteins, it creates novel 
epitopes which provoke an autoimmune response (reviewed in (310,311)). Indeed, the 
presence of antibodies generated against citrullinated fibronectin, is a common hallmark 
of RA and fibrosis (312). 
Fibronectin (Fn) is a large glycoprotein found in body fluids, cell surfaces and 
extracellular matrix (ECM). It functions as the key link between cells and ECM and is 
involved in a range of physiological processes such as cell adhesion, cell migration and 
signaling; events that are critical for embryogenesis, wound healing, haemostasis, and 
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thrombosis (reviewed in (313–315)). In body fluid including blood plasma and saliva, Fn 
is present as a soluble disulfide-linked protein and is responsible for mediating blood 
coagulation through its affinity for fibrin and platelets(316). On the other hand, cellular Fn 
found in ECM is multimer and fibrous, and interacts with cell receptors to promote cellular 
adhesion and cytoskeleton organization(313,315,317–319). While plasma Fn is 
expressed by hepatocytes, cellular Fn is secreted by a wide range of cells. Furthermore, 
several splice variants of Fn which differ in their cell-adhesive, ligand-binding, and 
solubility properties are expressed in a cell-type specific manner. This allows cells to 
modulate their ECM in a developmental and tissue-specific manner (reviewed in (313–
315)).  
Structurally, each monomer of Fn has a multi-domain architecture with three types 
of repeating units or modules (type I-III). There are 12 type I, 2 type II, and depending on 
the splice variant 15-18 type III units in a Fn monomeric protein. Compared to type III unit 
which is 90-100 amino acid long, type I and II units contains 43 and 49 amino acid 
residues. Additionally, all three modules (type I-III) contains at least two antiparallel -
sheets that fold over to form a central core. Combinations of these modules form distinct 
structural and functional domains that mediate binding to integrin, heparin, collagen, and 
fibrin (reviewed in (313–315)). A large number of different integrins, including 51 and 
v3, bind to Fn. In this regard, the RGD tripeptide sequence in typeIII-10th repeat has 
been found to be critical for integrin binding.  A second site in typeIII-9th repeat, PHSRN, 
synergizes with RGD sequence to promote specific integrin binding to Fn (320,321). 
These interactions between Fn and integrin modulate mechano-transduction signaling 
through FAK-Src and ILK-GSK3 proteins, adhesion dynamics, and cell migration; all of 
which is essential for embryonic development, immune cell homing, wound healing and 
angiogenesis. Moreover, dysfunction of Fn-integrin binding has been associated with 
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several diseases such as RA, fibrosis and cancer. Additionally, Fn has been frequently 
observed to be citrullinated by PADs 2 and 4 in such diseased patients (312,322–327). 
Indeed, citrullinated Fn is a hallmark of inflammatory diseases and the presence of 
antibodies against citrullinated Fn is a well-established and highly-specific biomarker of 
RA (323,328,329). Nevertheless, the physiological functions of citrullinated Fn remains ill-
defined. 
Given the scarcity of information about citrullinated fibronectin, and the implications 
of citrullination on the interaction profile of Fn, the Barker’s group decided to investigate 
citrullination of fibronectin mediated by in vitro activity of PADs 2 and 4. In our lab, we 
identified citrullination of 24 arginine residues, approximately 59% of which were found in 
regions important for protein-protein interactions such as binding to integrin, fibrin, or 
heparin. Importantly, 5 citrullines were in the type III 9-10 region involved in cell 
attachment. Of these sites, one modified arginine (R1410) was in the synergy site 
(PHSRN) for integrin binding, while another R1434 was proximal to the synergy site. Three 
additional citrullination sites (R1479, R1476, R1452) were close to the RGD sequence 
critical for integrin binding. Furthermore, not all arginine residues were equally citrullinated 
by PADs 2 and 4. Indeed, we found that PAD4 citrullinate Fn more efficiently than PAD2, 
although a considerable overlap was observed in their site-specificity. Additionally, 
Stefanelli et. al. showed that citrullination of Fn has prominent impact on its integrin binding 
specificity with increased preference towards 51 integrin. They further showed that this 
integrin switch to 51 subsequently accentuates mechano-transductive signaling 
through FAK-Src and ILK-GSK3 and the migratory nature of cells. Taken together, we 
report the comprehensive map of citrullination sites on Fn and its potential to alter cell 
signaling and behaviors, that can have implications in the pathophysiology of inflammatory 
diseases, such as RA. 
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5.3 RESULTS  
5.3.1. Identification of citrullination sites on human fibronectin. 
Fibronectins (Fn) are large glycoproteins composed of two nearly identical 
disulphide bonded subunuits; and are present in the extracellular matrix (insoluble form) 
and the plasma (soluble form) (313–315). Additionally, in humans, as many as 17 isoforms 
of Fn are generated by the alternative splicing of the pre-mRNA, that play important roles 
in cell adhesion, migration, growth and differentiation (313–315). Although several studies 
have linked citrullination of Fn to rheumatoid arthritis, fibrosis, and cancer; little is known 
about the citrullinated sites on Fn and its impact on the physiological function of Fn 
(312,323–327).  
To this end, we first used LC-MS/MS to map the positions of citrullinated residues 
in purified plasma Fn, which were subjected to in vitro enzymatic citrullination by PAD2, 
PAD4, or both. Using a combination of complementary in-gel digestion techniques (see 
methods), we achieved a total of 81% coverage across all samples with more than 25,000 
peptide spectral matches (PSMs) spanning across all isoforms of Fn, except isoforms 4 
and 16, the unique peptides of which were not detected. Citrullinated sites were identified 
by searching against a database comprising of all isoforms of Fn and were further 
confirmed by manual investigation of the peptide spectral patterns. In total, we identified 
24 citrullination sites, including the 3 previously reported sites (R1035, R1036, and 
R2356)(328,329). Figure 1A shows a schematic overview of all the sites mapped on the 
canonical Fn-1 comprising of a polypeptide of 2,386 amino acids. Of the 24 citrullinated 
sites identified, 58.3% were located on regions with defined function, such as fibrin and 
heparin binding, collagen binding, and cell attachment, with maximum citrullination (7 
sites) observed in region 1267-1540 involved in cell-attachment (Figure 1B). Interestingly, 
3 citrullination sites (R1479, R1476, R1452) were within the 9-10Fn-III domain near the 
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canonical integrin binding tripeptide, RGD (Figure 1C), although the RGD site itself was 
unmodified.  Additionally, the PHSRN synergy site (R1410), important for strengthening 
α5β1 integrin attachment in coordination with RGD10, was also found to be citrullinated, 
along with the nearby R1434 (Figure 1C). In conclusion, our work represents the most 
detailed mapping of the citrullination sites on Fn. Notably, the robust citrullination sites of 
Fn, specifically near integrin binding/specificity sites, could reflect a potentially critical role 
















5.3.2. Citrullination of human fibronectin is specific to PAD-activity. 
Citrullination is catalyzed by peptidylarginine deiminases (PADs) family of calcium-
binding enzyme. To date, five isoenzymes have been identified that differ in their calcium 
and pH preferences. Moreover, the expression of PADs is tissue-specific, for example, 
while PAD2 is ubiquitously expressed, PAD4 is specific to neutrophils and eosinophils. 
Additionally, amongst the 5 isoenzymes, PAD2 and PAD4 are most frequently associated 
with inflammation and cancer metastasis (reviewed in (311)). However, the extent to which 
either PAD2 or PAD4 contribute to citrullination of Fn is not known.   
To estimate the crude relative efficacy of PAD activity, we relied on the number of 
sites modified and percent of citrullinated peptide spectral matches (PSMs) normalized to 
the total PSM in each PAD treated Fn sample. As expected, citrullination of ariginine 
residues in Fn were specific to the enzymatic activity of PAD, with majority of residues 
Figure 5.1. Mapping citrullination sites on human fibronectin. (A) Schematic 
overview of citrullination sites mapped onto human Fn comprised of repetitive units 
of type I-III domains (depicted in different shapes). Tandem mass spectrometry was 
used to map the positions of citrullinated residues in purified plasma Fn, which were 
either untreated or subjected to in vitro enzymatic citrullination by PAD2, PAD4, or 
both. Three previously reported sites (R1035, R1036, and R2356) that were also 
detected here are shown (residue labeled in brown) ((a) van Beer et. al. 2012; (b) K. 
Sipila et. al. 2017). (B) Citrullination sites identified in this study were grouped based 
on location within regions of fibronectin and known physiological function (based on 
overlap with data compiled by UniProt: (http://www.uniprot.org/uniprot/P02751) 
(left). Of the 24 citrullinated sites identified, 58.3% were located in regions with 
defined function, such as fibrin and heparin binding, collagen binding, and cell 
attachment, with maximum citrullination observed in the region involved in cell-
attachment (right). (C) Three-dimensional structure of the 9th and 10th fibronectin type 
III domain (PDB 4LXO) highlighting residues previously shown to be essential for 
integrin binding (Redick et al, 2000) (Left). (Red) RGD and PHSRN sequences 
essential for synergistic integrin binding. (Cyan) residues with the greatest degree of 
binding influence outside the RGD site (R1410 and R1476). (Yellow) residues that 
help to facilitate PHSRN interactions. (Right) MS-identified citrullination sites within 
the 9-10FnIII domains showing overlap with integrin binding residues R1410 and 
R1476, as well as additional sites near the integrin binding interface (R1434, R1479) 
and R1452 (underneath R1476 and not shown here). 
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(84%) citrullinated only in the presence of PAD activity. In contrast, 16% of identified 
residues, corresponding to 4 arginine residues (R67, R1207, R1802, and R1891) were 
found citrullinated in plasma Fn in the absence of any PAD treatment in vitro. Amongst the 
remaining 20 sites, 4 sites (R290, R953, R2223, and R1410) and 6 sites (R515, R938, 
R1035, R1036, R1910, and R2356) were specific to PAD2 and PAD4 activity respectively. 
Whereas the specificity for 10 sites (R107, R751, R903, R911, R1274, R1284, R1432, 
R1452, R1476, and R1479) overlapped by both PAD2 and PAD4 (Figure 1A, Figure 2A). 
Interestingly, the frequency of PAD2 or PAD4 citrullinated PSMs was unique to each 
residue. Among the 10 sites modified by both PAD2 and PAD4, 7 sites (R751, R903, R911, 
R1432, R1452, R1476, and R1479) displayed relatively higher frequency of PSMs with 
PAD4 than PAD2. Moreover, the overall efficacy of in vitro citrullination by PAD4 was twice 
greater than by PAD2, as measured by the percent of PSMs for citrullinated peptides over 
the total PSMs (Figure 2B-C). Taken together, our data suggests that citrullination of Fn is 
relatively more efficient by PAD4 than PAD2. 
 
5.3.3. Citrullination of fibronectin enhances cell adhesion and migration 
Fibronectin functions in vivo as an anchor for cells in the extracellular matrix, and 
participates in complex interaction with other matrix proteins as well as integrin receptors 
on cell surface (313–315). The cell attachment activity of fibronectin is mediated via the 
binding of the RGD motif in 9-10Fn-III domain to special  heterodimeric transmembrane 
receptors – integrins - on cells (330–333). This binding event results in clustering of 
integrins and other adhesome proteins at the attachment site leading to formation of a 
focal adhesions (FAs) and organization of the actin cytoskeleton (330–334). Indeed, a 



















cell behavior such as cell adhesion and migration (333,335). Besides cell-matrix adhesion, 
Fn-integrin binding result in activation of downstream signaling through FAK/Src complex 
and GSK3 (glycogen synthase kinase 3) (330–334,336). Together, these cell behaviors 
and signaling are critical for several physiological processes such as wound healing and 
embryonic morphogenesis. Nevertheless, the implications of citrullination of Fn on 
controlling cell behaviors is yet to be determined. 
Stefanelli et. al. compared the efficiency of citrullinated Fn to unmodified Fn in 
modulating Fn-integrin binding specificity and the mechano-transduction signaling, which 
ultimately controls cell adhesion and cell migration. Through a series of biochemical and 
mechanical experiments, they made several key discoveries- citrullination of Fn lead to (i) 
integrin switch from v3 to 51, (ii) enhanced FAK/Src activation, (iii) reduced GSK 
activation, (iv) increased cell adhesion turnover, and (v) increased cell migration (Stefanelli 
et. al. in review). They  showed that citrullinated Fn has reduced affinity for v3 integrin, 
an observation consistent with a previous work in the field (328). Furthermore, they 
proposed that the switch to 51 integrin clusters in FA serves to compensate for the 
diminished v3 binding and triggers robust cytoskeletal remodeling. Moreover, since 
citrullination causes irreversible protein structural modifications, Steffanali et al. propose 
Figure 5.2. Frequency of identified citrullinated sites and peptide spectral 
matches (PSMs) for human fibronectin. (A) Table linking specific and shared 
citrullination sites between PAD2 or PAD4. Most sites (41.7%) were citrullinated by both 
PAD2 and PAD4, followed by PAD4 unique sites (25%). (B)Table showing the number 
of PSMs observed in each sample. Overall, the efficacy of in vitro citrullination by PAD4 
was twice greater than by PAD2, as measured by the percent of PSMs for citrullinated 
peptides over the total PSMs. (B) Plot showing the citrullinated PSMs corresponding to 
residue position of human fibronectin (UID P02751), with the known functional regions 
(as in Figure 1.1B) delimited as horizontal bars above the residues. Color codes 
represents respective enzyme treatment. PAD2 and PAD4 citrullinated some residues 
more frequently than others. Of the 10 overlapping sites, 6 sites (R751, R903, R911, 
R1434, R1476, and R1479) were citrullinated by PAD4 more efficiently in comparison 
to PAD2. The cumulative PSMs for each site (across all experiments/all PADs) is 
denoted in the parenthesis adjacent to the annotated residue. Comprehensive list of 






that citrullinated Fn could act as a memory store of inflammatory attacks (Stefanelli et. al. 
in submission). Together, Steffanali et. al. showed that citrullination of Fn can serve as 




5.4.1. Challenges in the identification of citrullination sites on fibronectin 
Citrullination, the product of protein arginine deiminase (PAD)- mediated 
deimination of arginine residues in a protein, has been implicated in several physiological 
and pathological processes (312,323,337–341). Indeed, citrullination of fibronectin is 
associated with RA, fibrosis and cancer metastasis. Commercially available anti-citrulline 
antibodies are often used to detect citrullination of proteins, including Fn. However, 
detection with antibodies is not optimal due to two key reasons. One, antibodies fail to 
provide sequence information of citrullines in a protein. Two, anti-citrulline antibodies often 
display overlap in reactivity and falsely detect carbamylation of lysine as citrullination(342). 
Currently, the best available method to accurately map citrullination sites is through the 
combination of high resolution MS and bottom up strategies.  Nevertheless, detection of 
citrullination by MS has few limitations. Unlike arginine, citrulline is resistant to proteolytic 
cleavage by the protease trypsin- an enzyme that cleaves the C-terminus peptide bonds 
of arginine and lysine and is routinely used in bottom up approaches to digest proteins to 
peptides by prior to MS analysis. This elimination of tryptic sites results in larger peptides 
that are harder to detect and sequence. Furthermore, deamidation of glutamine and 
asparagine produces monoisotopic mass difference of +0.984016, identical to citrullination 
of arginine, leading to misidentification of sites. Additionally, the limited number and 
uneven distribution of lysine and arginine throughout the fibronectin sequence of 2386 
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amino acids, results in poor sequence coverage by the conventional trypsin-based bottom 
up MS. Indeed, the maximum reported sequence coverage of Fn till date is approximately 
53 percent (329). In this study, we attempt to overcome these challenges by (i) employing 
multi-protease strategy that capitalizes on different proteolytic enzymes with specific 
cleavage chemistry to generate a diverse pool of peptides prior to MS analysis, which in 
turn increases sequence coverage and identification of citrullination sites; and (ii) including 
deamidation of glutamine and asparagine as dynamic modification parameter in the 
SEQUEST search algorithm as well as confirming the citrullinated sites by manual 
annotation.  
Indeed, by using three commercially available proteases- trypsin, gluC, and 
chymotrypsin- either individually or as a mixture (trypsin and gluC) to prepare digested 
samples for LC-MS analysis, we were able to achieve 81% sequence coverage across all 
samples. Such results were not attainable by performing multiple technical replicates of a 
single protease digest. Moreover, the diverse population of peptides generated due to 
multi-protease approach allowed substantial increase in the identification of citrullination 
sites, which otherwise would have been missed due to tryptic miscleavage. Indeed, prior 
to our report, only two groups have investigated in vivo citrullination of Fn in inflammatory 
synovial fluid and determined 7 citrulline sites (R241, R440, R1035, R1036, R1162, 
R1573, and R2356) (328,329) compared to the 24 sites identified in this study. Of the 7 
previously identified sites, 3 citrullination sites (R1035, R1036, and R2356) were also 
identified in our in vitro study; 2 sites (R241 and R440) were not covered by our LC-MS 
analysis; and the remaining two sites (R1162 and R1573) were covered but not found to 
be citrullinated. A key difference in our study vs previous studies is the source of 
citrullinated Fn- while our study is based on in vitro citrullinated Fn, previous studies are 
on in vivo citrullinated Fn. Thus, whether the increased number of citrullination sites 
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identified in this study is due to better sequence coverage of Fn or increased efficiency of 
PADs to citrullinate in vitro is debatable. Indeed, since PAD activity is dependent on 
calcium concentration, the efficiency of PAD may vary in in vitro experiment vs a natural 
physiological or inflamed microenvironment. Nevertheless, the comprehensive mapping 
of citrullination modifications on Fn have opened avenues to future studies aimed at 
determining the functional relevance of these citrullines in development of RA, fibrosis, 
cancer or other diseases. 
 
5.4.2. Implications of citrullination on fibronectin properties and its significance to 
disease progression  
Fibronectin, a large ECM protein, plays important roles in cell adhesion, migration, 
growth, and differentiation. Indeed, interactions between Fn and adhesion receptors, 
especially the members of the integrin family, mediate the anchorage of cells to ECM and 
orchestrate chemical and mechanical signal transduction critical for controlling cell 
behavior (314). Furthermore, fibronectin is extensively subjected to citrullination by PADs 
released by dying granulocytes (343) and has major implications in the pathogenesis of 
inflammatory diseases and tumor metastasis. Nevertheless, the mechanism by which 
citrullinated Fn interferes with its physiological functions or orchestrates the deterioration 
of healthy to pathological tissues remains poorly understood. In this collaborative work, 
Stefanelli et. al. showed that citrullination of Fn has a uniquely activating effect mediated 
through an induced switch in integrin profile from v3 to α5β1 that subsequently 
enhances mechano-transductive signaling and the migratory nature of stromal cells. 
Interestingly, 51 integrin, unlike v3, by virtue of its exposed RGD binding pocket and 
binding ability to the PHSRN synergy site has more affinity to soluble Fn (344–347). 
Notably, conversion of arginine to citrulline in a protein and the consequential decrease in 
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net charge, loss of potential ionic bonds, and interference of H-bonds has often been 
suggested to alter protein structure (348). Indeed, several PAD substrates such as 
filaggrin, trichohyalin, amyloid -protein, FET proteins (FUS, EWS, and TAF15), upon 
citrullination show reduced structural organization and ability to form aggregates 
(340,341,348). Thus, an interesting but yet answered question is whether citrullination of 
Fn favors the “soluble” over the “stretched” conformation of Fn and thereby affects the 
accessibility of the RGD and PHSRN motif which ultimately dictates the preference for 
specific integrin partner. 
Several studies have shown that overexpression of α5β1 coupled with its 
enhanced engagement with ECM proteins facilitate cancer cell invasion and tumor 
progression (349–351). Additionally, α5β1 integrin plays significant role during acute 
inflammatory conditions, including RA, wherein α5β1 induces increased leucocyte 
migration and protection of synovial cells from apoptosis (352–355). Thus, Stefanelli et al. 
suggest that the implications of citrullinated Fn in metastasis of cancer and inflammatory 
diseases could be mediated through the  v3 to α5β1 integrin switch and consequent 
changes in cell signaling and behavior. Furthermore, since citrullination is an irreversible 
PTM that renders proteins resistant to degradation (356), the impact of citrullinated Fn is 
long-lived. Thus, our findings further the understanding of the underlying mechanism by 
which ECM influence cancer metastasis and inflammatory disease progression.  
 
5.5 EXPERIMENTAL PROCEDURES 
In-gel Protein Digestion 
In-gel protein digestion was conducted as previously described (309), with 
modifications. Briefly, selected protein bands were excised from the Coomassie-stained 
gel, diced into small pieces, and then destained with HPLC-grade water (Avantor) and 1:1 
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acetonitrile (ACN)/ammonium bicarbonate (ABC) (Sigma-Aldrich). The de-stained gel 
pieces were then dehydrated with multiple ACN washes until rock hard, followed by air 
drying for ~10 minutes. The gel pieces were rehydrated for 30 minutes with 50mM 
dithiothreitol (Sigma-Aldrich) to reduce disulfide bonds, followed by replacement with 
100mM iodoacetic acid (Sigma-Aldrich) and 45 minutes shaking at 750 rpm in the dark to 
alkylate the reduced thiols. After reduction/alkylation, the gel pieces were once again 
washed and dehydrated as before, and then chilled on ice for 10 minutes. In-gel digestion 
was achieved by rehydrating the gel pieces with either trypsin (40µg/mL, Promega Cat # 
V511A), gluC (40µg/mL, Calbiochem Cat # 324713), chymotrypsin (50µg/mL, Promega 
Cat # V1062) or a mixture of trypsin and gluC. In each case, 50µL of the sequencing grade 
enzyme solution was added to the gel pieces and incubated on ice for 30 minutes. Excess 
enzyme solution was then removed and replaced with 100µL 50mM ABC and the pieces 
were incubated overnight at 37°C with shaking at 750 rpm. Resultant proteolytic peptides 
were extracted by two rounds of dehydration using 100L ACN and collection of the 
resulting extract into low-retention microfuge tubes, which were frozen solid at -80°C and 
then sublimated by centri-vapping. The dried peptides were reconstituted by sonication in 
5% ACN/0.1% formic acid and stored at -80°C prior to analysis. 
 
Mass Spectrometry   
LC-MS analysis of peptides produced by in-gel digestion was carried out with an 
UltiMate™ 3000 RSLCnano System UPLC system (Dionex) with Acclaim PepMap RSLC 
column (75m x 25cm nanoViper C18 2m, 100Å) coupled to a Q-Exactive Plus Orbitrap 
mass spectrometer (Thermo Scientific) run in data-dependent acquisition mode (top-8). 
Resultant RAW files were analyzed using Proteome Discoverer 2.1 with embedded 
SEQUEST search algorithm operating with an allowable 1% false-discovery rate, wherein 
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the human fibronectin (P02751) isoforms 1-17 were used as targets for spectral matching. 
Mass deviations for precursor ions and fragment ions were set to 10 ppm and 0.6 Da 
respectively. Besides citrullination (R), other modifications such as deamidation (N, Q), 
oxidation (M), phosphorylation (S, T, Y), acetylation (protein N-terminus), and 
caramidomethylation (C) were included in the analysis. Additionally, the citrullinated sites 









 6.1 CONCLUSIONS 
Fibronectin (Fn), a large extracellular matrix (ECM) protein, mediates various 
physiological processes through interactions with cell-surface integrin receptors and 
growth factors (313). Post-translational modification of Fn, specifically citrullination, is 
intimately involved in the pathogenesis of rheumatoid arthritis (RA), fibrosis and cancer 
metastasis (327,357). Citrullination is the conversion of peptidylarginine to citrulline 
catalyzed by peptidylarginine deiminase (PAD) (310). In this collaborative study, we 
investigated the citrullination of Fn and its implication on modulating the cell behavior. The 
key findings of this study are listed below.  
 
1. Fn has at least 24 in-vitro citrullination sites. Of these, 3 sites were previously 
reported (328,329), and 21 sites are unique to this study. Thus, our work 
represents the most detailed mapping of citrullination sites on Fn. 
2. Three citrullinated sites (R1452, R1476, R1479) are close to the integrin binding 
site (RGD) on Fn and 2 sites (R1410, R1434) are in or near the PHSRN synergy 
site. Collectively, these citrullines could modulate integrin-binding dynamics. 
3. Citrullination of Fn altered the integrin-binding dynamics resulting in a switch from 
v3 to 51 integrin, enhanced mechano-transduction signaling through FAK, 
Src, and ILC activation, and enhanced cell adhesion and migration. 
4. Since citrullination is an irreversible PTM and citrullinated Fn is resistant to 
degradation, citrullinated Fn influence future cell behaviors for a prolonged time 
and acts as an ECM memory.  
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6.2 FUTURE DIRECTIONS 
This collaborative study has provided an insight into the mechanism by which 
citrullination of fibronectin can modulate cell signaling and behaviors, and thereby inspire 
new approaches to exploit the mechanobiology of ECM in regenerative medicine as well 
as for diagnostic and therapeutic applications. Furthermore, this study opens up several 
avenues for future work, some of which are discussed below. 
 
What is the magnitude of citrullination of fibronectin in vivo in inflammatory 
microenvironments? 
A key regulator of PADs- enzymes that catalyze citrullination- is calcium. Indeed, 
different PADs require different calcium ion concentration and pH for their activity. In in 
vitro experiments, citrullination is observed only at very high concentration of calcium 
(358). However, under physiological conditions, the calcium concentration is in the range 
of 1 micromolar to 10 nanomolar which is insufficient for PAD activity. Thus, citrullination 
is only observed during inflammatory disease, such as RA, which is often accompanied 
by increase in calcium levels in the serum (approximate final concentration of calcium is 
2.2- 2.6mM) (359,360). For this study, Fn was citrullinated in a PAD reaction buffer 
containing final concentrations of 5mM CaCl2- almost double the concentration of calcium 
within inflammatory microenvironment. Thus, a key question is whether all the 24 
citrullination sites identified in this study will be citrullinated in vivo. Indeed, only a limited 
number of citrullination sites (7 sites in total) on Fn extracted from RA patients have been 
identified till date by using a trypsin-based bottom up MS approach (328,329). An 
interesting future work will be to utilize the advantage of multi-protease bottom-up MS 
approach used in this study, to explore citrullination of Fn that has been either extracted 
from patients (in vivo) or subjected to in vitro citrullination reaction in a buffer containing a 
range of calcium concentration that mimics inflamed sera.  
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Are all citrullination sites functionally equivalent? 
In this collaborative study, we identified 24 citrullination sites that spanned the 
entire length of Fn. Additionally, Stefanalli et.al. described the implications of global 
citrullination of Fn on cell signaling and behaviors; however site-specific function of 
citrulline is yet unknown. Thus, an enticing future direction is to determine the contribution 
of each citrullination site in the altered function of Fn. This question can be tackled by a 
strategy that couples emerging computational methods with the established 
biochemical/biomechanical assays in the field. In this unified approach, PTM function 
prioritization tool will be used to predict a set of high-priority citrullination sites that can be 
further studied by point mutations to decipher the site-specific function of citrullinated Fn.  
Furthermore, this study explored the implications of citrullination of Fn on cell 
adhesion and migration which is mediated through the interaction of Fn with cell adhesion 
receptors, integrins. However, Fn is a large protein with multiple functional domains that 
mediate interactions with not only cell receptors such as integrins, but also bind to other 
ECM proteins such as heparin and collagen (313). Thus, an extension of this work can be 
to determine the potential contribution of citrullinated Fn in altering interactions with other 
ECM proteins, and eventually affecting ECM structure. 
 
Which citrullination sites on fibronectin are immunogenic? 
Citrullination involves conversion of arginine to an uncommon amino acid, 
citrulline, which can act as antigens to provoke immunogenic reaction. Indeed, three 
citrullinated residues (R1035, R1036, and R2356) on Fn comprise two epitopes 
recognized by anti-citrullinated protein antibodies (ACPAs) that are routinely used for the 
diagnosis of RA (329). We have identified a total 24 citrullination sites on Fn, 21 of which 
are unique to this study and the immunogenic properties of which remains unclear. An 
interesting study will be to characterize the epitope specificity of the citrullination sites and 
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its ability to be recognized by ACPAs. This information can further our knowledge about 







BROADER THESIS SIGNIFICANCE- INTRA- VERSUS EXTRACELLULAR PTM-




With progress towards ever better detection of protein post-translational 
modifications (PTMs) continues in what appears to be an exponential manner, it 
becomes more evident that virtually all cellular process and phenotypes are in 
some way regulated by this understudied layer of the central dogma.  However, 
the exponential rate at which PTMs are detected far surpasses the rate at which 
we can understand their functional importance. Thus, a significant knowledge gap 
between these two aspects of any PTM remains extraordinarily large.  
Significant biological insight about a PTM can be gleaned through coupling 
high-resolution mass spectrometry, computational PTM prioritization tools, and 
biochemical and cellular assays. Through my utilization of such a unified approach 
has revealed several fascinating implications of PTM on cell signaling and 
behavior. Perhaps the most intriguing is that PTMs can not only rapidly reprogram 
cell signaling to elicit an immediate cell response but can also imprint proteins in 
an irreversible manner that influences future cellular behaviors – analogous to a 
memory. In this thesis I have observed both phenomena. Indeed, I have shown 
that dynamic regulatory phosphorylation can mediate negative synergistic 
interactions between G protein  subunits and a G effector proteins. Through 
collaboration with the Barker lab, I have seen that irreversible citrullination of 
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extracellular matrix (ECM) protein, fibronectin (Fn), is more prevalent than once 
thought and that these marks can influence the future behavior of cells that must 
adhere to or migrate through such proteins.  
This work also provides a unique perspective on the nature of PTM, 
particularly in regards to where it can and does occur and how this influences the 
manner in which one attempts to understand biological function. For example, 
PTMs of key intracellular or membrane bound proteins in the G-protein signaling 
pathway, such as phosphorylation of G effector proteins, dictate the phenotype 
through processes that are inherently intracellular. This has long been thought to 
be the realm of PTMs – as components of proteins that occur within a cell. 
Intriguingly, PTM of extracellular proteins falls outside of this paradigm. Indeed, 
citrullination of Fn, an inherently extracellular protein, is not intra- but rather 
extracellular. Thus, at first glance one might not consider the protein to be a target 
for PTM. I have used mass spec to reveal the largest map of citrullination sites in 
Fn to date and through collaboration with the Barker lab we have determined that 
citrullinated Fn can alter the intracellular signaling events of ECM-interacting cells. 
As such, this work necessitates a refinement of the existing paradigm that PTM 
regulation is largely an intracellular process. This further requires that principles 
underlying intracellular PTM will likely need to be readdressed for extracellular 
proteins, which undergo PTM in a manner that appears to be less well regulated 
by precise enzyme localization.  
Finally, a somewhat understated yet seminal discovery emerging from this 
work is that PTMs on distinct proteins can co-operate to elicit their regulatory 
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effects. I have discovered that phosphorylation of G proteins and their effectors, 
together regulate signaling and phenotypic outcome. To our knowledge, this type 
of PTM interaction is very rare, likely due to the fact that such a relationship can 
be difficult to detect given the complexity of the eukaryotic proteome. In the studies 
described herein, the well-characterized G protein signaling pathway in yeast 
served as an ideal model system that enabled the discovery of cross-protein PTM 
interaction/synergy that likely would’ve been difficult to detect in any other less 
characterized cell system. Moreover, given the constrained evolutionary phylogeny 
of G proteins and their effectors, these results may serve as a foundation for 
predictive models that can be used to identify other similar PTM interactions.  
These discoveries further serve as a testament to the continued utility of the yeast 
model system in elucidating novel mechanisms of PTM regulation that pioneer our 
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Supplemental Experimental Procedures  
Yeast strains and plasmids – Standard methods for cell growth, maintenance, and 
transformation of yeast, and for the manipulation of DNA were used throughout. Strain 
BY4741 (MATa leu2 met15 his3 ura3) and BY4741- derived mutants were used. 
Details of strains used are listed in Table A.S1. The fus3 kss1 double deletion mutant 
was created by replacing the KSS1 gene with LEU2 in the fus3 background strain 
obtained from Open Biosysytems. The non-docking mutants of Ste5 (Ste5ND; STE5 
Q292A, I294A, Y295A, L307A, P310A, N315A) were created in HA-STE18WT, HA- 
STE183A and HA-STE183E background strains (Dewhurst et al., 2015), using the two-
step dellitto perfetto mutagenesis method (Storici and Resnick, 2006). Briefly, a CORE 
cassette comprising of counter selectable marker and reporter gene was inserted via 
homologous recombination, in the 829-990 region of STE5 coding sequence containing 
the Fus3 docking region on the protein. The CORE cassette was later replaced by 
oligonucleotides containing the desired mutations and regions of homology to STE5. 
Similarly, GFP-tagged STE5 strains were constructed by integrating a CORE cassette at 
the 3-prime end of STE5 and replacing it with the coding sequence for Green Fluorescent 
Protein (GFP). Strains were verified at each step by PCR amplification and dideoxy 
sequencing (Eurofins MWG Operon). LRB341 and LRB345 strains harboring yck1 and 
temperature-sensitive yck2ts alleles were graciously provided by Dr. Lucy Robinson 
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(Robinson et al., 1993). Plasmids used in this study for kinase deletion screening 
(pRS316-CUP1- HA-STE18), were graciously provided (gift from T. Chernova).  
Yeast cell culture and treatments – Yeast Strains were grown in YPD growth medium 
(Yeast Extract, Peptone, 2% Dextrose media) unless otherwise noted. Cells were grown 
at 30C with shaking at 250 rpm and cell culture density was determined by absorbance at 
600nm (OD600). All experiments were conducted with log phase cells between OD600 
0.75-0.85. Log-phase cells were then treated with -factor peptide hormone (Genscript) 
at 3μM final concentration. 10ml aliquots of treated cells were harvested with 0.5ml 
trichloroacetic acid (TCA) on ice and centrifuged at 3724 x g in Allegra X-14R Beckman 
Coulter Centrifuge. Cells were then washed with 10ml MiliQ water, followed by transfer to 
microcentrifuge tubes that were immediately frozen at -80C.  
For kinase screening, deletion strains carrying the pRS316-CUP1-HA-STE18 plasmid 
were grown in synthetic media lacking uracil and other appropriate amino acids as 
necessary. An overnight saturated culture was then diluted to OD600 0.05 and allowed to 
grow until OD600 0.2. Expression of HA-STE18 was then induced by addition of 100μM 
copper sulfate. Cells were grown till log-phase (OD 0.75-0.85), followed by treatment with 
3μM -factor for an hour. The cells were harvested with TCA as described earlier. For 
yckts strains, HA-STE18 expression was induced as above. At OD600 0.8, each culture 
was split into two parts: One subjected to pheromone treatment and the other incubated 
at 37C for 30 minutes prior to stimulation with pheromone.  
Cell extracts and Immunoblotting - Protein extracts were resolved by 7.5% or 12.5% 
SDS-PAGE and immunoblotted with epitope-specific antibodies specific to: the 
hemagluttinin antigen epitope (HA) (Cell Signaling Technologies, Cat #3724) at 1∶5000; 
activating phosphorylated sites in Fus3 and Kss1 (Phospho-p44/42 MAPK) (Cell Signaling 
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Technologies, Cat #9101) at 1∶500; Fus3 protein (Santa Cruz, anti-Fus3 yC-19, Cat # sc-
6773) at 1:350; Kss1 protein (Santa Cruz, anti-Kss1 yC-19, Cat # sc-6775R) at 1:1500; 
GFP (Invitrogen, Cat# GF28R MA5-1526-HRP) at 1:1000; and glucose-6-phosphate 
dehydrogenase (loading control; LC) (Sigma-Aldrich, Cat #A9521) at 1∶50,000.  
Phosphatase Assay – Pheromone-treated cells were harvested as described earlier. The 
frozen pellets were resuspended in 1x phosphatase buffer mix (New England Biolabs), 
comprising of 1x PMP buffer (50mM HEPES (pH 7.5), 100mM NaCl, 2 mM DTT, 0.01% 
Brij 35), 1mM MnCl2, and 1x EDTAfree protease inhibitors (Roche). The resuspended 
pellet were equally aliquoted into three tubes- Control, AP (Alkaline phosphatase), and 
AP/I (Alkaline phosphatase Inhibitor). Each resuspended pellet was subjected to glass 
bead lysis in the absence (Control and AP sample) or presence (AP/I sample) of 
phosphatase inhibitors (50mM NaF and 1.3mM sodium orthovandate). The lysates were 
centrifuged at 21.1 x g in Thermo Pico21 centrifuge and the supernatant was collected in 
a fresh tube. The AP and AP/I samples were treated with phosphatase enzyme (final 
concentration of 2.25U/μl) for 30 mins at 30C; whereas the control sample was left 
untreated. The reaction was stopped by addition of 6x SDS loading dye, and the samples 
were immediately run on SDS-PAGE gel and subjected to immunoblotting.  
Phos-tag gel analysis – Protein extracts were resolved by 100μM Mn2+-Phos-tag in 
7.5% acrylamide SDS-PAGE as per manufacturer’s instructions (Wako Chemicals, 
Richmond, VA). The gel was run at a constant current of 30 mA per gel till dye ran off. 
Next, the gel was soaked in transfer buffer (0.125M tris, 0.96M glycine, 20% methanol v/v) 
containing 1mM EDTA, and later in transfer buffer without EDTA for 30 min each with 
gentle shaking. This process chelates Mn2+ and increases transfer efficiency of both 
phosphorylated and non-phosphorylated proteins. Wet-tank transfer in buffer containing 
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0.1% SDS was used to effectively transfer proteins onto nitrocellulose membrane. The 
proteins were then subjected to immunoblotting.  
Morphological response assay – The morphological response of STE18/STE5 mutants 
to -factor was measured as described previously (Coyle et al., 2013; Malleshaiah et al., 
2010). Briefly, an overnight culture was washed twice with MilliQ water, and then diluted 
to an OD600 0.05 in synthetic complete (SC) media. After 4h of growth at 30C with shaking 
at 250 rpm, the cultures were distributed into separate tubes, and serially diluted 
pheromone was added to each. The morphology of the cells was determined, 3h post-
stimulation, by differential interface contrast (DIC) confocal microscopy using a 
PerkinElmer UltraVIEW spinning disk confocal microscope. Number of cells with mating 
projections were counted as a percentage of total.  
Ste5-GFP localization assay – Live cells endogenously expressing either Ste5-GFP or 
Ste5ND-GFP were visualized by microscopy. Log phase cultures (OD 600 0.7-0.8) grown 
in SC media were briefly sonicated, centrifuged, and resuspended in SC media containing 
10μM -factor. Cells were immediately mounted on a SC agar (2.5%) pad with 30μM a-
factor and the GFP fluorescence was monitored for 200 minutes. Cells were visualized by 
fluorescence microscopy using a PerkinElmer Ultraview VoX spinning disk confocal 
scanner with a Hamamatsu ORCA FLASH 4 camera on a Nikon Ti-e microscope stand. 
Photomicrographs were obtained using a 60x NA 1.49 apochromatic objective. The 
488nm laser line was set at 10%, image exposure set to 500ms, and the Z-stacks were 
obtained for 4μm with 0.2μm step-size. A 525nm center, 50nm bandwidth emission filter 
was used for all fluorescence images. Images were analyzed using Volocity quantitation 
software (Perkin Elmer). Find object module was used to identify objects with the threshold 
set to 18.4% for fluorescence intensity. Images were linearly contrast enhanced for 
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visualization. Quantification was performed on raw data from which integrated pixel 
intensity was used for all further analyses.  
Co-immunoprecipitation – 50 ml cultures of cells expressing different combinations of 
wild type or mutant HA- STE18 and STE5-GFP were grown to an OD of 0.8 and treated 
with 10μM pheromone for 20 mins. Cells were then harvested, washed with water, snap-
chilled in liquid nitrogen and stored in -80C. Cell pellets were subjected to glass bead lysis 
in buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM MgCl2, 0.1% Triton X-
100 (Sigma Aldrich), 5% glycerol, 1 mM TCEP, 0.5mM PMSF, and protease and 
phosphatase inhibitor tablets (Pierce #A32959). The soluble protein extract was then 
collected in a fresh tube after centrifugation at 21,000xg for 10 min. For 
immunoprecipitation of Ste5-GFP, anti-GFP mAb-agarose (MBL, #D153-8) pre-
equilibrated with the lysis buffer was added to each lysate of fixed concentration and total 
mass followed by incubation with gentle agitation at 4C for 3 hours. Beads were washed 
with lysis buffer to reduce non-specifically bound proteins. Washed beads were 
resuspended in 1x SDS-PAGE buffer and boiled for 3 min to elute bound protein. Eluted 
proteins were separated by SDS-PAGE and immunoblotting with anti-GFP (Invitrogen, 
A11122) and anti-HA.  
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Table A.S2. Synergy tests for independent versus combined mutation of Ste18 
phosphosites and Ste5FBD. The independent or combined effects of Ste18/Ste5 
phosphorylation on Fus3 peak activation time (F3PAT) and Fus3 mean peak amplitude 
(F3MPA) was compared as a test for synergistic or additive effects. (A) Summary table of 
F3PAT and F3MPA raw, relative and integrated data. Red text indicates mutants 
representing a Ste18 element off state (Ste183A/Ste5WT) or Ste5 element off state 
(Ste18WT/Ste5ND). Blue text indicates the mutant representing both elements off 
(Ste183A/Ste5ND). (B) Sub-tables showing synergy test results for F3PAT, F3MPA, and 
Integrated Outcomes. The total integrated rate and amplitude enhancement observed for 
Fus3 activation in Ste183A/Ste5WT and Ste18WT/Ste5ND was ~4x lower than that of 
Ste183A/Ste5ND cells (compare 5.6 to 21.7) (bottom table). The greatest degree of synergy 
between Ste18/Ste5 elements were observed for Fus3 peak activation time (top table). In 
contrast, peak activation amplitude results from additive rather than synergistic effects of 
the two elements (since the sum of effects for removal of either Ste18 or Ste5 elements 





Table A.S3. Best-fit values for pheromone dose-response of independent or 
combined mutation of Ste18 phosphosites and Ste5FBD. Sigmoidal dose-response 
curves with variable slope were fit to data shown in Figure 4 to estimate switch or graded 
morphological responses for each indicated yeast strain. A constraint value of 100 was 








Figure A.S1. Ste18Nt phosphorylation in response to pheromone and dependence 
on scaffolded MAPKs. The abundance of phosphorylated HA-Ste18 in cells treated with 
pheromone for the indicated duration was determined by immunoblotting with anti-HA 
antibody. (A) Protein extracts from pheromone induced wild type cells were subjected to 
phosphatase treatment in the absence or presence of phosphatase inhibitor, and HA-
Ste18 was detected by immunoblotting. (B) Immunoblots showing Ste18-Nt 
phosphorylation as well as Kss1 and Fus3 activation measured in 30 second intervals 
within the first 15 minutes of the pheromone response in wild type cells. Immunoblot of 
activated Kss1 and Fus3 has been contrast enhanced to facilitate visualization, and 
equivalent loading of lanes in immunoblot is demonstrated by comparable levels of 
G6PDH (LC). (C-D) Yeast single gene deletion mutants transformed with the pCUP1-HA-
STE18 expression plasmid were stimulated with 3μM pheromone for 1 hour followed by 
immunoblot analysis of HA-Ste18, activated Kss1 and Fus3, and loading control proteins.  
The phosphorylation percentage of Ste18 (% of total) was compared between time 0 and 
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60 minutes with or without pheromone stimulation. (C) Representative immunoblots 
showing the phosphorylation of Ste18 in cells lacking the indicated kinase, or the MAPK 
scaffold (ste5). Activation of Kss1 and Fus3 were also measured to observe the effect of 
each mutant on pathway activation. (D) Average percent Ste18 phosphorylation and 
standard deviation for three independent colonies. Statistical significance determined by 
2-way ANOVA: (#) significant difference from the same pheromone treatment in wild type, 
and (*) significant difference between 60-/60+ pheromone treatment within the same 






Figure A.S2. Effect of SST2 and YCK1/2 on the phosphorylation of Ste18-Nt. Yeast 
single gene deletion mutants transformed with the pCUP1-HA-STE18 expression plasmid 
were stimulated with 3μM pheromone for 1 hour followed by immunoblot analysis of HA-
Ste18, activated Kss1 and Fus3, and loading control proteins (as in Figure S1). 
Representative immunoblots and quantification of Ste18 phosphorylation percentage are 
shown for three independent colonies with error bars representing standard deviation. 
Results are shown for yeast lacking: (A) the RGS protein (sst2), (B) the yeast casein 




Figure A.S3. N-terminal phosphorylation of Ste18 is required for delayed peak 
activation of Fus3 in response to pheromone. (A) Yeast strains harboring wild type, 
phospho-null (3A) or phospho-mimic (3E) versions of HA-Ste18 expressed from the 
endogenous genomic locus and stimulated with 3M pheromone for the indicated times 
followed by immunoblot analysis of pKss1 and pFus3. Both long and short film exposures 
(LE and SE, respectively) are shown. (B) Quantitative comparison of activated Kss1. (C) 
Quantitative comparison of activated Fus3. Average and standard error bars are shown 





Figure A.S4. Effect of phosphorylation synergy between Ste5 and Ste18 on cell 
polarization and MAPK activation level in response to GPCR activation. Morphology 
and MAPK activation profile of cells harboring the indicated combinations of HA-Ste18 
and Ste5 were analyzed in the absence or presence of pheromone stimulation 
respectively. (A) Immunoblots for Fus3 and Kss1 proteins from experiment shown in 
Figure 3C (B) The different Ste18/Ste5 mutants were visualized by differential interference 
contrast (DIC) microscopy in the absence of pheromone. Multiple fields are shown to 
provide additional views of the cell population. White arrows highlight polarized elongated 
growth that was exclusively observed in Ste183A/Ste5ND cells. No other signs of similarly 
extreme morphology could be found in any other cell type. (C-E) Pheromone- dependent 
activation of Fus3 and Kss1 was measured for the desired amount of time. (C) 
Representative immunoblots showing the result of endpoint assays for HA-Ste18, 
activated MAPKs Kss1 and Fus3, and the loading control (LC). (D and E) Graphical 
representation of the mean ± SD of the activated MAPK levels (Kss1 in C, and Fus3 in D) 
in wild type and mutant cells. Statistical significance was determined by two-way ANOVA 
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tests between each strain within a time point and is indicated by (p<0.05, *), (p<0.01, **), 
(p<0.001, ***), and (p<0.0001, ****). Each test result is color matched to each compared 
strain for which statistically significant differences were observed. Black asterisks indicate 





Figure A.S5. Ste18/Ste5 phosphorylation cooperatively impact the mono- and di-
phosphorylation of Fus3. Protein extracts from cells treated with 3μM -factor for the 
desired duration (same as in Figure S4) were resolved on a phos-tag gel and 
immunoblotted with anti-Fus3 antibody. (A) Representative immunoblot showing the 
mono-phosphorylated (pFus3), di-phosphorylated (ppFus3) and non-phosphorylated 
Fus3 (Fus3). The relative abundance of Fus3 di-phosphorylation (ppFus3) confirms 
results from di-phospho-specific antibody blots shown in Figures 2 and 3. This same trend 
was also observed for mono-phosphorylated Fus3 (pFus3). (B) Quantification of the band 
intensity of ppFus3, pFus3 and Fus3 is denoted as percentage of total Fus3 in each lane. 
(C) Graphical representation of the percentage of mono- and di-phosphorylated Fus3 from 
B. Before pheromone stimulation (time 0), neither pFus3 nor ppFus3 are detectable in 
Ste18WT/Ste5ND cells since the Ste5FBD is needed for allosteric activation and mono-
phosphorylation of Fus3. Both pFus3 and ppFus3 are significantly elevated in 
Ste183A/Ste5ND cells and moderately elevated in Ste183A/Ste5WT cells (relative to wild type 
cells) before the addition of pheromone, suggesting that phosphorylation of both proteins 
contributes to the inhibition of MAPK activation in the absence of pheromone. Consistent 
with this conclusion, we found that pFus3 was diminished or completely abolished in wild 
type or Ste183E/Ste5ND cells, which mimics partial inhibition. Overall, these data suggest 
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that either Ste18-Nt phosphorylation or Ste5 phosphorylation (controlled by Fus3 docking 
on Ste5), can effectively inhibit the aberrant di-phosphorylation of Fus3 in the absence of 
pheromone. Furthermore, simultaneously preventing phosphorylation on both proteins 
results in aberrant di-phosphorylation of Fus3 in the absence of pheromone. Data 




Figure A.S6. The steady state level of Ste5-GFP in cells used for PM translocation 
experiments. Cells expressing either Ste5-GFP or Ste5ND-GFP along with different 
phospho-mutants of Ste18 (same cells as used in Figure 3) were treated with 10μM -
factor for the desired time. Protein extracts were separated by 7.5% SDS- PAGE until 
higher molecular weight markers (110-160kDa markers of the Novex Sharp pre-stained 
protein standard [LC5800]) were well resolved, which was ~20 minutes after the loading 
dye ran off of the gel. Ste5-GFP ran at its expected size of approximately 130kDa (Ste5: 
102 kDa and GFP: 27kDa). The abundance of Ste5 was probed using anti-GFP antibody. 
LC: loading control.  
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Figure A.S7. Phylogenetic analysis of the Ste18/Ste5 phospho-regulatory system. 
(A) Bootstrapped phylogenetic tree of Ste18 orthologs with bootstrap replicates 
conforming to the illustrated phylogenetic tree indicated (out of 100). (B) Multiple sequence 
alignment of Ste18 yeast orthologs correlated with the predicted secondary structure of 
Ste18, including the N-terminal intrinsically disordered region (N-term IDR) and alpha 
helical residues. (C) Alignment from B with all alignment gaps removed to illustrate the 
lengthening of the N-term IDR in S. mikatae, S. bayanus, S. paradoxus, and S. cerevisiae 
– yeast strains that also harbor Fus3 binding domains (FBD) in their Ste5-orthologous 
scaffolds. Sequences in the alignment shown are in order of appearance (from top to 
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Figure B.S1. Osmotic stress induced phosphorylation of Ste18-Nt is 
independent of kinases in HOG pathway. Kinase deletion strains harboring 
the CUP1-HA-Ste18 expression plasmid were stimulated with 0.75 KCl for 15 
minutes. The phosphorylation percentage of Ste18 (% of total) was compared 
between time 0 and 15 minutes with or without stress. (A) Representative 
immunoblots showing the phosphorylation of Ste18 in cells lacking the indicated 
kinase. Activated MAPKs (pHog1, pKss1 and pFus3) were also measured. (B) 
Quantification of average and standard deviation for the HA-Ste18-Nt 
phosphorylation percentage (% of total) is shown for three independent 





Figure B.S2. None of the kinases screened so far are essential for 
phosphorylation of Ste18-Nt in response to osmotic stress. Kinase deletion 
strains harboring the CUP1-HA-Ste18 expression plasmid were stimulated with 
0.75 KCl for 15 minutes (same as in Figure B.S1). Representative immunoblots 
(top) and quantitative graph (below) showing the phosphorylation of Ste18 in 
cells lacking the indicated kinase. Data shown is mean  S.D. for three 
independent experiments for each strain. 
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Table C. S1: List of unique citrullinated Fn peptides identified and the 
corresponding modified residue (r) position in the native protein. 
PAD 
Treatment 




PAD4 QINQQWErTY 7 67  
Untreated QINQQWErTY 2 67  
PAD2 TGNTYrVGDTY 2 107  
PAD2+4 TGNTYrVGDTY 1 107  
PAD4 TGNTYrVGDTY 1 107  
PAD2 TDVrAAVY 1 290  
PAD2 VrAAVYQPQPHPQPPPYGHcVTD 1 290  
PAD2+4 VrAAVYQPQPHPQPPPYGHcVTD 3 290  
PAD4 SQLrDQcIVDDITY 1 515  
PAD2 ITASSFVVSWVSASDTVSGFrVE 1 751  
PAD4 ITASSFVVSWVSASDTVSGFrVE 3 751  
PAD2 TTPFSPLVATSESVTEITASSFVVSWVSASDTVSGFrVE 1 751  
PAD2 AVEENQESTPVVIQQETTGTPrSDTVPSPRDLQF 1 903  
PAD4 TTGTPrSDTVPSPR 18 903  
PAD2+4 TTGTPrSDTVPSPRD 3 903  
PAD2 TTGTPrSDTVPSPrDLQFVE 1 903 911 
PAD2 TTGTPrSDTVPSPRDLQFVE 5 903  
PAD2+4 TTGTPrSDTVPSPrDLQFVE 1 903 911 
PAD2+4 TTGTPrSDTVPSPRDLQFVE 26 903  
PAD4 TTGTPrSDTVPSPRDLQFVE 9 903  
PAD2 AVEENQESTPVVIQQETTGTPRSDTVPSPrDLQF 1 911  
PAD4 TTGTPRSDTVPSPr 1 911  
PAD2 TTGTPRSDTVPSPrDLQFVE 1 911  
PAD2+4 TTGTPRSDTVPSPrDLQFVE 7 911  
PAD4 TTGTPrSDTVPSPrDLQFVE 3 911  
PAD4 TTGTPRSDTVPSPrDLQFVE 13 911  
PAD2+4 SAVTGYrVDVIPVNLPGE 1 938  
PAD4 SAVTGYrVDVIPVNLPGE 1 938  
PAD2 RVDVIPVNLPGEHGQrLPISRNTF 2 953  








PAD4 LTVGLTrrGQPR 15 1035 1036 
PAD2 ITGYrITTTPTNGQQGNSLEE 2 1207  
PAD2+4 ITGYrITTTPTNGQQGNSLEE 3 1207  
PAD4 ITGYrITTTPTNGQQGNSLEE 1 1207  
Untreated ITGYrITTTPTNGQQGNSLEE 1 1207  
PAD2 RSTTPDITGYrITTTPTNGQQGNSLEE 3 1207  
PAD2+4 RSTTPDITGYrITTTPTNGQQGnSLEE 1 1207  
PAD2+4 RSTTPDITGYrITTTPTNGQQGNSLEE 1 1207  
PAD4 RSTTPDITGYrITTTPTNGQQGNSLEE 23 1207  
Untreated RSTTPDITGYrITTTPTNGQQGNSLEE 24 1207  
PAD2 LrFTNIGPDTMRVtWAPPPSID 13 1274  
PAD2 LrFTNIGPDTMRVTWAPPPsID 11 1274  
PAD2+4 LrFTNIGPDTMRVtWAPPPSID 4 1274  
PAD2+4 LrFTNIGPDTMRVTWAPPPsID 2 1274  
PAD4 LrFTNIGPDTmrVtWAPPPSID 1 1274 1284 
PAD4 LrFTNIGPDTmrVTWAPPPsID 1 1274  
PAD4 LrFTNIGPDTMRVtWAPPPSID 10 1274  
PAD4 LrFTNIGPDTMRVTWAPPPsID 11 1274  
PAD2 SVPISDTIIPAVPPPTDLrFTNIGPD 2 1274  
PAD2+4 SVPISDTIIPAVPPPTDLrFTNIGPD 2 1274  
PAD4 SVPISDTIIPAVPPPTDLrFTNIGPD 2 1274  
PAD2 SVPISDTIIPAVPPPTDLrFTNIGPDTmrVTWAPPPSID 3 1274 1284 
PAD2 SVPISDTIIPAVPPPTDLrFTNIGPDTmRVTWAPPPSID 1 1274  
PAD2+4 SVPISDTIIPAVPPPTDLrFTNIGPDTmrVTWAPPPSID 1 1274 1284 
PAD4 SVPISDTIIPAVPPPTDLrFTNIGPDTmrVTWAPPPSID 3 1274 1284 
PAD2 TIIPAVPPPTDLrFTNIGPD 3 1274  
PAD2+4 TIIPAVPPPTDLrFTNIGPD 2 1274  
PAD4 TIIPAVPPPTDLrFTNIGPDTmrVTWAPPPSID 1 1274 1284 
PAD2 LRFTNIGPDTMrVTWAPPPsID 2 1284  
PAD2+4 LRFTNIGPDTMrVtWAPPPSID 1 1284  
PAD2+4 LRFTNIGPDTMrVTWAPPPsID 9 1284  
PAD4 LRFTNIGPDTMrVTWAPPPsID 2 1284  
PAD2 DRVPHSrNsITLTNLTPGTEYVVsIVALnGREE 1 1410  
PAD2 DRVPHSrNsITLTNLTPGTEYVVsIVALNGrEE 1 1410 1434 
PAD2 DRVPHSrNSItLTNLTPGTEYVVsIVALnGREE 1 1410  
PAD2 DRVPHSrNSItLTNLTPGTEYVVsIVALNGrEE 1 1410 1434 
PAD2+4 YVVSIVALNGrE 1 1434  
PAD2+4 YVVSIVALNGrEE 1 1434  








PAD2 YVVSIVALNGrEESPLLIGQQSTVSDVPrDLE 1 1434 1452 
PAD2 YVVSIVALNGrEESPLLIGQQSTVSDVPRDLE 1 1434  
PAD2+4 YVVSIVALNGrEESPLLIGQQSTVSDVPrDLE 1 1434 1452 
PAD2 ESPLLIGQQSTVSDVPrDLE 4 1452  
PAD2+4 ESPLLIGQQSTVSDVPrDLE 3 1452  
PAD4 ESPLLIGQQSTVSDVPrDLE 5 1452  
PAD2 VVAATPTSLLISWDAPAVTVrYYrITYGE 1 1476 1479 
PAD2+4 VVAATPTSLLISWDAPAVTVrYYrITYGE 2 1476 1479 
PAD4 VVAATPTSLLISWDAPAVTVrYYrITYGE 2 1476 1479 
PAD4 rITYGETGGNSPVQEF 2 1479  
PAD2 VVAATPTSLLISWDAPAVTVRYYrITYGE 3 1479  
PAD2+4 VVAATPTSLLISWDAPAVTVRYYrITYGE 1 1479  
PAD4 VVAATPTSLLISWDAPAVTVRYYrITYGE 3 1479  
PAD2 DTLTSrPAQGVVTTLENVSPPR 1 1802  
PAD2+4 DTLTSrPAQGVVTTLENVSPPR 2 1802  
Untreated DTLTSrPAQGVVTTLENVSPPR 4 1802  
PAD2 TLTSrPAQGVVTTLE 2 1802  
PAD2 TLNDNArSSPVVIDASTAIDAPSNLRF 6 1891  
PAD4 TLNDNArSSPVVIDASTAIDAPSNLRF 2 1891  
Untreated TLNDNArSSPVVIDASTAIDAPSNLRF 1 1891  
PAD4 TLNDNARSSPVVIDASTAIDAPSNLrF 1 1910  
PAD2 AVGDEWErmSESGF 1 2223  
PAD4 GTTGQSYNQYSQrYHQR 22 2356  
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